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1.1. Mononuclear phagocytes in the immune system 
The first line of defense that protects us against pathogens is the innate immune system. It is 
an ancient natural defense mechanism that comprises the physical barriers (skin, mucous 
membrane, body fluids or normal bacterial flora), blood proteins as well as cellular 
components (Abul K.Abbas & Andrew H.Lichtman, 2003). The innate immune response to a 
pathogen is rapid, antimicrobial but incomplete, initiating the slower, more definitive, 
acquired response of the adaptive immune system (Fearon & Locksley, 1996).  
Macrophages were first described as phagocytic cells and are the most ancient cellular 
component of the innate immune system. They were discovered in 1880 by Elie Metchnikoff 
in invertebrates (sea stars) and were soon found to exist in vertebrates as well (Tauber, 2003). 
Macrophages are the terminally differentiated cell type of the mononuclear phagocyte system, 
which includes the bone marrow monoblasts, promonoblasts as well as the peripheral 
monocytes (van Furth, 1982). All these cells arise from a common pluripotent stem cell in the 
bone marrow (Figure 1.1).  
 
 
Figure 1.1 Differentiation of mononuclear phagocytes.  
Monoblasts develop in the bone marrow from hematopoeitic stem cells. After differentiation, 
monocytes enter the blood and later migrate to extravascular tissues where they differentiate into 
macrophages. Depending on external stimuli, macrophages are either activated or differentiated into 
tissue macrophages (Abul K.Abbas & Andrew H.Lichtman, 2003). 
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In the bone marrow interleukine 3 (IL-3), granulocytes-macrophage colony-stimulating factor 
(GM-CSF) and macrophage-CSF (M-CSF) are the major cytokines that direct the maturation 
of progenitor cells towards monocytes and their release into the bloodstream (Abul K.Abbas 
& Andrew H.Lichtman, 2003). 
1.1.1. Monocyte heterogeneity and differentiation 
1.1.1.1. Monocyte heterogeneity 
In the blood, at least two major subsets of monocytes exist, each characterized by different 
markers and properties. Human monocytes are characterized by a differential expression of 
CD14 and CD16 markers. An inflammatory subset was described as CD14+CD16+ and a 
“classical” subset as CD14hiCD16- (Ziegler-Heitbrock, 2000; Gordon & Taylor, 2005). In 
mouse, “resident” monocytes were reported to replenish the tissue resident macrophage and 
dendritic cell (DC) populations under homeostatic conditions and are negative for the 
monocyte chemotactic protein (MCP)-1 receptor (CCR2) and express high levels of the 
fractalkine receptor (CX3CR1) (Gordon & Taylor, 2005; Geissmann et al., 2003). Under 
inflammatory conditions the release of chemokines, such as MCP-1 by activated endothelial 
and epithelial cells, increases the recruitment of a monocyte subset expressing the MCP-1 
receptor at high levels (Gosling et al., 1999; Gu et al., 1998; Boring et al., 1998). 
1.1.1.2. Monocyte differentiation 
After a short transitory passage in the blood, monocytes attach to the endothelium, roll and 
diapedese into extravascular tissues, where they differentiate into macrophages and DCs. In 
culture, monocytes differentiate into macrophages upon exposure to M-CSF (Stanley et al., 
1997), and into DCs upon exposure to GM-CSF and IL-4 (Bender et al., 1996; Sallusto & 
Lanzavecchia, 1994).  
However, in vivo, the situation is different because monocytes are under the constant 
influence of the local microenvironment, whose tremendous variety is reflected in the 
heterogeneity of these cells (Burke B & Lewis Claire E., 2002). Apart from the influence of 
cytokine, the endothelium plays a pivotal role in the differentiation of monocytes. In fact, 
cultured monocytes on unstimulated monolayers of human umbilical vein endothelial cells 
(grown on a collagenous matrix), diapedese into the subendothelial collagen layer. A 
proportion of these monocytes “reverse transmigrate” and become DCs, and those that 
remained differentiated into macrophages. Phagocytosis of particle or exposure to 
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microorganism enhance the transmigration and differentiation of monocytes. This cytokine 
independent culture system mimics entry of monocytes from bloodstream into tissues and 
confirm the influence of the cellular milieu (Randolph et al., 1998).  
1.1.2. Macrophage heterogeneity 
Macrophages are distributed through the body and form a very heterogeneous cell population, 
which fulfills various functions. On one side, resident macrophages are responsible for 
immune surveillance and maintenance of tissue homeostasis. On the other side, upon 
inflammation, macrophages are activated and thus play a major function in the attenuation 
and elimination of inflammation and restoring the homeostasis of the inflamed milieu (Burke 
B & Lewis Claire E., 2002) (see section 1.1.3).  
 
Tissue macrophages are long-lived cells that locally demonstrate modest proliferation activity 
and whose phenotype and function may depend on the cytokine repertoire produced by 
surrounding stroma cells as well as the extracellular matrix (endothelial cells, fibroblasts and 
macrophages) (Gordon et al., 1988; Burke B & Lewis Claire E., 2002). Tissue resident 
macrophages colonize the whole body. Amongst others are the one described below. 
1.1.2.1. Brain macrophages 
Microglia, present in the parenchyma of the central nervous system (CNS), constitute the 
main resident macrophage subset in the brain. In the fetus, microglia plays a central role in 
structural remodeling by phagocytosing apoptotic cells. In adult, they are characterized by a 
rapid response to injury and infection (Rezaie & Male, 1999). Microglia contributes to the 
restoration of damage in the CNS, however they were also associated with multiple sclerosis 
(MS) and Alzheimer’s disease processes (Bar-Or et al., 1999; McGeer et al., 1993). Three 
other subtypes of macrophages are less abundant in the brain: the perivascular (lining small 
blood vessels), the meningeal (present in the meninge, membranes surrounding the brain) and 
the choroids-plexus (present between the blood and the cerebrospinal fluid interface) 
macrophages. Whereas the meningeal macrophages are involved in restricting the movement 
of antigens from the blood to the CNS, the two remaining subtypes function mainly as APCs. 
In addition to endogenous macrophages, there is recruitment of monocytes through the 




1.1.2.2. Alveolar macrophages 
Alveolar macrophages play a critical role in the defense against airborne pathogens in the 
lung and are characterized by high capacity to phagocytose. In addition, alveolar macrophages 
produce a wide range of cytokines, enzymes, as well as reactive oxygen radicals and 
respiratory burst acting against bacteria (Burke B & Lewis Claire E., 2002).  
1.1.2.3. Kupfer cells 
Kupffer cells represent the resident macrophages of the liver located in the line sinusoid in 
direct contact with the blood stream. They play an important role in the clearance of 
pathogens and soluble substances due to their high phagocytotic capacity. In addition, Kupffer 
cells were associated with the acute phase protein response which is characterized by fever, 
tachycardia, shock and changes in concentration of circulating protein. Hepatocytes are the 
main producers of acute phase proteins under the influence of IL-6 secreted by activated 
Kupffer cells (Burke B & Lewis Claire E., 2002).  
1.1.2.4. Macrophages in peripheral lymphoid organs 
The initiation of the adaptive immune response takes place in peripheral lymphoid organs, 
where antigens are trapped and presented to lymphocytes. Macrophages play a major role in 
presenting and clearing antigens in lymph nodes and thymus (Charles A.Janeway et al., 2001). 
In spleen, macrophages form a very heterogeneous population. In the marginal zone, potent 
phagocytotic macrophages filtrate the blood from foreign antigens as well as effete red blood 
cells. These marginal zone macrophages express scavenger receptors, which facilitate the 
clearance of blood borne pathogens (Kraal, 1992). In the white pulp the metallophilic 
macrophages may play a role in viral infections (O'Riordain et al., 1999; Takahashi et al., 
1994). 
1.1.2.5. Macrophages of the vascular system 
In arteries, macrophages are found within the intima layer and function in maintaining the 
cholesterol homeostasis in the artery membrane. Cholesterol uptake and its endogenous 
synthesis is balanced with its metabolism and export outside the cell. Several enzymes, 
receptors and proteins were found to contribute to this balance. An excess of cholesterol in the 
blood drives an accumulation of free sterol in macrophages transforming them into so called 
foam cells, a process that is thought to play a main role in the development of atherosclerosis 
(Burke B & Lewis Claire E., 2002).  
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1.1.2.6. Placenta macrophages 
Macrophages reside in every organ of the female genital tract and are involved in various 
processes. Decidual macrophages are abundant in the deciduas (endometrial lining developed 
along the implantation event) and closely associated with extravillous trophoblasts. Decidual 
macrophages are also involved in the local immune regulation including maternal tolerance 
against fetal antigens and immune surveillance during pregnancy. Moreover, after the 
implantation of the embryo, interactions between macrophages and trophoblasts are crucial 
for the maintenance of pregnancy (Katabuchi et al., 2003; Lea & Clark, 1989).  
1.1.3. Macrophages in inflammation 
Upon infection, toxin exposure or cell injury, an inflammation is initiated for protection and 
subsequent repair of damaged tissues (Abul K.Abbas & Andrew H.Lichtman, 2003). 
Recruited monocytes into inflamed tissues differentiate into macrophages, whose phenotype 
and function depend on the stimuli.  
For a rapid clearance of microbes, macrophages express surface receptors that mediate 
phagocytosis and subsequent elimination of the pathogen. Amongst others, Toll-like receptors 
(TLRs) allow the direct recognition of a wide variety of pathogens, such as the bacterial 
lipopolysaccharide (LPS). LPS is the product of Gram-negative bacteria, which is recognized 
by TLR4 leading to the alteration of the gene expression in macrophages. This so called 
“innate” activation involves only the innate immune system and provides macrophages with 
microbicidial activity and triggers their inflammatory cytokines production, such as IL-1, and 
tumor necrosis factor (TNF)-α (Abul K.Abbas & Andrew H.Lichtman, 2003).  
Once pathogens were eradicated, scavenger receptors (SR) are involved in the clearance of 
apoptotic cells by inducing phagocytosis and inhibition of pro-inflammatory cytokine 
production (Fadok et al., 1998), switching off previously activated macrophages. This 
deactivation process is important to avoid destruction of tissues and persistence of 
inflammation (Gordon, 2003), and can be achieved with anti-inflammatory cytokines, such as 
IL-10 (Berrebi et al., 2003).  
If inflammation persisted, cells of the adaptive immune system, primed for the pathogen by 






1.1.3.1. Classically activated macrophages 
“Classically” activated macrophages are found in chronic inflammation, when the innate 
defense did not succeed in eliminating a microbe. The immune response involves, amongst 
others, the T helper 1 (Th1) cells of the adaptive immune system with interferon (INF)γ as the 
key cytokine. INFγ is produced by activated Th1 cells and also by natural killer (NK) cells 
and primes macrophages for a more efficient killing of intracellular pathogens (Dalton et al., 
1993). When primed macrophages encounter a microbial stimulus (such as LPS), they are 
classically activated and exhibit a phenotype different from the innate activated macrophages 
(described above). Classically activated macrophages produce pro-inflammatory cytokines 
(IL-1 and TNFα) (Gordon, 2003). IL-12 secreted by DCs enhances additional INFγ 
production by Th1 cells, which in turn promote additional classical activation of new 
macrophages (Abul K.Abbas & Andrew H.Lichtman, 2003). Moreover, the classical 
activation is coupled with enhanced surface expression of MHC class II and costimulatory 
molecules as well as increased production of antimicrobial proteins such as elastase, 
collagenase and lipase. High levels of intracellular reactive oxygen intermediate (ROI) and 
nitric oxide (NO) are also efficient weapons of the classically activated macrophages against 
intracellular but also extracellular pathogens (Burke B & Lewis Claire E., 2002; Abul 
K.Abbas & Andrew H.Lichtman, 2003). Interestingly, as long as the pathogenic stimulus is 
present, INFγ suppresses an alternative activation of macrophages (described in the following 
section) keeping a pro-inflammatory state until the eradication of the pathogen (Dickensheets 
et al., 1999). 
1.1.3.2. Alternatively activated macrophages 
Alternatively activated macrophages are associated with a suppression of inflammation 
(Gordon, 2003). T helper 2 (Th2) cytokines, mainly IL-4 and IL-13 induce this phenotype, 
which is distinct from the deactivation described above (Gordon, 2003; Stein et al., 1992). 
Alternatively activated macrophages are characterized by an upregulation of mannose 
receptors (MR), which contribute to clearance of cells debris to avoid the persistence of 
inflammation and to restore the tissue homeostasis (Taylor et al., 2005). Moreover, their nitric 
oxide production is reduced resulting from the induction of arginase-I. The later promotes cell 
growth and collagen production, leading to wound healing of the previously inflamed tissues 
(Gordon, 2003). The high MHC II molecule expression in alternative activated macrophages 
enhances the antigen presentation and thus further Th2 cell activation. Alternatively activated 
macrophages are found in parasitic infection associated with excess fibrosis (Mora et al., 
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2006), they inhibit the progression of parasitic infections, thus protecting the host against a 
disseminated inflammation (Baetselier et al., 2001; Rodriguez et al., 2004).  
Taken together, a plausible scenario for macrophage activation is depicted in Figure 1.2. 
However, in reality the situation is likely to be more complex, because macrophages in vivo 
not only display different patterns of functions, depending on their microenvironment, but 
also interact continuously with other components of the immune system. Moreover, the nature 
of the pathogen inducing the inflammation plays a major conducting role in the polarization 
of the immune response. 
                 
Figure 1.2 Macrophage activation during inflammation. 
Recruited macrophages into inflammation sites respond to different stimuli by developing different 
activation phenotypes. The innate activation (left panel) occurs upon the first pathogenic stimulus. It 
may be followed by a deactivation under the influence of cytokines, such as IL-10. In an INFγ milieu 
macrophages are primed and are respond to a second insult by a classical activation phenotype (middle 
panel), triggering a strong anti-inflammatory response. An IL-4 primed macrophage became 
alternatively activated (right panel) promoting an anti-inflammatory response and tissue repair. TNF, 
tumor necrosis factor; MR, mannose receptor; NO, nitric oxide; ROI, respiratory oxygen intermediate.  
Introduction 
8 
1.2. MMD, a putative seven transmembrane protein 
As detailed above, the differentiation of monocytes to macrophages is a complex process 
which involves a wide range of proteins, receptors, cytokines, and other mediators. During 
differentiation and activation, macrophages acquire many new properties and functions not 
only as cellular components of the innate immune system, but also as important accessory 
cells in the adaptive immune response. They play also a crucial role in tissue remodeling and 
healing. This complexity in function reflects a phenotype heterogeneity, which is illustrated 
by a broad range of specific markers.  
Our lab has been focusing on the identification and characterization of new marker proteins, 
which may provide more insights into the molecular mechanisms underlying the 
differentiation of macrophages and their newly acquired functions. In this context, a 
Representational Difference Analysis (RDA) of cDNA was performed leading to the 
identification of new genes expressed in macrophages and not in monocytes (Rehli M, 1996). 
Amongst others, the human monocyte to macrophage differentiation (hMMD) gene was 
identified as absent in monocytes but high expressed in macrophages. hMMD was isolated, 
cloned and used to screen a cDNA library to obtain its complete nucleotide sequence (Rehli et 
al., 1995).  
 
The full-length human MMD (hMMD) cDNA encodes a putative polypeptide of 238 amino 
acids. Transmembrane prediction analysis of the deduced human MMD protein sequence 
revealed a seven transmembrane (7TM) domain with paralogues in different species. Blast 
search showed that hMMD shared 99% amino acid sequence identity with the mouse 
orthologue mMMD, and both share a conserved UPF0073 motif. The UPF0073 motif was 
termed after Hemolysin (Hly)-III, which is a protein produced by Bacillus cereus, that forms 
pores in cell membranes (Baida & Kuzmin, 1996). It is considered as a virulence factor of this 
bacterium, driving the lysis of erythrocytes.  
After starting with this project, the full open reading frame (ORF) of mouse and human MMD 
homologues were published as the monocyte to macrophage differentiation factor 2 (MMD2). 
Mouse and human MMD2 genes also encode predicted 7TM proteins, which share a high 
level of sequence identity (94%) and contain the same UPF0073 motif. Beside a study 
associating MMD2 with testis development, the function of this protein is still unclear 
(Menke & Page, 2002). 
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Recently, Tom Tang Y. et al. (Tang et al., 2005) defined a new protein family, the Progestin 
and AdipoQ Receptors (PAQRs), which were characterized by a 7TM domain wholly 
encompassed within the UPF0073 motif. This family includes eleven proteins with conserved 
amino acid residues and a broad range of functions. MMD and MMD2 were termed as 
PAQR11 and PAQR10 respectively.  
1.3. PAQR family 
The PAQR family was identified by performing a tBLASTn analysis using the sequence of 
the adiponectin receptors, AdipoR1 and 2 (Tang et al., 2005). The input of this assembly 
analysis was a collection of public and private expressed sequence tags (ESTs) as well as 
predicted exons from the human genome and it allowed the identification of weak but relevant 
sequence similarities (Altschul et al., 1997).  
 
Figure 1.3 Phylogenetic analysis of PAQR family proteins. 
MMD and MMD2 (red stars) belong to Hemolysin III proteins diverging from the rest of PAQR 
family. The protein name prefixes relate to source species of the sequence: HS, Homo sapiens; MM, 
Mus musculus; RN, Rattus norvegicus; SC, Saccharomyces cerevisiae; SP, Schizosaccharomyces 
pombe; CE, Caenorhabitis elegans; DR, Danio rerio; XL, Xenopus laevis; DM, Drosophila 
melanogaster; BC, Bacillus cereus; AG, Anopholes gambiae; AT, Arabiodopsis thaliana; CN, 
Cynoscion nebulosus; OL, Oryzias latipes; SS, Sus scrofa (Fernandes et al., 2005). 
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PAQR family members 1 to 11 are structurally and topologically distinct from the 
G protein-coupled receptors (GPCRs) (Tang et al., 2005). Within the protein sequence of 
PAQRs, N- and C-terminal regions show very low sequence homology, but a significant 
portion of amino acid residues were conserved in the transmembrane region. MMD and 
MMD2 represent the most divergent proteins of this receptor family with the greatest 
sequence similarities to bacterial Hly-III (Tang et al., 2005). Based on phylogenetic analyses 
PAQR1-9 were classified as adiponectin receptor and membrane progesterone receptor 
(mPRs) related proteins (Figure 1.3) (Fernandes et al., 2005; Tang et al., 2005). 
1.3.1. Adiponectin receptor related proteins 
1.3.1.1. Adiponectin receptors, PAQR1 and PAQR2 
AdipoR1 and AdipoR2 encode proteins that include a 7TM domain characterized with the 
PFAM conserved UPF0073 motif and show marked conservation from yeast to mammals. 
Although no significant sequence homology was detected with other PAQR proteins, at the 
protein sequence level, human and mouse AdipoR1 and AdipoR2 share 96.8% and 95.2% 
identity respectively (Yamauchi et al., 2003a).  
In mouse, the AdipoR1 transcript is mainly expressed in the skeletal muscle but also in the 
lung, liver, spleen, heart, kidney and very weak in the brain and testis. By contrast, AdipoR2 
expression is restricted to the liver and very weak in the heart, lung and skeletal muscle 
(Yamauchi et al., 2003a).  
In human, the Reference Database for Expression Analysis (RefEXA) (www.lsbm.org) 
reported a high transcript expression of AdipoR1 in the peripheral blood and bone marrow. 
Interestingly, both AdipoRs were found highly expressed in monocytes and slightly 
upregulated in macrophages (Figure 1.4).  
Although not much is known about the downstream signaling of these receptors, it was 
reported that the peroxisome proliferator-activated nuclear receptors (PPARs) α and γ regulate 
AdipoRs expression in macrophages and adiponectin concentration in the plasma (Chinetti et 
al., 2004; Tsuchida et al., 2005).  
The adiponectin protein (also called adipocyte complement related protein (Acrp30), or 
AdipoQ) is the known ligand of AdipoRs, synthesized and secreted exclusively by adipose 
tissues. It shares significant homology to subunits of the complement factor C1q with a 
collagenous structure at the N-terminus and a globular domain at the C-terminus (Hu et al., 
1996; Scherer et al., 1995). Adiponectin is abundantly present in the human and mouse 
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plasma (Arita et al., 1999) and exerts anti-inflammatory, anti-atherogenic and 
insulin-sensitizing (Hu et al., 1996) effects. The two latest were identified in mouse models 
studies (Kubota et al., 2006; Combs et al., 2004; Yamauchi et al., 2003b).  
The anti-inflammatory effect was illustrated by a suppression of LPS-induced TNFα 
production (Ouchi et al., 2001) and induction of anti-inflammatory cytokine secretion (IL-10) 
by macrophages (Kumada et al., 2004). However another study reported that adiponectin 
anti-inflammatory effects is rather modulated by the induction of TNFα and IL-6 production 
thus rendering macrophages resistant to pro-inflammatory stimuli (Tsatsanis et al., 2005).  
In the bone marrow, secreted adiponectin was found to suppress the proliferation of 
myelomonocytic progenitor, thus influences the hematopoeisis, in addition it inhibits the 
phagocytic activity of macrophages (Yokota et al., 2000). 
The protective effect of adiponectin against atherosclerosis disease is mediated by the 
inhibition of the surface expression of adhesion molecules in endothelial cells in response to 
TNFα. Consequently, the attachment of monocytes to aortic endothelial cells is blocked 
(Ouchi et al., 1999; Kawanami et al., 2004). The migration and proliferation of smooth 
muscle cells, which is the second factor promoting the formation of atherosclerosis, may also 
be hindered by adiponectin (Matsuda et al., 2002). In macrophages, adiponectin inhibits the 
cholesterol ester accumulation and the uptake of oxidized LDL. Thus, it negatively influences 
the development of foam cells, which are the main cellular component of the atherosclerotic 
plaque (Ouchi et al., 2001).  
It is still not known if this wide range of adiponectin function is only mediated by AdipoRs. It 
seems that other “missing links” may mediate the signal inside the cell and their identification 
may drop more light in the function of the PAQR1 and PAQR2 (Yamauchi et al., 2003a). 
1.3.1.2. PAQR3, PAQR4  
PAQR3 is a predicted 7TM protein, ubiquitously expressed in all human tissues and without 
any attributed function (Tang et al., 2005). Fernandes M.S. et al (Fernandes et al., 2005) 
found that PAQR3 expression in the endometrium and myometrium was constant during 
pregnancy and after labor, suggesting its role in tissue homeostasis (Fernandes et al., 2005). In 
Drosophila the PAQR3 orthologue, CG7530, with unknown function, was associated with 
resistance to oxidative stress (Monnier et al., 2002).  
To date, PAQR4 has been related to adiponectin receptors without any known function. Its 




1.3.2. Membrane progestin receptor (mPR) related proteins 
1.3.2.1. PAQR5, 7 and 8 
The novel putative mPRα, β and γ, also termed PAQR 7, PAQR 8 and PAQR 5 were 
identified in fish and human as progestin binding proteins (Zhu et al., 2003a; Zhu et al., 
2003b). Progestin, a synthetic modification of progesterone, is a hydrophobic signaling 
molecule able to diffuse through the plasma membrane and binds to the progesterone receptor 
(PR) within the cell nucleus. Progestin binding promotes the dissociation of heat shock 
proteins from the nascent receptor, which dimerizes and gets phosphorylated. This active 
form of the PR recruits and stabilizes transcription factors at the target gene promoter, leading 
to its transcription. This “classical” also called “genomic“ mechanism of action of steroid 
hormones is well known (Li et al., 2004).  
However, steroid membrane receptors on the cell membrane were found to be responsible for 
the rapid “non-genomic” steroid action (Orchinik et al., 1992). It was reported that mPRs are 
such steroid receptors with high affinity for progesterone and characterized by rapid 
association and dissociation rates (Zhu et al., 2003a). mPRs were predicted to have a 7TM 
domain with extracellular N-terminal and intracellular C-terminal tails, and thus resembling 
the GPCRs (Tang et al., 2005). PAQR5, 7 and 8 orthologues share high protein sequence 
identities, comparable with AdipoR1 and 2 orthologues: 
• Mouse/Human mPRα: 83% 
• Mouse/Human mPRβ: 94% 
• Mouse/Human mPRγ: 92% 
Although mPRs were believed to be plasma membrane proteins, mPRα was described to be 
localized in the intracellular tubuloreticular network (Fernandes et al., 2005), and mPRβ (also 
termed lysosomal membrane protein in brain (LMPB)-1) was associated to lysosomes (Suzuki 
et al., 2001). The cellular localization of mPRγ is still unknown. 
On the RNA level, mPRα expression was detected in kidney and reproductive tissues 
(placenta, uterus, testis, and ovary), whereas mPRβ is restricted to the neural tissues, and 
mPRγ to the kidney, colon, and lung. This differential expression pattern of mPR subtypes 
may reflect various physiological functions. It has been suggested that mPRα might play a 
role in pregnancy (Chapman et al., 2006; Fernandes et al., 2005) as well as in the acrosome 
reaction and the hyperactivity of human sperm in response to progesterone (Revelli et al., 
1994; Zhu et al., 2003a). mPRβ was described in association with a form of juvenile 
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myoclonic epilepsy (JME) in human (Suzuki et al., 2001).To date the function of mPRγ has 
still not been identified.  
Also, little is known about the signaling cascade following the binding of progestin to mPRs. 
It was found that in sea trout, mPR has a rapid influence on the oocyte maturation by 
activating an inhibitor G-protein which decreases the intracellular cyclic adenosine 
monophosphate (cAMP) (Zhu et al., 2003b).  
1.3.2.2. PAQR6  
PAQR6 was also related to the membrane progestin receptors on the basis of protein sequence 
homology, however, its function has not yet been defined. Tom Tang Y. et al (Tang et al., 
2005) found that PAQR6 transcript is restricted to brain, although they did not include the 
female reproduction system in their mRNA expression analysis. 
1.3.2.3. PAQR9 
PAQR9 was first described by Fernandes M.S. et al (Fernandes et al., 2005) in the context of 
the female reproduction system. So far no function has been attributed to the protein. A high 
expression of PAQR9 mRNA was found in placenta and cycling endometrium. In addition 
PAQR9 transcript was predominant in the liver, brain, testis, heart, thymus, in the adult bone 
marrow, skeletal muscle and kidney (Tang et al., 2005). Although PAQR9 was classified in 
the mPR family, it is not known in which mechanism it may be involved. 
 
Finally, the discovery of the novel PAQR family introduced three subgroups of receptors 
which include proteins related to adiponectin, membrane progestin and to the Bacillus cereus 
Hly-III. Although PAQRs share a conserved protein architecture and key amino acid residues, 
they differ in their transcript expressions and function (for the one that has been described). 
While PAQR1 and PAQR2 were associated with lipid metabolism, PAQR5, PAQR7 and 
PAQR8 appeared to be involved in the nongenomic action of steroids, but little is known 
about PAQR3, PAQR4, PAQR6 and PAQR9 ligands and functions (Table 1.1). The 
Reference Database for Expression Analysis (www.lsbm.org) reported a high RNA 
expression of PAQR1, and PAQR2 in monocytes and macrophages. However, PAQR8 and 





Table 1.1 PAQR family in human and mouse  
PAQR      Synonyms Reported ligand                        Reported functions 
     1        AdipoR1 
     2        AdipoR2 
     Adiponectin     Associated with antidiabetic metabolic effects 
     3             --             ?                                       ? 
     4             --             ?                                       ? 
     5          mPRγ       Progestin                                       ? 
     6             --             ?                                       ? 
     7          mPRα      Role in the hyperactivity of the human sperm 
     8 mPRβ or LMPB-1 
      Progestin 
     Associated with the JME and the placenta cycle 
     9             --              ?                                       ? 
    10         MMD2              ?                                       ? 
    11          MMD              ?                                       ? 
 
























































Figure 1.4 RNA expression levels of PAQRs in human monocytes and macrophages. 
PAQR1 and PAQR2 are highly expressed in monocytes (grey) and slightly upregulated in 
macrophages (black). PAQR8 and PAQR11 expressions are at least 2-fold upregulated, in contrast to 
PAQR6 which is down-regulated in macrophages. The residual PAQRs expression is less significant. 
No data are reported concerning PAQR9 expression. Values used to generate this diagram were taken 
from the Reference Database for Expression Analysis (RefEXA) and indicate the mRNA expression 
level obtained from microarray data of Affimetrix GeneChip U133A (www.lsbm.org). 
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2. Research objectives 
The gene Monocyte to Macrophage Differentiation-associated (MMD) was originally 
identified in our lab during a differential screen for macrophage-differentiation associated 
transcripts. The MMD gene encodes a hydrophobic orphan seven transmembrane protein that 
is highly conserved during evolution. As its homologue MMD2, it contains a conserved 
Hemolysin III domain. The biological function of both MMD genes is unclear, however, due 
to their exceptional degree of conservation, it was hypothesised that this gene family may 
have an important function.  
The aim of this thesis was to characterize MMD properties and functions, in particular during 
monocyte to macrophage differentiation, using both molecular and biochemical approaches. 
Thereby, a major objective was to establish tools, including over-expressing cell lines and 
knock-out ES cells to enable further studies on the biological function of the highly conserved 
MMD gene product. 
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3. Material  
3.1. Equipment  
Autoclave Technomara, Fernwald, Germany 
Centrifuges Heraeus, Hanau; Eppendorf, Hamburg, Germany 
Densitometer Molecular Dynamics, Krefeld, Germany 
Electrophoresis equipment Biometra, Göttingen; BioRad, Munich, Germany 
Electroporation system and cuvettes Biometra, Götingen; BioRad, München 
Heat sealer (Fermant 400) Josten & Kettenbaum, Bensberg, Germany 
Stratalinker® UV Crosslinker Stratagene, Germany 
Incubators Heraeus, Hanau, Germany 
Laminar air flow cabinet Heraeus, Hanau, Germany 
Luminometer (Sirius) Berthold Detection Systems, Pforzheim, Germany 
Microscopes Leitz, Heidelberg, Germany 
PCR thermocyclers MJ Research, Hessisch Oldendorf, Germany 
pH-Meter Knick, Berlin, Germany 
Power supplies Biometra, Göttingen; Bachofer, Reutlingen, Germany
Spectrophotometer Perkin Elmer, Überlingen, Germany 
Typhoon™ Amersham Biosciences, Germany 
Thermomixer Eppendorf, Hamburg, Germany 
Ultracentrifuge Optima L-70 Beckman, Munich, Germany 
Water purification system Millipore, Eschborn, Germany 
3.2. Material 
Cell culture flasks and pipettes Costar, Cambridge, USA 
Cryo tubes Nunc, Wiesbaden, Germany 
Sterile micropore filters Millipore, Eschborn, Germany 
Nylon transfer membrane Roche, Germany 
Nitrocellulose membrane (Protran) Schleicher & Schuell, Dassel, Germany 
PVDF membrane (Immobilon-P) Millipore, Eschborn, Germany 
Hyperfilm Amersham Biosciences, Buckinghamshire, UK 
Whatman 3MM paper Whatman, Maidstone, UK. 
Micro test tubes (0.5, 1.5, 2 ml) Eppendorf, Hamburg, Germany 




Unless noted otherwise, chemicals included in these studies were purchased either from 
Sigma Chemicals (Deisenhofen, Germany) or from Merck (Darmstadt, Germany). Ready-
made buffers and cell culture media were obtained from Biochrom (Berlin, Germany) or from 
Invitrogen (Karlsruhe, Germany). Water was generally of Millipore-purified/distilled quality. 
When denoted, ultra-pure, DEPC-treated H2OUSB purchased from USB Corp. through 
Amersham (Braunschweig, Germany) was used. 
3.4. DNA oligonucleotides 
Oligonucleotides primers were generated by the following companies: TIB Molbiol (Berlin, 
Germany); Metabion (Martinsried, Germany); and Qiagen (Hilden, Germany). 
General primers 
T7 5’-TAATACGACTCACTATA-3’ 
M13 (-20) forward 5'-TTG TAA AAC GAC GGC CAG TG-3' 
M13 reverse 5'-GGA AAC AGC TAT GAC CAT GAT-3' 
 

















EF1alpha_S 5'-TAGTTCTCGAGCTTT TGGAGT-3' 
End MMD_S 5'-AGCCTTGGTGGTGACATCAA-3' 
HA tag-S 5’-AATGCGGCCGCTCATGTACCCATACGATGTTCCAG 
    ATTACGCTATGCGGTTCAGGAATCG-3’ 
MMD-stop-AS 5’-CCCTCGAGTCATAAATGCCGAATAAAGTCTG-3’ 
myc tag-S 5’-ACTCATCTCAGAAGAGGATCTGTTGAGAACAGTGG 




Primers for tagged-MMD in pIRES-hrGFP-1a (continued) 
myc tag-AS 5’-CAGATCCTCTTCTGAGATGAGTTTTTGTTCGTGGCT 
    CTTCTTCCATGATACTA-3’ 
Flag-tag_S 5’-AATGCGGCCGCGCCACCATGGATTACAAGGATGAC
    GATAAGATGCGGTTCAGGAATCGATTC -3’ 
HAc-term_AS 5’-AAGTCTCGAGTCAAGCGTAATCTGGAACATCGTATG
    GTATAAATGCCGAATAAAGTCTGT-3’ 
Mu2-stop-AS 5’-CCCTCGAGTCATAAATGCCGAATAAAGTCTG-3’ 
Myc1-tag_S 5’-GAACAAAAACTCATCTCAGAAGAGGATCTGGACTG
    CTGGGAGAAGATAACA-3’ 
Myc1-tag_AS 5’-CAGATCCTCTTCTGAGATGAGTTTTTGTTCATCAGA 
    CAGCCGATGGAG-3’ 
 
Primers for tagged-MMD in pQCXIP 
pQCXIP 5’ primer 5’-ACGCCATCCACGCTGTTTTGACCT-3’ 
pQCXIP 3’ primer 5’-AAGCGGCTTCGGCCAGTAACGTTA-3’ 
BamHI-stopMMD-AS 5’-CGCGGATCCGCTCATAAATGCCGAATAAAGTCTG-3’ 
  
Primers for targeting construct I    
LKA_S 5’-ACTGGCGGCCGCGTGATTGGTCAGAATAGATACTG 









Primers for targeting construct II 
1.Arm5’-1_S   5'-ATATGCGGCCGCCCACCTCTTAGACTCACATTACA 



















Primers for targeting construct IV 
SA-Not_S 5'-ATAAGAATGCGGCCGCGGTAAGATAGCATCCTGTA 
    CC-3' 
SA-EcoR_AS 5'-CCGGAATTCATAGATGCAAATGACAAAGG-3' 
Laex6-1_S 5'-ACGCGTCGACGGGAACTTCAGTATAAGAGTGTTAC 
    ATTA-3' 
LAex6-1_AS 5'-ATTGCTATTTGGAAAGTCTACAGG -3' 
LA 6ex6-2_S 5'-AATAATGAATTAAAGCTGCGGGC-3' 
LA ex6-2_AS 5'-ATGTTACTGAAGAAGTACCCTCACAAC-3' 
LA ex6-3_S 5'-TAGTAAGGAATATGCAACCTGACAAG-3' 




LA ex6-1-in 5’-AGTCTCCTATTGAACGGAAAC-3’ 
LA ex6-3-in 5’-AATACTACCGGTTGAACC-3’ 
  






Mouse anti-FLAG M2 (IgG1)    SIGMA-ALDRICH, Germany 
Rat anti-HA high affinity (clone 3F10)   Roche, Germany 
Mouse anti-cMyc     Werner Falk 
(FITC)-conj. rat anti-mouse CD107a (LAMP-1)  BD Biosciences Clontech, Germany 
 
Polyclonal antibodies 
Alexa Fluor® 546 goat anti-mouse IgG (H+L)  Molecular Probes, Inc. USA 
Alexa Fluor® 546 goat anti-rat IgG (H+L)  Molecular Probes, Inc. USA 
Rabbit anti-rat HRP     DakoCytomation, Denmark 
Goat anti-mouse HRP     DakoCytomation, Denmark 
 
3.6. Enzymes and kits 
Restriction endonucleases, DNA polymerases and protease inhibitors were purchased from 
ROCHE (Germany)and New England Biolab (Frankfurt Germany), unless noted otherwise. 
DIG Easy Hyb.  Roche, Germany 
DIG Easy wash and block buffer set Roche, Germany 
Lipofectamin transfection reagent Invitrogen, Karlsruhe, Germany 
DNA molecular weight standard Invitrogen, Karlsruhe, Germany 
Mouse ES cell transfector® kit Amaxa biosystems, Cologne, Germany 
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NucleoSpin® Extract II  Macherey-Nagel, Düren, Germany 
NucleoSpin® Plasmid Quick Pure Macherey-Nagel, Düren, Germany 
PCR DIG probe synthesis kit Roche, Germany 
Plasmid preparation kits Qiagen, Hilden, Germany 
QIAEX II gel extraction kit Qiagen, Hilden, Germany 
Qiagen-Effectene transfection reagent Qiagen, Hilden, Germany 
RetroMax™ System  IMGENEX, San Diego, USA 
RNeasy Midi kit Qiagen, Hilden, Germany 
  
3.7. Molecular weight standards 
DNA Ladder 1 kB Plus was purchased from Invitrogen (Karlsruhe, Germany). For Southern 
blot analysis, DIG-labeled DNA Molecular Weight Marker III, was purchased from Roche, 
(Germany). The Kaleidoscope Prestained standard protein marker was purchased from 
BioRad (Munich, Germany).  
3.8. Plasmids 
pCR®2.1-TOPO  Invitrogen, Karlsruhe, Germany 
pEF6/V5-HIS-TOPO Invitrogen, Karlsruhe, Germany 
pBluescript II KS+ Stratagene, La Jola CA, USA 
pIRES-hrGFP-1a Stratagene, La Jola CA, USA 
pQCXIP BD Biosciences Clontech, Germany 
pCLEco IMGENEX, San Diego, USA 
pCL-10A1 IMGENEX, San Diego, USA 
  
3.9. E.coli strains 
The following bacterial strains were used:  
TOP10  F- mcrA ∆(mrr-hsdRMS-mcrBC) Ф80lacZ∆M15 ∆lacΧ74 recA1 deoR   
  araD139 ∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG  
DH10B  F-mcrA ∆(mrr-hsdRMS-mcrBC) Ф80lacZ∆M15 ∆lacΧ74 recA1 deoR  
  araD139 ∆(ara-leu)7697 galU galK rpsL endA1 nupG  
3.10. Antibiotics 
Antibiotic Selection Working concentration Stock solution 
Ampicillin Prokaryotic cells 50-100 µg/ml 100 mg/ml in H2O 
Neomycin (G420) Eukaryotic cells 200-350 µg/ml 10-50 mg/ml 
Puromycin Eukaryotic cells 1 mg/ml 4 µg/ml in PBS 
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3.11. Animal cell lines culture 
Murine cell lines 
NIH 3T3  Swiss mouse embryo fibroblast (DSMZ no. ACC 59) 
RAW 264.7  Mouse monocyte-macrophage BALB/c (ATCC TIB-71) 
P815   Mouse mastocytoma (ATCC TIB 64) 
BV-2   Mouse microglia (Zürich, W.Milipiero) 
HT-2   Spleen helper T-cell, IL-2 dependent (ATCC CRL-1841) 
J774A.1  Mouse monocytes-macrophage BALB/c (DSMZ no. ACC 170) 
ES   E14.1 embryonic stem cells (129/Ola mouse) 
EF   Embryonic fibroblast (CD1 mouse) 
EFneo   Embryonic fibroblast (Nc1 neomycin resitant +/- mouse) 
 
Human cell lines 
THP-1   Human acute monocytic leukemia (DSMZ no. ACC 16) 
HL-60   Human acute myeloid leukemia (DSMZ no. ACC 3) 
Hep G2   Hepatocellular carcinoma (ATCC HB-8065) 
Mono-Mac-6  Human acute monocytic leukemia (DSMZ no. ACC 124) 
CaCo-2   Human colon adenocarcinoma (DSMZ no. ACC 169) 
HT-29   Human colon adenocarcinoma (DSMZ no. ACC 299) 
U-937   Human hystiocytic lymphoma (DSZM no. ACC5) 
 
3.12. Databases research 
PubMed  www.ncbi.nlm.nih.gov/entrez 
Ensembl Browser www.ensembl.org 
BLAST  www.ncbi.nlm.nih.gov/BLAST 
ClustalW  www.ebi.ac.uk/clustalw 
ExPASy Proteomic www.expasy.org 
USCS Gen. Browser www.genome.ucsc.edu 
LSBM   www.lsbm.org 




Unless otherwise mentioned, all methods were based on protocols described in the Current 
protocols of Molecular Biology (Ausubel Frederick et al., 2006), and in the Molecular cloning 
laboratory manual (Sambrook & Russel, 2001).  
4.1. General molecular biology 
4.1.1. Bacterial culture 
4.1.1.1. Bacterial growth medium 
E.coli strains were streaked out on solid LB-agar with antibiotic and grown overnight. Single 
colonies were then picked and grown in liquid cultures overnight. For blue/white screening of 
insert-containing clones after transformation, 40 µl of X-gal was dispersed on the pre-warmed 
LB plates, that were incubated at 37°C for an additional 30 min prior to use. The 
transformation was then spread out using a Drigalski spatula.  
Liquid cultures were grown overnight, at 37°C with shaking at 200 rpm, in LB medium with 
the appropriate antibiotics (see section 3.10). 
 LB medium  10 g NaCl 
   10 g Bacto Tryptone (Difco) 
   5 g Yeast extract 
   Add H2O to 1 l, autoclave. 
 
 LB-agar 15 g Agar 
 plates  10 g NaCl 
   10 g Bacto Tryptone (Difco) 
   5 g Yeast extract 
   Add H2O to 1 l, autoclave, cool to 50°C and add antibiotic. 
   Pour the agar solution into 10cm Petri dishes, and store inverted at 4°C. 
 
 X-gal  40mg  X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) 
   In 1 ml DMF, store in a brown bottle at -20°C in the dark. 
 
4.1.1.2. Preparation of chemically competent E.coli 
The desired bacterial strain was streaked out on solid LB agar with antibiotic, grown 
overnight and a single bacterial colony was picked into 5 ml Ψ Broth. Bacteria were grown at 
37°C with shaking to an OD550 of 0.3, and the 5 ml culture was used to inoculate 100 ml 
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Ψ Broth prewarmed to 37°C. After growing to an OD550 of 0.48, cells were chilled on ice 
and pelleted at 1300 g and 4°C for 5-10 min. The pellet was loosened up by vortexing and 
resuspended in 30 ml ice-cold TfBI. After incubation on ice for 5 min, cells were collected by 
centrifugation (5 min, 4000 g, 4°C) and resuspended in 4 ml ice-cold TfBII. The suspension 
was dispensed into 50 µl aliquots and frozen at -80°C. 
Required buffers: 
  Ψbroth  2%  20 g Bacto Tryptone (Difco) 
   0.5%  5 g Bacto Yeast Extract (Difco) 
   0.4%  8,18 g MgSO4.7H2O 
   10 mM   0.745 g KCl 
   Adjust to pH 7.6 with KOH and add H2O to 1 l. 
 
 TfBI  100 mM  6.045 g RbCl2 
   50 mM  4.5 g MnCl2 
   30 mM  1.472 g KOAc 
   10 mM  0.735 g CaCl2.2H2O 
   15%  75 ml Glycerol 
   Adjust to pH 5.8 with 0.2 M HOAc 
   Add H2O to 500 ml, filter sterilize and store at 4°C. 
 
 TfBII  10 mM  1.047 g MOPS/NaOH, pH 7.0 
   10 mM  0.605 g RbCl2 
   75 mM  5.513 g CaCl2 
   15%  75 ml Glycerol 
   Add H2O to 500 ml, filter sterilize and store at 4°C. 
4.1.1.3. Transformation of chemically competent E.coli 
Chemically competent E.coli (50 µl) were thawed on ice, 1-25 ng plasmid DNA in 2-5 µl 
volume was added and the suspension was mixed gently and incubated on ice for 30 min. 
Cells were heat-shocked in a water bath at 42°C for 130 s, immediately cooled on ice for 
2 min and 250 µl SOC medium was added. To express the resistance, bacteria were incubated 
for 1 h at 37°C with shaking and 50-150 µl of the transformation were plated and incubated 
overnight  at 37°C on LB-agar containing the antibiotic necessary for selection of transformed 
cells.  
Required medium: 
 SOC medium 2%  20 g BactoTrypton (Difco) 
   0.5%  5 g BactoYeastExtract (Difco) 
   10 mM  0.6 g NaCl 
   3 mM   0.2 g KCl 
   Add H2O to 1 l, autoclave and add to the cooled solution: 
   10 mM  10 ml MgCl2 1M, sterile filtered 
   10 mM  10 ml MgSO4 1M,sterile filtered 
   20 mM  10 ml Glucose 2 M, sterile filtered. 
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4.1.1.4. Glycerol stock 
For long-term storage, bacteria were stored in 20% glycerol by adding 500 µl liquid culture to 
200 µl of 80% glycerol, mixing and freezing at -80°C.  
4.1.2. Plasmid isolation from E.coli 
To check if the isolated single E.coli colonies contained the correct plasmid, a DNA mini-
prep was carried out using NucleoSpin® Plasmid Quick Pure Kit from Macherey-Nagel 
following the supplied instructions. To isolate larger amounts of ultra pure DNA (100 µg) for 
transfection experiments, plasmids were isolated using QIAGEN Plasmid Midi, Maxi and 
Mega Kits. 
4.1.3. Molecular cloning 
Direct cloning of PCR-products was done using the TOPO-TA Cloning kit (Invitrogen) 
according to the manufacturer’s instructions. Alternatively DNA fragments were 
PEG-precipitated (see section 4.1.3.3) and the precipitate as well as the cloning vector were 
digested with the necessary endonuclease. For directional cloning, restriction sites were 
introduced by adding the appropriate recognition sequences to the primer sequences The cut 
fragment and vector were gel-purified (see section 4.1.3.4), and combined in a 10 µl ligation 
reaction at a 3- to 5-fold molar excess of insert to vector, using 25-50 ng of vector. Ligation 
was carried out overnight at 16°C with 1U T4 DNA ligase buffer. Two µl of the reaction was 
used to transform chemically competent E.coli (see sections 4.1.1.2 and 4.1.1.3).  
Successful insertion of the fragment into the vector was checked by preparing plasmid DNA 
from liquid cultures (see section 4.1.2). To check for correct insertion and sequence integrity, 
plasmid constructs were sequenced using vector-specific primers.  
4.1.3.1. PCR 
The polymerase chain reaction (PCR) allows in-vitro synthesis of large amounts of DNA by 
primed, sequence-specific polymerization of nucleotide triphosphates catalyzed by DNA 
polymerase. PCRs were generally performed in PCR tubes in 20-100 µl of reaction volume in 
a MJ research PTC 200 thermocycler (Biozym). The "calculated temperature" feature was 
used to decrease temperature hold times. The nucleotide sequences of the utilized primers are 
given in 3.4. The primer annealing temperatures varied between 57 and 65°C. 
Typical reaction parameters for analytical PCR were: 
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         Action        PTC 200 
Initial Melting 95°C 2 min 
 Melt 95°C 15 sec 
 Anneal 65°C 15 sec 20-35 Cycles
 Extend 72°C 1 min 
Final Extension 72°C 5-7 min
Cool to 15°C     ∞ 
 
If PCRs were performed from bacterial colonies, the initial melting step was prolonged to 
2 min. To avoid generating unspecific products during the first heating phase, reaction tubes 
were transferred into thermocycler, once the block temperature reached 95°C.  
Required: 
 DNA polymerase 0.04-0.67  U/µl Taq DNA polymerase or Expand High Fidelity 
      polymerase mix with the supplied reaction buffer 
 Primers   0.2-1 µM Sense-/antisense primers (10-100 µM) 
 dNTPs   0.2-0.25 mM dATP, dCTP, dGTP, dTTP (25 mM each). 
 
4.1.3.2. PCR-based site specific mutagenesis 
For site-specific mutagenesis of single sites, and to generate tagged-internally constructs, two 
overlapping fragments containing the desired mutation at their ends were generated by PCR 
using sense/antisense mutant primers (primer I-AS and primer II-S), which contained the 
mutation in the centre of the oligonucleotide together with fragment-specific (outer) primers 
featuring endonuclease restriction sites for directional cloning in two separate reactions 
(primer I-S and primer II-AS respectively). The PCR products were gel-extracted together to 
give 20 µl of gel extract (GE) which served as template for a second PCR employing the outer 
primers (Primer I-S and primer II-AS) to assemble the two fragments at their overlapping 
portion. The ensuing PCR product was PEG-precipitated and TOPO cloned into the pCR2.1 
vector. The insert was sequenced to confirm the incorporation of the mutation and the 
integrity of the sequence, then subcloned into the desired vector. 
To facilitate incorporation of the mutation into the PCR product, the first round of PCRs was 
performed with Taq polymerase which does not possess a 3’→5’ proofreading activity. For 
maximum accuracy, the second PCR was carried out using a DNA polymerase mix (Expand 
High Fidelity, Roche) with proofreading activity.  
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 PCR-Reactions:  PCR 1  PCR 2  PCR 3 
 DNA template   1 µg  1 µg  20 µl GE PCR1+2 
 10x Taq Buffer   10 µl  10 µl    - 
 10x HiFi Buffer     -    -  10 µl 
 dNTP (10 mM each)   2 µl  2 µl  2 µl 
 Primer I-S (10 pmol/µl)  5 µl    -  5 µl 
 Primer I-AS (10 pmol/µl)    -  5 µl  5 µl 
 Primer II-S (10 pmol/µl)     -  5 µl    - 
 Primer II-AS (10 pmol/µl) 5 µl    -    - 
 H20    to 98 µl  to 98 µl  to 98 µl 
 Taq    2 µl  2 µl    - 
 HiFi      -    -  2 µl 
 
To avoid producing amplification errors due to high cycle numbers, PCRs were performed in 
quadruplicates for 6, 9, 12 and 15 cycles and the product generated by the lowest number of 
cycles was used for the residual the procedure. PCRs were performed using the following 
program:  
         Action        PTC 200 
Initial Melting 95°C 3 min 
 Melt 95°C 15 sec 
 Anneal 65°C 20 sec 20-35 Cycles
 Extend 72°C 1:10 min
Final Extension 72°C 7 min 
Cool to 15°C     ∞ 
 
4.1.3.3. Precipitation of DNA using PEG 
To precipitate DNA from small volumes, e.g. PCR reactions or endonuclease digestion, one 
volume of PEG-mix was added to the DNA-containing solution, vortexed and incubated for 
10 min at RT. After centrifugation (10 min, 13000 rpm, RT), the supernatant was discarded 
and the precipitated DNA was washed by carefully adding 200 µl 100% EtOH to the tube 
wall opposite of the (often invisible) pellet, followed by a centrifugation step (10 min, 
13000 rpm, RT) and careful removal of the supernatant. The pellet was dried and resuspended 
in H2O at half to three-quarters of the initial volume. 
 PEG-mix 26.2 %  26.2 g PEG 8000 
   0.67 M  20 ml NaOAc (3 M) pH 5.2 
   0.67 mM  660 µl MgCl2 (1 M) 
   Add H2O to 250 ml. 
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4.1.3.4. Purification of DNA fragment by gel extraction 
DNA fragments were purified by running on an ethidium bromide-containing agarose gel, 
excising the band containing the fragment under UV illumination and subsequent gel 
extraction using QIAEX II Gel Extraction Kit (Qiagen) or NucleoSpin® Exract II following 
the manufacturer's instructions.  
4.1.3.5. Agarose gel electrophoresis 
The required amount of agarose as determined according to table 3.1 and table 3.2 was added 
to the corresponding amount of TAE (1x). The slurry was heated in a microwave oven until 
the agarose was completely dissolved. The ethidium bromide was added after cooling the 
solution to 50-60°C. The gel was cast and mounted in the electrophoresis tank and covered 
with TAE (1x). DNA-containing samples were diluted 4:1 with DNA loading dye (5x), mixed 
and loaded into the slots of the submerged gel. Depending on the size and the desired 
resolution, gels were run at 40-100 V for 30 min to 3 h. 
Required buffers: 
 TAE (50x)  2 M   252.3 g Tris 
    250 mM 20.5 g  NaOAc/HOAc, pH 7.8 
    50 mM  18.5 g EDTA 
    Add H2O to 1 l. 
 
 EDTA (0.5 M)  0.5 M  18.6 g EDTA/NaOH, pH 8.0 
    Add H2O to 100 ml. 
 
 DNA loading dye 50 mM  500 µl Tris/HCl, pH 7.8 
 DNA-LD (5x)  1%  500 µl SDS (20%) 
    50 mM  1 ml EDTA (0.5 M), pH 8.0 
    40%  4 ml Glycerol 
    1%  10 mg Bromophenol blue 
    Add H2O to 10 ml, and store at 4°C.  
 
 1.0% Agarose  1%  1 g Agarose (Biozym) 
    Add 1x TAE to 100 ml, and till agarose dissolves.  
    Cool to 50°C and add 2.5 µl Ethidium bromide (10 mg/ml) (Sigma). 
 
Table 4.1 Agarose concentration for different separation ranges   
 Efficient range of separation (kb)        Agarose in gel (%)
                        0.1-2                      2.0 
                        0.2-3                      1.5 
                        0.4-6                      1.2 
                        0.5-7                      0.9 
                        0.8-10                      0.7 
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4.1.3.6. Restriction endonuclease digestion 
To verify the presence and orientation of plasmid-insert, or to clone insert DNA into a 
plasmid, DNA was digested with appropriate restriction enzymes. Enzymes and their buffers 
were purchased from Roche or New England Biolabs (Germany). The digestion of plasmid 
DNA or PCR products was carried out using 5 U enzyme/1 µg DNA in 20 µl at 37°C for 
2 hours. Digestion of genomic DNA was performed overnight with 1.5 U/µg DNA in 30 µl 
reaction volume. 
4.1.3.7. Dephosphorylation of DNA with alkaline phosphatase 
To prevent the self ligation, digested vectors were treated with CIAP (calf intestinal alkaline 
phosphatase, Roche) at 37°C for 30 min before gel extraction. 
4.1.3.8. Fill in 5’-overhang with Klenow DNA-polymerase 
To ligate two DNA fragments cut with two incompatible enzymes, blunt ends were generated 
by filling the 5’- or the 3’-overhangs (see section 4.1.3.9). To fill in 5’-overhanging ends of 
DNA fragments, digested DNA was mixed with 1 µl of dNTPs (0.5 mM each), 4 U Klenow 
fragment and H2O to a total volume of 20 µl, and incubated for 15 min at 30°C. The 
inactivation of Klenow was done by heating for 10 min at 75°C. The DNA fragment with 
blunt ends was then either digested with a second enzyme or purified and used for ligation.  
4.1.3.9. Generation of blunt ends with T4 DNA-polymerase 
To fill in 3’-overhanging ends of DNA, T4 polymerase was used. Digested DNA was 
incubated with T4 polymerase at 11°C for 20 min. T4 polymerase was then inactivated for 
20 min at 70°C. 
4.1.3.10. DNA sequencing and sequence analysis 
Sequencing was performed by Entelechon or GeneArt (Regensburg, Germany). Database 
searches in GenBank were performed with BLAST v2.11.1 at the NCBI 
(URL: http://www.ncbi.nlm.nih.gov/BLAST/). 
4.1.3.11. Generation of different MMD tagged constructs 
Mouse MMD construct tagged C-terminally with 3xFLAG was prepared as following. Briefly 
mMMD cDNA, previously cloned into pGEM3, was amplified by PCR using 
“Tag241pIRES_S” and “Tag241pIRES_AS” primers, introducing NotI and XhoI restriction 
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sites respectively. In addition the Stop codon at the C-terminus of mMMD cDNA was 
removed to allow fusion of 3xFLAG-tag with mMMD protein. The PCR product was digested 
with NotI and XhoI and inserted into pIRES-hrGFP-1a vector upstream of 3xFLAG-tag 
sequence. MMD-3xFLAG construct was used as template to generate additional constructs. 
For this purpose, PCR reactions were performed with pIRES-MMD-3xFLAG as template and 
using different primer pairs, introducing NotI restriction site upstream of the ATG start codon, 
and XhoI downstream of the insert. PCR products were purified via gel extraction and cloned 
into the pCR2-1-TOPO vector. After sequence confirmation, the insert was cut with NotI and 
XhoI restriction enzymes and cloned into pIRES-hrGFP-1a vector. A schematic presentation 
of the cloning strategies are depicted in Figure 5.12.  
¾ Cloning of pIRES-HA-MMD 
To tag MMD N-terminally with an HA-eptitope, a PCR reaction was performed using 
“HA tag-S” primer containing NotI site followed by a start codon and HA-tag sequence. 
A stop codon was introduced at the C-terminus of mMMD with antisense “Mu2-stop-AS” 
primer to prevent the translation of 3xFLAG-tag (Figure 5.12C) 
¾ Cloning of pIRES-HA-MMD-3xFLAG 
For tagging MMD at the N- and C-terminus with HA and 3xFLAG respectively, the same 
PCR amplification reaction was performed as described above but using “Tag241pIRES_AS” 
antisense primer to allow transcription of 3xFLAG-tag (Figure 5.12B). 
¾ Cloning of pIRES-FLAG-MMD-HA 
To incorporate a single FLAG-tag (in contrast to 3xFLAG usually used) at the N-terminus 
and an HA-tag at the C-terminus of mMMD, a PCR reaction was performed with 
“Flag-tag-S” as sense primer inserting a NotI restriction site upstream of FLAG-tag. The 
antisense primer, “HAc-term-AS” incorporates the HA-tag sequence followed by a stop 
codon and a XhoI restriction site (Figure 5.12D).  
¾ Cloning of pIRES-HA-MMD(c-Myc2)-3xFLAG 
To incorporate an additional c-Myc-tag in the second extramembrane loop of MMD protein, a 
PCR-based site specific mutagenesis was done (see section 4.1.3.2). It consists in generating 
initially two PCR products with pIRES-MMD-3xFLAG as template. The first reaction was 
done using “HA-tag-s” and “myc-tag-AS” (containing c-Myc sequence) primers. The second 
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PCR reaction was performed using “myc-tag-S” and “Tag241pIRES_AS”. After gel 
extraction both PCR products were mixed and used as template for the third reaction done 
with primers “HA-tag_s” and “Tag241pIRES_AS” (Figure 5.12E).  
¾ Cloning of pIRES-MMD(c-Myc2)-3xFLAG 
In order to tag MMD with c-Myc at the second extramembrane loop and 3xFLAG on the 
C-terminus, a PCR-based site specific mutagenesis was performed, as described above using 
“Tag241pIRES_S” and “myc-tag-AS” primers for the first PCR, and “myc-tag-S” and 
“Tag241pIRES-AS” primers for the second PCR. After gel extraction of the PCR product, it 
was used as template in the third PCR done with primers “Tag241pIRES_S” and 
“Tag241pIRES_AS” (Figure 5.12F). 
¾ Cloning of pIRES-HA-MMD(c-Myc2) 
For the creation of this construct, the first PCR product of pIRES-HA-MMD(c-myc)-3xFLAG 
was mixed with a PCR product, generated using primers “myc-tag-S” and “MMD-stop-AS”. 
This mix was used as template for the third PCR reaction with primers “HA-tag-s” and 
“MMD-stop-AS” (Figure 5.12G).  
¾ Cloning of pIRES-MMD(c-Myc2)  
To generate a MMD tag construct with only c-Myc integrated in the second extramembrane 
loop, again a PCR site specific mutagenesis was carried out. The first PCR product of 
pIRES-MMD(c-myc)-3xFLAG was mixed with the second PCR product of 
pIRES-HA-MMD(c-myc), and used as template for a third reaction using primers 
“Tag241pIRES_S” and “MMD-stop-AS” (Figure 5.12I).  
¾ Cloning of pIRES-MMD(c-Myc1) 
In this construct c-Myc tag was integrated in the first extramembrane loop of MMD protein. 
Following the same PCR reactions as described above except that “myc1-tag-S” replaced 
“myc-tag-S” primer (Figure 5.12H). 
4.1.4. RNA related molecular methods 
It is important to prevent the introduction of RNases in all RNA related molecular methods. 
Therefore, gloves, RNase-free pipettes, tips and tubes were used. All aqueous solutions were 
prepared using water treated with diethylpyrocarbonate (DEPC). DEPC (0.1%) was added to 
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the water, mixed and incubated overnight to eliminate protein (including RNases). Afterwards 
the inactivation of DEPC by autoclaving twice for 20 min was necessary to eliminate its 
toxicity. 
4.1.4.1. Isolation of RNA by GTC-Phenol-Chloroform extraction 
Up to 1.5x107 cells were lysed per 3 ml of solution D. Adherent cells were directly lysed in 
the culture vessel followed by scraping with a sterile rubber policeman. Suspension cells, after 
pelleting and discarding the supernatant, were resuspended in the residual medium before 
addition of solution D. The lysate was transferred to sterile 14 ml centrifuge tubes, and DNA 
was sheared by passing the lysate 10 times through a 20G (0.9 mm x 40 mm) needle fitted to 
a syringe. Acetate (0.1 volumes of 2 M) was added to the lysate which at this point could be 
stored at -20°C. For each 1 ml solution D, 1 ml phenol and 0.2 ml CHCl3/IAA were added. 
The RNA was extracted into the aqueous phase by vigorous shaking, phase separation on ice 
(15 min) and centrifugation (20 min, 10000 g, 4°C). The upper aqueous phase was carefully 
aspirated without disturbing the protein-containing interphase and combined with an equal 
volume of cold 100% isopropanol in a fresh tube. Total RNA was precipitated by mixing 
thoroughly, incubation at -20°C for at least 1 h and centrifugation for 20 min at >10000 g and 
4°C. The supernatant was discarded, the RNA pellet dissolved in 0.3 ml per 1 ml lysate of 
solution D, transferred to a sterile 1.5 ml screw-cap micro centrifuge tube and precipitated a 
second time by adding an equal volume of isopropanol. After mixing and incubation for > 1 h 
at -20°C, a centrifugation step followed for 20 min at >10000 g and 4°C. The supernatant was 
discarded and the pellet was washed twice each with 1 ml of 80% ethanol (15 min, 10000 g, 
4°C), dried and dissolved in H2ODEPC. RNA yield and purity were determined on a 
spectrophotometer and its integrity was assessed by running 1 µg of RNA on an 
agarose/formaldehyde gel (intact RNA has a 28S:18S rRNA band intensity ration of 2:1, and 
the highest RNA density around 2 kb).  
Required solutions:  
 Solution D  4 M  47.2 g Guanidine thiocyanate (GTC) 
    25 mM  2.5 ml Sodium citrate 1 M/HCl, pH 7.0 
    0.5 %  1.67 ml Sodium N-lauroylsarcosine solution (30%) 
    Add H2ODEPC to 100 ml, store at 4°C for up to 3 months. 
    Add 7.2 µl/ml β-mercaptoethanol (fume hood) directly before use. 
 
 2 M Acetate  2 M  16.4 g NaOAc⋅3H2O  
    Dissolve in 40 ml H2ODEPC, adjust to pH 4.0 with 2 M 




 Phenol  unbuffered,  Melt redistilled phenol in water bath 
 saturated with   Add   0.1% 8-Hydroxyquinoline 
 H2ODEPC:   2x  40% H2ODEPC 
    Shake well and let sit overnight. 
    Top water layer should be ¼ of the phenol phase. 
  
 CHCl3/IAA (49:1) 1x  vol   2 ml Isoamyll-alcohol 
    49x vol  98 ml Chloroform 
 100% Isopropanol Stored at 4°C 
 
 80% Ethanol  80 %  80 ml Ethanol 
    Add H2ODEPC to 100 ml, chill on ice. 
 
4.1.4.2. Isolation of total RNA with Qiagen RNeasy Midi Kit 
Alternatively, for Northern blots and microarray analysis, RNA was isolated using the 
RNeasy Mini and Midi Kit (Qiagen) according to the manufacturer's instructions. 
4.1.4.3. Formaldehyde agarose gel 
The agarose was dissolved in MOPS/H2ODEPC by heating in a microwave oven, and cooled to 
60°C. Formaldehyde was added while stirring the solution under a fume hood and the gel was 
cast, mounted in an electrophoresis tank and overlaid with 1x MOPS as electrophoresis 
buffer. RNA samples were prepared by diluting with four volumes RNA loading buffer (1:4), 
denaturing for 20 min at 65°C and brief incubation on ice. Samples were centrifuged and 
loaded into the gel slots. Gels were run at 40-60 V; for subsequent Northern blotting, they 
were run overnight at 13-16 V. 
Required buffers: 
 MOPS (20x)  0.4 M   42 g MOPS/NaOH, pH 7.0 
    100 mM  4.1 g NaOAc 
    20 mM  3.7 g EDTA 
    Add H2ODEPC to 500 ml, stored in the dark. 
 
 RNA loading buffer 50%  10 ml Formamide, deionised 
    2.2 M  3.5 ml Formaldehyde (37%) 
    1x  1 ml MOPS (20x) 
    0.04%  0.8 ml Bromophenol blue (1% in H2O) 
    1%  0.2 g Ficoll 400, Pharmacia (dissolve in 2 ml H2O) 
    Add H2ODEPC to 20 ml, stored in 1 ml aliquots at -20°C 







4.1.4.4. Northern blot - RNA transfer 
Following separation on formaldehyde/agarose gels, the RNA was transferred to nylon 
membranes by capillary elution. A nylon membrane (Magna NT, MSI) was cut to gel size, 
wetted with H2O, and briefly soaked in 20x SSC. The RNA gel was placed upside-down on 
two layers of 20x SSC-soaked Whatman 3MM filter papers on a glass plate, the ends of which 
were reaching into a buffer reservoir placed below and filled with 20x SSC. The membrane 
was laid on top of the gel, avoiding to trap air bubbles. One corner of the membrane was 
marked by cutting it off. Plastic stripes were placed on the membrane borders to avoid 
short-circuiting the capillary flow past the membrane to the two layers of 20x SSC-soaked 
Whatman filters which were put on top of the membrane and the plastic covers. A 6-8 cm 
stack of cellulose wadding was placed on top to draw the 20x SSC through the gel and the 
membrane. The cellulose was weighed down with a glass. After an overnight transfer, 
completeness of the transfer was checked under UV illumination. The gel lanes, 18S and 28S 
rRNA bands were marked with a soft pencil. RNA was fixed to the membrane by 
UV-crosslinking with 1.20x106 mJ/cm2 (Autocrosslink) in a Stratalinker. 
Required buffer: 
 SSC (20x)  0.3 M   88 g Na3Citrate⋅2H2O/HCl, pH 7.0 
    3 M   175 g NaCl 
    Add H2O to 1 l and autoclave. 
 
4.1.4.5. Northern blot hybridization 
Northern blot prehybridization and hybridization steps were pursued with ULTRAhyb™ 
solution (Ambion) because of its high sensitivity and low background. Northern blot 
membranes were prehybridized in a total volume of 25 ml ULTRAhyb solution (prewarmed 
at 65°C) with continuous shaking at 42°C for 3 h. The radioactive probe was denaturated for 
10 min at 95°C and chilled out on ice for 2 min. It was then added (2.5x106 cpm/25ml) 
directly to the prehybridization solution. Blots were hybridized overnight at 42°C, the 
following day rinsed twice each with fresh NWB1 for 5 min at RT. The overall radioactivity 
was then measured with a Geiger counter. Blots with values over 0.1-5 Bq/cm2 were further 
rinsed with NWB2 at 50°C till the overall radioactivity was reduced. Thereafter blots, with a 
small amount of wash buffer, were heat-sealed in plastic bags, fixed with adhesive tape in an 
exposure cassette with a storage phosphor screen and exposed for up to three days. The screen 
was later scanned using a Typhoon™ phosphoimage (Amersham Biosciences, Germany). 
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MTN blots contain 2 µg polyA+ RNA per lane, which allows a specific and sensible detection 
of RNA transcripts in various tissues. 
Required buffers: 
 Northern Wash Buffer 1 2x SSC  SSC (20x) 
 (NWB1)   0.05% SDS SDS (20%) 
 
 Northern Wash Buffer 2 0.1x SSC SSC (20x)  
 (NWB2 )   0.1% SDS SDS (20%) 
 
4.1.4.6. Stripping Northern blots 
For rehybridization of blots with different DNA probes, the radioactively labeled DNA was 
removed by stripping the membrane. This was done by incubating it in heated H2O (90°C) 
with 0.5% SDS for 10 min. Afterwards, blots were dried and kept ready for a subsequent 
hybridization, or were stored at -20°C for later use. 
4.1.4.7. Generation of specific radioactive DNA probes 
To generate probes for hybridization of Northern blots, DNA fragments were PCR-amplified 
from the 3’-untranslated Region (UTR) of MMD cDNAs, where the lowest similarity grade 
between the homologues was found. This is important to prevent cross-hybridization between 
MMD and MMD2 in mouse and human. As a template cDNA, mouse MMD cDNA was 
previously cloned into pGEM3 vector in our lab. Mouse MMD2 (in pBS vector), human 
MMD and MMD2 (in pCMV-SPORT6) cDNAs were purchased from the German Resource 
Center for Genome Research (RZPD) under the following clone IDs: 
• Mouse MMD2:  IRAKp961O 0461Q2 
• Human MMD: IRAKp961D1732Q2 
• Human MMD2: IMAGp998H2211791  
Afterwards the PCR products were labelled with 32P by Hartman Analytic (Braunschweig, 
Germany). 
4.1.4.8. Reverse transcription (RT) and quantitative real time-PCR (qRT-PCR) 
To quantify mRNA transcript of tagged-mMMD in stably transfected NIH3T3 cells (see 
section 5.3.2.1), or of mMMD in BMM after stimulation (see section 5.2.3), and in cell lines 
after siRNA silencing (see section 5.5), qRT-PCR was performed. For this purpose, total 
RNA was first transcribed. This was achieved by using the M-MLV reverse transcriptase 
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(Promega, Germany) combined with the random decamers (Ambion, Germany) in a total 
reaction volume of 20 µl. The reaction was pursued as follows: 
 RT PCR reaction:  1 µg Total RNA 
    1 µl Random decamers 
    1 µl  dNTPs (10 pmol/ml) 
    Add H2OUSB, incubate for 5 min at 65°C, cool on ice, and centrifuge 
    4 µl  M-MLV Buffer (5x)  
    Mix, and incubate for 2 min at 42°C  
    1 µl M-MLV Reverse transcriptase 
    Incubate for 50 min at 42°C followed by 15 min at 70°C.  
 
Quantitative RT- PCR was performed using QuantiTect SYBR green kit (Qiagen, Germany) 
and the LightCycler® apparatus (Roche, Germany) following the manufacturer’s instructions. 
The primers used in the PCR reaction were generated by Metabion.  
The quantitative real-time PCR program was: 
          Action    LightCycler 
Initial Melting   94°C  15 min 
 Melt   94°C  15 sec 
 Anneal   57°C  15 sec    55  Cycles
 Extend   72°C  25 sec 
Melting point   60°C  90°C 
Cool to   4°C     ∞ 
 
The amplification was carried out in a total volume of 20 µl containing 10 µl SYBR green 2x 
PCR mix, 1 µl of each of the sense and antisense primers, and 2 µl of the cDNA (5-fold 
diluted). A standard curve was generated for each primer pair by amplifying four dilutions (1; 
1:10; 1:50; 1:100) of the most concentrated sample (also 5-fold diluted). The Hprt 
housekeeping gene served as an internal control and was used to normalize for differences in 
the amount of cDNA. The slope of the standard curve was an indicator of the amplification 
efficiency, and should be between 3.3 and 3.8. Standard curves were subsequently used to 
calculate the relative abundance of each transcript in each sample. The measurements were 






4.1.5. Gene silencing by short interference RNA  
siRNA involves the use of dsRNA to target a post-transcriptional degradation of the mRNA 
of the gene of interest, thereby inhibiting the protein synthesis and leading to gene silencing. 
Short siRNA duplexes (22-23 nucleotides) are the effector molecules. Once introduced into a 
cell, they are incorporated into a nuclease complex to form the so called RNA induced 
silencing complex (RISC). RISC targets the endogenous homologous transcript by base pair 
interaction cleaving the mRNA (Elbashir et al., 2001). 
siRNA silencing experiment of mouse MMD was conducted using siRNA duplexes purchased 
from QIAGEN (Germany). siRNA duplexe (30 pmol) was transfected into NIH3T3 or 
RAW264.7 cell lines (1.5x105 cells/well) using Invitrogen Lipofectamine™ RNAiMAX 
transfection reagent following the manufacturer’s instructions. As negative control, a non 
silencing duplexe was provided and separately transfected. At different time points after 
transfection (48, 72 and 96 h) cells were harvested and used to isolate total RNA, which were 
reverse transcribed into cDNA. Afterwards, mMMD expression was controlled by performing 
a qRT-PCR analysis (see section 4.1.4.8).  
4.1.6. Whole-mount in situ hybridization 
Whole-mount in situ hybridization (ISH) was performed to determine the spatial and temporal 
distribution of MMD and MMD2 in mouse embryo. Therefore embryos were isolated, 
pretreated and hybridized to digoxigenin (DIG) labeled RNA. Detection was performed by 
using an enzyme-conjugated antibody to DIG (Ausubel Frederick et al., 2006). 
4.1.6.1. Isolation of embryos 
Mouse embryos were dissected free of any extra-embryonic membranes at 10, 11, and 13 dpc 
(day post coitus) (see section 4.5.2.2). In order to preserve their morphology, they were 
fixated in a 6-well culture plate with 5 ml 4% PFAPBS overnight at 4°C, and afterwards 
washed twice in PBT at RT for 5 min before proceeding with the dehydration.  
¾ Dehydration:  
To improve the permeabilization of the tissues and increase the sensitivity of the ISH, fixed 
embryos were dehydrated by successive washes in 25%, 50%, 75% and 100% methanol/PBT 
at RT for 5 min each. It is possible to store fixed embryos in 100% methanol at -20°C for up 
to 3 months. Before proceeding with the rehydration step, brain ventricle cavities were 
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punctured carefully in order to avoid a high background signal due to trapped antibodies in 
these cavities.  
¾ Rehydration:  
To rehydrate the embryos, a reverse order of the methanol/PBT series was performed, and 
samples were then washed twice in PBT at RT for 5 min.  
¾ Proteinase K treatment and postfixation:  
In order to facilitate the hybridization of the riboprobe with its complementary RNA, embryos 
were treated with proteinase K (10 µg/ml PBT) at 37°C. The length of the treatment depends 
on the embryos age in dpc. Late-stage embryos are more difficult to permeabilize. 
• For embryos at 10 dpc:  13 min 
• For embryos at 11-13 dpc:  15 min 
Digestion was stopped by adding freshly prepared glycin (2 mg/ml in PBT) (Sigma) and 
incubating for 10 min at RT. After washing twice each for 5 min in PBT, embryos were 
postfixed with freshly prepared 0.2% glutaraldehyde/4% paraformaldehyde in PBT for 20 min 
at RT. This step was necessary to stabilize digested tissues and conserve their morphology 
during subsequent hybridization. After washing (2x 5 min with PBT at RT), embryos were 
separated and each transferred carefully to a 1.5 ml microfuge tube to proceed with 
hybridization (see section 4.1.6.3). 
Required reagents: 
 4% PFA  4%  4 g Paraformaldehyde (PFA) 
    Add 66 ml warmed H2ODEPC (60°C), cover and stir. 
    In the fume hood add 1 drop 2 N NaOH, the solution will clear. 
    Add 33 ml 3x PBS, adjust pH to 7.2 with HCl. 
    Cool to RT, aliquot and store at -20°C.  
 
 20% PFA  20%  20 g Paraformaldehyde (PFA) 
    Prepared as a 4% PFA solution. 
    Aliquot and store at -20°C. 
 
 PBT (1x)  1x  100 ml PBS (1x) (Gibco) 
    0.1%  200 µl Tween 20. 
 
 0.2% Glutaraldehyde 0.2%  120 µl Glutaraldehyde (25%) (Sigma) 
 /4% PFA  4%  3 ml PFA (20%) 





4.1.6.2. Synthesis of sense and antisense RNA probe 
Sense and antisense DIG-labeled RNA probes were generated using an RNA in vitro 
transcription kit (Roche). The cDNA containing plasmid template was linearized by digestion 
with the appropriate restriction enzyme 5’ or 3’ of the cDNA region of interest, to prepare 
sense or antisense RNA probes, depending on the orientation of the cDNA in the plasmid.  
MMD cDNA, cloned in pGEM3 vector, was cut either with XbaI or HindIII restriction 
enzymes to be used as template for the RNA in vitro transcription reaction to generate 
MMDas and MMDs probes respectively. MMD2 cDNA purchased in pCMV-SPORT6 vector 
(RZPD, Germany) was cut either with EcoRI or NotI to generate MMD2as and MMD2a 
probes respectively (Table 4.2; Figure 4.1). 
 
Table 4.2 DNA template and restrictions enzymes used for the generation DIG-RNA probes.  
     DIG-RNA probe       DNA template   Restriction enzyme     RNA polymerase 
MMD antisense pGEM3-MMD                 XbaI                Sp6 
MMD sense pGEM3-MMD               HindIII                T7 
MMD2 antisense pCMV-Sport6-MMD2                EcoRI                T7 
MMD2 sense pCMV-Sport6-MMD2                  NotI                Sp6 
 
  
Figure 4.1 Structure of pGEM3-MMD and pCMV-SPORT6-MMD2 vectors. 
MMD and MMD2 inserts are depicted in the MCS of the template vector. T7 and Sp6, are RNA 
polymerase promoters used in the in vitro RNA transcription. 
Digested template DNA was examined by agarose gel electrophoresis to confirm that the 
cleavage was complete, phenol/chloroform extracted, precipitated with 1/10 3 M Na-acetate 
pH 5.2, plus 2 volumes 100% ethanol. The DNA pellet was dissolved in 20 µl H2ODEPC.  
In vitro DIG-labeling of RNA probes was performed in 20 µl reaction according to Roche’s 
protocol. Reagents were mixed at RT in the order described below, and incubated at 37°C for 
2 h. RNA transcript was synthesized from linearized DNA template using bacteriophage 
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polymerase, and later purified by Na-acetate/Ethanol precipitation. DIG-labelled RNA probes 
were stored at -80°C.  
 Probe labelling 1x  2 µl 10x transcription buffer  
 reaction:  20 U  0.5 µl RNase inhibitor  
    1x  2 µl 10x DIG-nucleotide mix  
    2 µg  2 µl linearised DNA (1 µg/µl) 
    Add 11.5 µl H2ODEPC. 
    2 µl  T7 or Sp6 RNA polymerase. 
    Reagents were mixed in the described order at RT 
    2 h incubation at 37°C. Add the following: 
    40 U  1 µl RNase inhibitor 
    10 U  1 µl RNase free DNase 
    15-30 min incubation at 37°C. 
    Add 180 µl H2ODEPC, and the following: 
    10 µg/µl 1 µl tRNA 
    10%  20 µl Na-acetate (3M), pH 5.2 
    3x volume 600 µl 100% ethanol  
    Mixed and incubated at -70°C for at least 30 min 
    Spined at 12000 rpm at 4°C for 20 min. 
    Pellet dissolved in 40 µl H2ODEPC. 
 
4.1.6.3. Hybridization procedure on whole-mount 
¾ Prehybridization: 
Each embryo was incubated in 500 µl prewarmed hybridization solution (Hyb.mix) for 1 hour 
at 70°C to block non-specific hybridization sites.  
¾ Hybridization:  
Digoxigenin-labeled riboprobe (0.5 µg) (see section 4.1.6.2) was denaturated at 80°C for 
2 min and transferred directly from the heating block to 500 µl prewarmed fresh Hyb.mix 
replacing the old Hyb.mix solution in the embryo tube. The hybridization followed overnight 
at 70°C.  
Required solution:  
 Hyb. mix solution 50%  50 ml deionised formamide (Roche) 
    5x  25 ml SSC (20x), pH 4.5 
    50 µg/ml 500 µl tRNA (10 mg/ml) (Roche) 
    1%  5 ml SDS (20%) 
    50 µg/ml 100 µl Heparin sodium (50 mg/ml) H3393 (Sigma) 







4.1.6.4. Post-hybridization and detection procedures 
¾ Post-hybridization washes:  
The hybridization solution was removed and embryos were carefully washed with 1 ml 
solution I, II and III as follows: 
• 2x 30 min with solution I (prewarmed to 70°C) at 70°C. 
• 1x 10 min with solution I + solution II (1:1) (prewarmed to 70°C) at 70°C. 
• 3x 5 min with solution II at RT. 
• 1x 30 min incubation in solution II + 100 µg/ml RNase A at 37°C. 
• 1x 5 min with solution II at RT. 
• 1x 5 min with solution III at RT. 
• 2x 30 min with solution III (prewarmed to 65°C) at 65°C. 
¾ Blocking and antibody incubation: 
After removal of nonspecifically bound riboprobes, embryos were washed carefully 3x 5 min 
with MAB at RT, to equilibrate the samples. A 3 hours incubation step followed in 
MAB/BR/NSS reagent at RT, to block nonspecific antibody binding.  
Embryos were then incubated with anti-DIG-AP Fab fragment solution (previously prepared) 
overnight at 4°C. The next day, samples were washed 3x 5 min at RT with MAB (cooled at 
4°C). Embryos were then transferred into 15 ml tubes and further washed with MAB every 
hour all day at RT, to be left in the buffer overnight at 4°C with very gentle agitation. 
¾ Visualization of hybridized RNA: 
MAB was removed carefully and embryos were washed 3x 10 min with NTMT at RT, later 
transferred into a 12-well plate and incubated with BM purple AP substrate (Roche) 
containing Levamisol (0.5 mg/ml) for 5 h at dark. After the signal has developed embryos 
were washed with PBT, and stored in 4% PFA/PBS at 4°C. 
Required solutions: 
 Solution I  50%  20 ml Formamid (Roche) 
    5x  8 ml SSC (20x), pH 4.5 
    1%  4 ml SDS (10%) 
    Add H2ODEPC to 40 ml. 
 
 Solution II  0.5 M  8 ml NaCl (5M) 
    10 mM  0.8 ml Tris (1M), pH 7.5 
    0.1%  80 µl Tween 20 
    Add H2ODEPC to 80 ml. 
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 Solution III  50%  20 ml Formamid  
    2.5x  4 ml SSC (20x), pH 4.5 
    Add H2ODEPC to 40 ml. 
 
 Maleic acid buffer 100 mM 11.6 g maleic acid 
 (MAB)   150 mM  8.8 g NaCl  
    Add H2ODEPC to 900 ml, adjust pH to 7.5 with ~20 ml NaOH (10 N) 
    0.1%  1 ml Tween 20 
    2 mM  500 mg Levamisole (Sigma L-9756) 
    Add H2ODEPC to 1000 ml. 
 
 MAB/BR  2%  200 mg Blocking reagent (BR) (Roche) 
    Add 9 ml MAB, dissolve at 70°C and cool on ice. 
 
 MAB/BR/NSS  10%   1 ml Normal Sheep Serum (NSS) (Sigma S-3772) 
    Add MAB/BR to 10 ml. It should be prepared fresh on day of use. 
 
 MAB/Ab  10%  5 µl NSS 
    1.5 U  2 µl AP-conjugated anti-Digoxigenin (Roche) 
    Add 500 µl MAB/BR, and incubate for 1h at 4°C. 
    Antibody was recovered by spinning for 10 min at 4°C. 
    Add to the supernatant 6 ml MAB/BR and 60 µl NSS (1%), vortex. 
  
 NTMT   100 mM 2 ml NaCl (5M) 
    100 mM 10 ml Tris.Cl (1M), pH 9.5 
    50 mM  5 ml MgCl2 (1M) 
    0.1%  0.1 ml Tween 20 
    Add to 100 ml H2ODEPC. NTMT should be fresh prepared. 
 
4.2. Protein biochemical methods 
4.2.1. Preparation of cell protein extracts from mammalian cells 
4.2.1.1. Extraction of whole cellular protein  
NIH3T3 cells were scrapped, and washed twice with cold PBS to remove residual proteins of 
the FCS that cause high background signals by binding unspecifically the antibody. The cell 
pellet volume was estimated, after removing the supernatant completely, and the pellet was 
resuspended on ice with 1x volume sample buffer (2x). Samples were denatured by 
incubating at 95°C for exactly 3 min, centrifuged at 10000 rpm for 1 min and stored on ice or 








 Sample buffer (2x) 20%  10 ml Glycerol 
    125 mM 5 ml Tris buffer (1.25 M), pH 6.8 
    4%  2 g SDS 
    10%  5 ml 2-mercaptorethanol 
    0.02%  10 mg Bromophenol blue 
    Add to 50 ml H2O and dissolve. Stored at 4°C. 
 
4.2.1.2. Extraction of cellular membrane protein  
In order to extract only membrane protein, NIH3T3 cell pellet was prepared as described 
above and gently resuspended on ice in 1x volume of ice-cold EP-w/o. Two volumes of ice-
cold EP-NP was added, the sample was incubated on ice for 15 min and centrifuged at 
13000 rpm for 5 min at 4°C. The supernatant containing the cytoplasmic fraction was 
collected, mixed with 1x volume sample buffer (2x) and incubated at 95°C for exactly 3 min. 
Required buffers (prepared fresh on day of use and stored on ice): 
 Extraction buffer: 100 mM 1 ml Tris (1 M) pH 7.4 
  (EP) 2x  4 mM  200 µl EGTA (0.2 M) 
    2 mM  20 µl MgCl2 (1 M) 
    Add H2O to 10 ml.  
 
 EP-w/o(1x):  1x  500 µl EP (2x) 
 (freshly prepared) 1 mM  10 µl DTT (100mM) 
    2.5 µg/ml 2.5 µl Leupeptin (1 µg/µl) 
    1 µg/ml 1 µl Pepstatin (1 µg/µl)  
    2 µg/ml 1 µl Aprotinin (2 µg/µl) 
    1 mM  10 µl PMSF (100 mM) 
    1 mM  10 µl Sodium-o-vanadate (100 mM) 
    Add H2O to 1 ml (465 µl).  
 
 EP-NP (1x)  same as EP-w/o 
    1%  100µl NP-40 (10%) 
    Add H2O to 1 ml (365 µl). 
 
4.2.2. Discontinuous SDS-PAGE 
Protein samples were separated by using a discontinuous gel system, which is composed of 






Table 4.3 SDS-PAGE stock solutions 
Stock solution Separating gel stock solution  Stacking gel stock solution 
Final AA concentration                   13.5% 5% 
Stacking gel buffer                       - 25 ml 
Separating gel buffer                    25 ml    - 
SDS (10%)                    1 ml 1 ml 
Rotiphorese Gel 30 (30%)                   45 ml 16.65 ml 
H2O         Add H2O to 100 ml 
 
Table 4.4 SDS-PAGE gel mixture 
Stock solution Separating gel 13.5%         Stacking gel 5% 
Stock solution                    10 ml  5 ml 
TEMED                    10 µl  5 µl 
AP (10%) fresh prepared                    50 µl  40 µl 
  
The separating gel was cast the day before electrophoresis, and overlaid with water-saturated 
isobutanol until polymerized. Isobutanol was exchanged for separating gel buffer diluted 1:3 
with water and the gel was stored overnight at 4°C. The following day, the stacking gel was 
poured on top of the separating gel, and the comb inserted immediately. After polymerization, 
the stacking gel was mounted in the electrophoresis tank, which was filled with 1x Laemmli 
buffer. Meanwhile, the protein lysate (prepared as described above) was thawed on ice, 
cleared by centrifugation and loaded in the wells. The gel was run with 25 mA/110 volts till 
the sample buffer bands reached the surface of the stacking gel, then the current was increased 
to 200 volts and the gel was run for 2-4 h. Proteins were then resolved through the separating 
gel according to their size. 
Required buffers and solutions. 
 Separating gel buffer 1.5 M  90.83 g Tris/HCl, pH 8.8 
    Add H2O to 500 ml. 
  
 Stacking gel buffer 0.5  M  30 g Tris/HCl, pH 8.8 
    Add H2O to 500 ml. 
 
 SDS (10%)  10%  10 g SDS 
    Add H2O to 500 ml. 
  
 Ammonium persulfate 10%  100 mg Ammonium persulfate 






 Laemmli buffer (5x) 40 mM  15 g Tris 
    0.95 M  21 g Glycin 
    0.5%  15 g SDS 
    Add H2O to 3000 ml. 
 
4.2.3. Western blot analysis 
After separation by SDS-PAGE, proteins were blotted electrophoretically onto PVDF 
membrane (Immobilon-P, Millipore) using a three-buffer semi-dry system. The membrane 
was cut to gel size, moistened first with methanol followed with buffer B, and placed on top 
of two sheets each of 3x Whatman3MM filter paper soaked with buffer A (bottom, on the 
anode) and buffer B, respectively. The SDS-PAGE gel was removed from the glass plates, 
immersed in buffer B and placed on top of the membrane. Another 3x Whatman 3MM filter 
papers soaked with buffer C were placed on top of the gel followed by the cathode. Air 
bubbles in-between the layers were avoided. Protein transfer was conducted for 1 h at 
0.8 mA/cm2 gel surface area.  
Required buffers and materials: 
 Buffer A  0.3 M  36.3 g Tris, pH 10.4 
    20%  200 ml Methanol 
    Add H2O to 1000 ml. 
 
 
 Buffer B  25 mM  3.03 g Tris, pH 10.4 
    20%  200 ml Methanol 
    Add H2O to 1000 ml.  
 
 Buffer C  4 mM   5.2 g ε-amino-n-caproic acid, pH 7.6 
    20%  200 ml Methanol 
    Add H2O to 1000 ml. 
 
4.2.4. Immunostaining of blotted proteins 
Blotted membranes were blocked either with 5% milk in PBST (for FLAG and c-Myc 
staining) or in TBST +1% BSA (for HA staining) for 1 h at RT then washed once for 5 min 
with PBST or TBST before incubation at RT for 1 h with the primary antibody. After washing 
3x 10 min with the appropriate washing buffer, the membrane was incubated for 1 h at RT 
with a horseradish-peroxidase (HRP)-coupled secondary antibody, detecting the isotype of the 
first antibody. The working concentrations and conditions of each antibody are given in the 
following table. A last 3x 10 min washing steps preceded the visualization of bound antibody 
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using ECL kit. Blots were exposed to an autoradiography film (HyperfilmTM ECL, 
Amersham) for 5 seconds to 30 min depending on the signal intensity. 
Table 4.5 Antibody dilution for Western blot analysis. 
Primary antibody Dilution factor Secondary antibody Dilution factor 
Mouse anti-Flag M2  1:4000 in 5% milkPBST Rabbit anti mouse HRP 1:10 000 in 5% milkPBST
Rat anti-HA 1:100 in 1% BSATBST Rabbit anti-rat HRP 1:1500 in 5% milkTBST 
Mouse anti-c-myc 1:200 in 5% milkPBST Goat anti mouse HRP 1:10 000 in 5% milkPBST
 
Required buffers and materials: 
 TBS (2x)  20 mM  9.16 g Tris /HCl, pH 7.4 
    150 mM  35.1 g NaCl 
    Add H2O to 2000 ml. 
 TBST (1x)  1x  500 ml TBS 
    0.1%  1 ml Tween 20  
    Add H2O to 1000 ml. 
 
4.2.5. Immunocytochemistry 
NIH3T3 cells were transiently transfected (see section 4.4.1) with various tagged MMD in 
Lab-TekTM 2-wells chamber slides (Nalge Nunc International, USA) and further stained as 
described below. Additionally, to examine the orientation of MMD within the lipid membrane 
bilayer, NIH3T3 cell lines stably over-expressing tagged MMD were generated using a 
retroviral transfection system (see section 4.4.2). NIH3T3 cells were seeded in chamber slides 
(5x104 cells/chamber) and cultured at 37°C for 48 h to reach around 80% confluency before 
proceeding with the staining. Coating of chamber slides with a 0.2% gelatin solution before 
cell seeding improved the cell adherence during the staining procedure. 
4.2.5.1. Fixation and permeabilization 
Cells were washed twice with PBS at RT, then fixed on ice for 8 min with 
2% paraformaldehyde (PFA) (freshly prepared from a 4% stock solution), followed by 
3x 5 min washing with PBS at RT. Afterwards cells were either incubated with ice cold 
acetone/methanol (1:1) for 1 min to achieve a complete membrane permeabilization or with 
digitonin for selectively perforating the plasma membrane.  
Digitonin is a mild non-ionic detergent that aggregates with cholesterol creating pores in the 
lipid membranes. Since the endoplasmic reticulum (ER) contains a reduced amount of 
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cholesterol compared to the plasma membrane, digitonin is capable, at low concentration and 
short incubation, to disrupt the plasma membrane leaving the ER intact. Digitonin solution 
should be fresh prepared. Short incubation between 10 and 20 seconds was enough to disrupt 
the cytoplasmic membrane of NIH3T3 leaving the ER membrane intact. 
Required solutions:  
 Gelatine  0.2%  0.2 g Gelatine (Sigma) 
   Add H2O to 50 ml and autoclave.  
  
 Digitonin  0.003% 0.003 g Digitonin (Sigma) 
   Add 100% ethanol to 100 ml and dissolve by vortexing. 
   Fresh prepared. 
4.2.5.2. Blocking and antibody staining 
After permeabilization, cells were washed 3x 5 min with PBS, and blocked in blocking buffer 
for 1 h at 4°C. They were then stained with the primary antibody, washed 3x 10 min with PBS 
to remove unbound antibodies, followed by the fluorescence-labelled secondary antibody 
incubation in the dark. The incubation with antibodies followed in blocking buffer for 1 h at 
4°C and their concentrations are given in the following table. Cells were then washed 
3x 10 min with PBS and for staining of lysosomes incubated with FITC-conjugated LAMP-1 
antibody (CD107a) in a 1:1000 dilution in blocking buffer for 1 h at 4°C. For nuclei staining, 
cells were incubated with DAPI working solution at RT for 3 min in the dark. After final 
washing steps of 3x 5 min, the upper structure of the chamber slide was removed, slides were 
mounted with DakoCytomation Fluorescent mounting medium (Dako, Hamburg), and stored 
at 4°C in the dark until pictures were taken at the fluorescence microscope “Axioskop 2 plus” 
from Zeiss. 
Required buffer and solution: 
 Blocking buffer  3%  3 g BSA (Sigma) 
    2.5%  2.5 ml FCS  
    Add PBS to 100ml. Prepared fresh.  
 DAPI working   5 ng /ml 1 µl DAPI (0.5 µg/ml) (Sigma) 
 solution  Add 99 µl Glycerin /PBS (1:3).  
    Prepared fresh and stored in the dark. 
 
Table 4.6 Antibody dilution for immunocytochemistry 
Primary antibody Dilution factor            Secondary antibody Dilution factor 
Mouse anti-Flag M2         1:2500  Alexa Fluor® 546 goat anti-mouse          1:1000  
Rat anti-HA        1:400  Alexa Fluor® 546 goat anti-rat         1:1000  
Mouse anti-c-myc        1:200  Alexa Fluor® 546 goat anti-mouse          1:1000  
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4.3. General cell culture methods 
4.3.1. Cell culture conditions and passaging 
4.3.1.1. Cell culture medium and supplements 
If not noted otherwise, cells were cultured in RPMI 1640 (PAA) or DMEM (Gibco) 
supplemented with 10% inactivated FCS, L-Glutamine (2 mM), sodium pyruvate (1 mM), 
antibiotics (50 U/ml penicillin and 50 µg/ml streptomycin), 2 ml vitamins and non-essential 
amino acids and 50 µM β-mercaptoethanol (Table 4.7). FCS was previously incubated at 
56°C for 30 min in order to inactivate the complements. An exceeding incubation time and a 
higher temperature should be avoided because some other necessary heat sensitive growth 
factors could be damaged. Each batch of FCS was tested before use. 
Table 4.7 Cell lines growth and subculture conditions. 
Cell lines Growth medium Subculture conditions 
RAW264.7 RPMI (Biochrom) Split by scraping 
NIH3T3 DMEM high glucose (PAN) Split by trypsination 
HEK293T DMEM + GlutaMax (Gibco)  Split by trypsination  
BV-2 DMEM (Gibco) Split by scraping 
J-774A.1 DMEM (Gibco) Split by scraping 
P815 RPMI (Biochrom) Shaking the flask 
HT-2 RPMI (Biochrom) + IL-2 Cell in suspension 
 
4.3.1.2. Cell passaging 
Cell cultures were split 1:4 to 1:8 in fresh medium every 2-4 days. Adherent cells were 
washed once with PBS and either scrapped or disaggregated by incubation with 0.05% 
Trypsin /0.02% EDTA/PBS (3 ml per 75 cm2 culture vessel area) at 37°C for 5 min until cells 
detached. Trypsin was then inactivated by adding 6 ml medium with 10% FCS.  
4.3.2. Assessing cell vitality 
The number of viable and dead cells was determined by trypan blue exclusion. The cell 
suspension was diluted with trypan blue solution and the cells counted in a Neubauer 
haemocytometer. The concentration of viable cells was then calculated using the equation:  
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Number of viable cells/ml C= N x D x 104 
With : N: average of unstained cells per corner square (1mm containing 16 sub-squares) 
 D: dilution factor 
Required solution: 
 Trypan blue solution:   0.2% (w/v)  Trypan blue in 0.9% NaCl solution. 
 
4.3.3. Freezing and thawing cells 
Cells were harvested and suspended at 4-6x 106 cells/ml in 800 µl ice-cold medium, including 
10% FCS. After inverting the mix and transferring it in cryo-vials, 160 µl DMSO (Sigma) and 
640 µl FCS were added and the tubes were rapidly inverted to mix cells properly. To allow 
gradual freezing at a rate of 1°C/min, the cryo-vials were placed in isopropanol-filled 
cryo-containers (Nalgene) and frozen at -20°C for only 2 h then transferred to -80°C for 48 h. 
For long-term storage, samples were transferred to liquid nitrogen (-196°C). 
4.3.4. Mycoplasma assay 
Cells were routinely checked for mycoplasma contamination by ELISA with a Mycoplasma 
Detection Kit (Roche, Germany) or by a biochemical test with a MycoAlert® Mycoplasma 
detection assay (Cambrex, Rockland USA) according to the manufacturer's instructions. 
4.3.5. Mouse bone marrow macrophage preparation 
Mouse bone marrow-derived macrophages (BMM) were extracted from the femurs of 8- to 
12-week-old mice. Cells from several animals were pooled before plating into non-charged 
bacteriological plates (5x105 cells/ml culture media). After five days the medium was changed 
and cells were harvested on day 6 and replated at a density of 10x106 cells/20 ml media in 
10-cm tissue culture dish. Experimental time courses were started on day 7. Afterwards cells 
were harvested and total RNA was isolated (Rehli et al., 2005).  
Required cell culture medium: 
 BMM growth medium: 500 ml   RPMI with supplements (see section 4.3.1.1) 
     200 ng/ml rCSF (Cetus) 






4.4. Transfection of mammalian cells 
4.4.1. Transient transfection  
4.4.1.1. Effectene transient transfection 
To introduce different tagged-MMD constructs into NIH3T3 cell line, Effectene™, a cationic 
lipid transfection reagent, was used following Qiagen instructions. One day prior to 
transfection 5x104 NIH3T3 cells were seeded per well into chamber slides or into a 6-well 
culture plate. On day 2, 0.5 µg DNA diluted in 150 µl EC buffer were supplemented with 8 µl 
Enhancer, shortly vortexed and incubated at RT for 5 min. The Enhancer facilitates DNA 
condensation. Afterwards 25 µl Effectene was added, vortexed and further incubated for 
10 min at RT to allow the formation of the Effecten-DNA complex. Finally, 800 µl normal 
growth medium was added to the mix and applied to the cells. On day 4, the cell lysate was 
prepared or an immunocytochemistry staining was performed.  
4.4.1.2. Lipofectamine transient transfection  
NIH3T3, HEK293T as well as RAW264.7 transfection with various tagged MMD constructs 
was carried out using Lipofectamin™ 2000 according to Invitrogen’s instructions. In brief, 
for transfection in 6-well plates, for each well the following solutions were taken:  
• Solution A: 1 µg DNA was mixed with 100 µl Opti-MemI. 
• Solution B: 7 µl Lipofectamin was mixed with 100 µl Opti-MemI.  
Combined together, solutions A + B were incubated for 30 min at RT, 800 µl Opti-MemI was 
added, and the transfection cocktail applied into 1.5x105 cells/well seeded on day prior to 
transfection. After 5 h, transfection mix was removed and replaced with normal growth 
medium. After 48 h, transient transfected cell were ready for further experiments.  
4.4.2. Retroviral stable cell transfection 
To generate NIH3T3 cell lines stably expressing tagged MMD, a combination of the 
RetroMaxTM System (Imgemex) and the retroviral vector pQCXIP from BD Biosciences 
(Clontech) was used. The procedure is based on a transient cotransfection of a packaging cell 
line, HEK293T, with pCL-ECO, a RetroMax packaging vector, and pQCXIP containing the 
gene of interest. Once introduced into the packaging cell line, pCL-ECO vector produces the 
viral Gag-Pol elements and the ecotropic viral envelope (Eco) at high level. The envelope 
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allows viral particles to infect specifically mouse and rat target cells by binding to receptors 
only present on the surface of these cells. The retroviral vector, pQCXIP, expresses a viral 
genomic transcript containing a CMV immediate early promoter, the gene of interest, an 
Internal Ribosomal Entry Site (IRES) and the puromycin selection marker. In addition, these 
elements are fused with a retroviral packaging signal Ψ+, which allows the packaging of 
Gag-Pol and envelope viral proteins into viral particles. Once released into the culture 
medium of the packaging cell line, the replication-defective virus is capable of infecting 
mouse target cell lines. After genomic integration, the gene of interest is then expressed 
constitutively along with a puromycine resistance gene, which allows the selection of positive 
cells (Figure 4.2). 
4.4.2.1. Generation of retroviral constructs 
To generate retroviral expression vectors, HA-MMD and MMD-3FLAG cDNA were cloned 
separately into the pQCXIP vector as follows: 
Mouse MMD cDNA fused with 3xFLAG at the C-terminus was cut from 
pIRES-MMD-3xFLAG construct(Figure 5.12A) with BstEII and KpnI restriction enzymes, 
and subcloned into the BamHI-KpnI sites of pQCXIP vector. 
The construction of pQCXIP-HA-MMD vector was accomplished by amplifying mMMD 
(cloned previously in pGEM3) by PCR using “HA-tag-S” and “BamHI-stopMMD-AS” 
primers. The PCR product (containing HA-tag sequence at its N-terminus) was intermediately 
cloned into pCR2-TOPO vector. After sequencing, NotI-BamHI fragment was subcloned into 
NotI-BamHI site of pQCXIP vector.  
4.4.2.2. Transfection of the packaging cell line HEK293T 
As a transduction control, EYFP gene (Enhanced Yellow Fluorescent Protein) cloned into 
pQCXIP was used. After successful infection, cells expressing EYFP protein were visualized 
via the fluorescence microscope. An empty retroviral vector was also used to produce a 
negative control cell line. 
Two independent cell lines stably producing tagged-MMD or EYFP were generated following 
two different transfection protocols. The following plasmids pQCXIP-HA/MMD, 
pQCXIP-MMD/3xFLAG, pQCXIP-EYFP or pQCXIP were cotransfected with the RetroMax 




¾ Transient transfection of HEK293T with CaCl2/HeBS 
Following the protocol described in (Schneider-Brachert et al., 2004), 3x106 HEK293T cells 
were seeded 48 h prior to transfection into 10-cm tissue culture dishes to reach 80% 
confluency. At least 1 h prior to transfection, DMEM medium was replaced with 10 ml 
DMEM + GlutaMaxI (Gibco) to increase the transfection efficiency. The transfection mix, 
containing 30 µg of each the expression and the packaging plasmids diluted in a total water 
volume of 450 µl, was prepared. After adding 50 µl CaCl2, the DNA/CaCl2 mix was dripped 
into a 15 ml tube containing 500 µl 2xHeBS under slight vortexing. The DNA/CaCl2/HeBS 
mix was added immediately to HEK293T cells. After 6 h incubation, the DNA mix was 
replaced with normal growth medium. The retroviral supernatant was collected after 48 h. 
Required buffers and solutions:  
 2x HeBS 50 mM  11.9 g HEPES 
   280 mM 16.4 g NaCl 
   1.5 mM 0.27 g Na2HPO4 
   Add H2O to 1000 ml and adjust pH to 7.05 with NaOH (10 N).  
   Filter, aliquot and store at -20°C. 
 
 CaCl2  2.5 M  183.7 g CaCl2.2 H2O 
   Add H2O to 500 ml , filter, aliquot and store at -20°C. 
 
¾ Transient transfection of HEK293T with LipofectamineTM 
Following the protocol described in section 4.4.1.2, 3x105 HEK293T cells were seeded in 
6-well culture plates 24 h prior to transfection. Duplicates for each sample were done. The 
packaging and the tagged-MMD expression vectors (2 µg each) were mixed with 200 µl 
Opti-MEM® to form the solution A. The solution B was prepared by adding 200 µl 
Opti-MEM® to 14 µl Lipofectamine™. Both solutions were mixed and incubated for 30 min 
at RT. After adding 1.2  ml Opti-MEM®, the transfection mix was transferred to each well 
and cells were incubated for 5 h. Afterwards Opti-MEM® mix was replaced with 5 ml growth 
medium. The retroviral supernatant was also collected 48 h after transfection.  
4.4.2.3. Transduction of the targeting cell line 
In order to transduce the target cell line, 3x105 NIH3T3 cells were seeded in a 6-well culture 
plate at the day of transfection (for each construct two wells were prepared). Virus particles 
containing medium was harvested from transfected HEK293T and passed through a sterile 
HT Tuffryn low protein-binding 45 µm filter (PALL Gelman Laboratory, USA).  
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To enhance the infection efficiency, Polybrene (4 µg/ml growth medium, Chemicon) was 
added, which is a polycation molecule that binds to the cell surface and neutralizes its surface 
charge facilitating the penetration of the retrovirus. The infection solution (2.5 ml /well)) was 
diluted 1:1 with normal growth medium and added to NIH3T3 cells. The rest of the viral 
supernatant was stored at 4°C and used after 6 h to perform a second infection overnight. 
Another infection round was pursued the next day by collecting a new HEK293T supernatant. 
4.4.2.4. Selection and expansion of stable cell lines 
Once the infection was completed, the target cells were incubated with normal growth 
medium for 24 h to recover. Afterwards, cells were selected with 4 µg/µl puromycin for 48 h. 
After all cells of the non-transfected control were dead, cells carrying GFP or MMD were 
then transferred into culture flasks, expended and frozen. 
 
Figure 4.2 The retroviral transfection system  
The packaging vector, pCL-Eco and the expression vector, pQCXIP, were transfected into the 
packaging cell line, which produced replication deficient retroviral particles in the supernatant. These 
were collected and used to transduce a target cell line, integrating into its genome to stably express the 
gene of interest.  
4.5. Gene targeting protocols 
4.5.1. Cloning of targeting vectors 
In the course of this work, five “replacement” targeting consctructs were generated, which 
contains elements described in section 5.4.2. 
4.5.1.1. Targeting vector I 
The targeting vector I, TOPO-[KA-GFP-Neo-LA]-TK (13.2 kb) was prepared as follows: 
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(1) The short arm, KA, was amplified by PCR from E14.1 genomic DNA using the primer 
pair: “KA-S” (with 5’NotI site) and “KA-AS” (with 3’ BamHI site). After checking the PCR 
product by sequencing, the 500-bp fragment was subcloned into pBS-loxP-Neo-loxP vector 
using NotI-BamHI restriction sites, resulting in pBS-[KA-Neo] construct. 
(2) The GFP reporter gene in pCR2-TOPO vector was cut using BamHI and EcoRI restriction 
enzymes and ligated into the BamHI-EcoRI site of pBS-[KA-Neo] construct in frame with the 
short arm of mMMD gene. 
(3) The long arm, LA, was also amplified by PCR from E14.1 genomic DNA using “LA_S” 
and “LAn_AS” primers (introducing 5’SalI and 3’XhoI restriction sites). The 2500-bp PCR 
product was cloned into pCR2.1-TOPO vector.  
(4) The fragment [KA-GFP-Neo] was then cloned into NotI-SalI site of TOPO-LA vector. 
(5) The negative selection TK-cassette was prepared from pGEM7-TK vector by digestion 
with KpnI, and ligated into KpnI site of TOPO-[KA-GFP-Neo-LA] construct in the same 
orientation of the Neo-cassette. 
4.5.1.2. Targeting vector II 
In the targeting vector II, TOPO-[LLA-GFP-Neo-LA]-TK (17 kb), the short 500-bp arm (KA) 
of the targeting vector I has been replaced by a longer 4600-bp arm to improve the 
recombination efficiency. For this purpose, the “long long arm” (LLA) was generated in three 
steps as follows: 
(1) The first fragment of LLA was amplified from ES genomic DNA using “1.Arm5’-1_S” 
(introducing a 5’NotI site) and “1.Arm5’-1_AS” primers, and afterwards subcloned into 
pCR2.1-TOPO vector.  
(2) The second fragment of LLA was also generated by PCR using “1.Arm5’-2_S” and 
“1.Arm5’-2_AS” primers, and subcloned into pCR2.1-TOPO vector.  
(3) The last fragment was amplified using “1.Arm5’-3_S” and “1.Arm5’-3_AS” primers 
(introducing a 3’BamHI site). Each fragment of LLA was checked for mutation by 
sequencing. 
(4) The pBS-[KA-GFP-Neo] construct from step 2 section 4.5.1.1, was digested with NotI and 
BamHI restriction enzymes to excise the KA short arm. 
(5) The 1.step fragment cut with NotI-NcoI together with the 2.step fragment, cut with 
NcoI-BamHI were subcloned into the pBS-[GFP-Neo] prepared in the previous step. 
(6) The 3.step fragment of LLA, cut with BamHI, was subcloned into the construct of step 5 
(cut with BamHI), to yield pBS-[LLA-GFP-Neo].  
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(7) [LLA-GFP-Neo] fragment was excised using NotI and SalI restriction enzymes and 
ligated between NotI and SalI sites into TOPO-[LA]-TK vector. 
4.5.1.3. Targeting vector III 
Taking advantage of the results of previous targeting vectors, the targeting vector III, 
pBS-[SA3-GFP-Nep-LA]-DT (11.1 kb) was generated as follows: 
(1) The pCR2.1-TOPO backbone was suspected to be inappropriate for amplification and 
purification of large constructs. Therefore, the [GFP-Neo-LA] fragment was excised from 
TOPO-[KA-GFP-Neo-LA] using BamHI-XhoI restriction enzymes, and ligated into an empty 
pBS vector. The resulting construct is pBS-[GFP-Neo-LA].  
(2) The PCR product, SA3 of LLA (targeting construct II, section 4.5.1.2, step 3) was taken as 
short arm for the targeting construct III: it was cut from pCR2.1-TOPO vector with BamHI, 
and subcloned into pBS-[GFP-Neo-LA].  
It was reported that the DT-ApA cassette leads to a more efficient elimination of negative 
clones, which integrated randomly the targeting vector (Yanagawa et al., 1999), therefore: 
(3) the DT-ApA negative selection cassette was excised with KpnI from the pBS-DT-ApA 
vector and ligated into the KpnI site of pBS-[SA3-GFP-Neo-LA] downstream of the long arm 
(LA).  
4.5.1.4. Targeting vector IV 
In the construct IV, pBS-[SAex5-Neo-LAex6]-DT, the short homologous arm (1.4 kb) was 
positioned between exons IV and V, and the long arm (4.4 kb) upstream of exon VI of 
mMMD gene. The cloning procedure was carried out as follows: 
(1) The SAex5 was generated by PCR amplification using “SA-Not_S” and “SA-EcoR_AS” 
primers. The PCR product was then subcloned into the NotI-EcoRI site of pBS-Neo vector. 
(2) DT-ApA cassette was subcloned into pBS-[SAex5-Neo] construct using the KpnI site, to 
yield pBS-[SAex5-Neo-DT]. 
(3) LA-ex6 long arm was generated in a single PCR reaction with the “Laex6-1_S” and 
“Laex6-3_AS” primers and by using the Herculase® enhanced DNA polymerase (Stratagene, 
Germany). Afterwards, the PCR product was cloned into pCR2.1-TOPO vector and controlled 
by sequencing using the following primers: “Laex6-1_in”, “Laex6-1_AS”, “Laex6-2_S”, 
“Laex6-2_AS”, “Laex6-3_S”, and “Laex6-3_in”. Finally, the LAex6 long arm was cut with 
SalI and ligated into SalI site located between the Neo and DT cassettes of pBS-[SAex5-Neo-
DT] vector. The resulting construct has the size of 11.8 kb. 
Methods 
55 
4.5.1.5. Targeting vector V 
The elements of targeting vector V, TOPO-[KA-GFP-Neo-LA], are the same described in 
section 4.5.1.1 but without the TK negative selection cassette, which was excluded to 
minimize its toxicity and increase the number of clones after positive selection. Additionally, 
the size of the vector is reduced which may positively influence the transfection efficiency. 
4.5.2. Mouse Embryonic Fibroblast (MEF) cell culture 
4.5.2.1. Setting up mating 
To prepare mouse embryonic fibroblast (MEF), fertile female mice were mated with fertile 
C57BL6 males. To enhance the ovulation, the male mouse was isolated in a cage and 4 h later 
a female was transferred into the same cage and kept there overnight. A successful copulation 
was controlled in the early morning by a simple visual examination of the vulva looking for a 
plug. The plug is a coagulum of particular component of the male ejaculate that blocks the 
entrance of the vagina. Once it was detected, the potentially pregnant female was isolated, 
controlled for pregnancy and sacrificed to isolate mouse embryos after 14.5 days post-coitus 
(dpc). To prepare neomycin resistant EF, C57BL6 male were mated with an available 
knock-out female mouse (Rehli et al., 2005), which expressed the neomycin resistant (neoR) 
gene constitutively from a gene targeted mutation, giving birth to embryos heterozygous for 
the neoR gene. 
4.5.2.2. Isolation of embryo 
To isolate mouse embryos, a pregnant mouse was killed by cervical dislocation and 
transferred under a laminar flow hood. The mouse was laid on its back, the belly swabbed 
with 70% ethanol, and the uterus dissected out by using sterile forceps and avoiding contact 
with the fur to minimize bacterial contamination. The uterus was then placed into a Petri dish 
filled with sterile PBS to remove blood, transferred to a second Petri dish where the embryos 
were isolated out of the embryonic sac. From each embryo, head and internal red organs were 







4.5.2.3. Preparation of MEF cells  
¾ Protocol  I 
MEF cells used in the first two targeting experiments were prepared from isolated embryo 
bodies as following: embryos were cut into small pieces, gently pushed through a metal sieve 
which was rinsed continuously with PBS. Cells were collected and washed twice with PBS, 
centrifuged (8 min, 300 g) and cultured in MEF growth medium on 15 cm culture dishes for 
48 h (3 embryos on 1x15 cm plate). Afterwards cells were detached from the plates by 
incubation with trypsin/EDTA for at least 10 min and split at a 1:2 ratio. After an incubation 
for another 48 h, cells were frozen in liquid nitrogen (5 vials/2x15 cm plates). 
The day before MEF cells were needed, one vial was thawed and cultured. Once confluency 
reached, plates were incubated at 37°C for 2.5 h in MEF medium supplemented with 
10 µg/ml mitomycin-C (Medac, Hamburg) to inactivate their mitosis. Mitomycin treated 
MEFs can be used for up to 3 days.  
¾ Protocol II 
The protocol II (personal communication with Dr. Markus Moser Max Planck Institute, 
München) was followed to prepare MEF neomycin resistant cells, which were used during 
neomycin selection in most of the targeting experiments. Isolated embryos were cut into small 
pieces and incubated in a 50 ml tube with 20 ml trypsin/EDTA for 15 min. MEF medium was 
then added to inactivate trypsin and with a 25 ml pipette, embryo debris were pipetted up and 
down till the tissues disassociate. MEF medium was added and cells were then cultured in 
T175 flask (2 embryos/T175 flask). The next day cells were split at a ratio of 1:4, and 48 h 
later at a ratio of 1:2. Once 100% confluency was reached, cells were trypsinized and 
collected in 50 ml tubes filled with MEF medium.  
To inactivate mitosis, they were exposed to 4000 rads (376 seconds) of γ-irradiation. 
Afterwards mitotic inactivated MEFs were centrifuged, the cell pellet was dissolved in MEF 
medium, with an equal volume of 2x Freezing medium, and immediately frozen overnight at 
-80°C (3 vials /T175 flask). The next day cells were transferred into liquid nitrogen.  
Independently of the protocol, the cell density used to obtain a confluent MEF monolayer 






Table 4.8 MEF cell density on different size tissue culture plates. 
MEF cells  Number of MEF plates or flasks   Medium (ml/plate or well) 
    1x 14 cm plate or T175 flask                         25 
  1.5x105    3x 10 cm plates or T75 flask                         10 
    3x 24-well plates                           1  
 
Required media: 
 MEF growth medium: 500 ml  DMEM (Cat. No. 41960-029, Invitrogen) 
     2 mM 5 ml L-Glutamine (100x) (Invitrogen) 
     5 µM 500 µl β-Mercaptoethanol (1000x)  
     1x  5 ml penicillin (50 U/ml) 
      and streptomycin (50 µg/ml) 
     5%  50 ml FCS (PAN Biotech) 
 
 MEF freezing medium: 60 %  6 ml MEF growth medium (with 5% FCS)   
 (2x, fresh prepared)  20%  2 ml FCS 
     20% 2 ml DMSO (Sigma). 
 
4.5.3. Embryonic stem (ES) cell culture 
4.5.3.1. General conditions of ES cell culture and freezing 
ES cells require special conditions to maintain their full developmental potential and their 
capability to contribute to the germ line. ES cells were cultured at 37°C with 7% CO2, 
supplied daily with fresh ES medium supplemented with LIF (Leukemia Inhibitory Factor), 
which prevented their differentiation. Additionally, for long-term culture, ES cells were 
grown on a monolayer of MEF cells providing them with additional growth factors. ES cells 
culture should be subconfluent and were split in a 1:4 ratio. Passaging was kept at a minimum 
because prolonged culture may decrease ES cell contribution to the germ line. Cultured 
inappropriately, ES cells can accumulate mutations, thus increasing their growth rate on the 
cost of their pluripotency (Nagy et al., 2003). 
For freezing ES cells, a pellet of 2x106 cells was dissolved in an equal volume of ES growth 
medium and ES freezing medium (2x), immediately transferred into cryovial, placed into cryo 
container at -80°C overnight, and on the next day, stored in liquid nitrogen.  
The embryonic stem E14.1 cell lines used in the targeting experiments were kindly provided 






 ES growth medium:  500 ml  DMEM (Cat. No. 41960-029, Invitrogen) 
     2 mM 5 ml L-Glutamine (100x) (Invitrogen) 
     5 µM 500 µl β-Mercaptoethanol (1000x)  
     1x  5 ml penicillin (50 U/ml) 
      and streptomycin (50 µg/ml) 
     5%  50 ml FCS (PAN Biotech) 
     5x105 U 50 µl ESGRO-LIF (107 U/ml) (ESG-1107, Chemicon). 
 
 ES freezing medium:  60%  6 ml ES growth medium (with 15% FCS)   
 (2x, fresh prepared)  20%  2 ml FCS 
     20% 2 ml DMSO (Sigma). 
 
4.5.3.2. Testing serum batches 
It is crucial to culture ES cells with FCS batches that do not influence their morphology and 
growth. To select an appropriate FCS, three batches, recommended for ES cell culture, were 
ordered from PAN Biotech GmbH (Aidenbach, Germany), and tested as following: ES cells 
were plated at low density with different concentration of FCS (10%, 15% and 30%). Their 
density and morphology was monitored for 5 days after ES colonies appearance and during 
three passages. The FCS batch P231610-ES conserved morphology and ES cells and plating 
efficiency in high FCS concentration (30%) after 5 days, and was chosen for ES cell culture.  
4.5.4. ES cell electroporation 
Preceding electroporation, MEF coated culture plates were prepared with the appropriate cell 
density (Table 4.8). Two different electroporation protocols were carried out.  
¾ Amaxa ES cell electroporation 
ES cell electroporation was performed by Amaxa Nucleofactor (Amaxa Biosystems, Köln, 
Germany) following the instructions of the manufacturer. In brief, ES cells split on the 
previous day, were trypsinised and plated for 30 min to allow MEF cells to adhere. The 
supernatant was centrifuged and cell pellet was dissolved in Nucleofactor solution mixed with 
5, 10 or 15 µg linearized plasmid DNA in a total volume of 100 µl. The electroporation was 
performed immediately and cell-DNA mix was transferred with 500 µl warmed medium on 
two previously prepared MEF plates with ES growth medium (day 0). The number of ES cells 




¾ BioRad ES cell electroporation 
One day after splitting the ES cells, they were trypsinized, counted, washed and resuspended 
in PBS before addition of the DNA. Cell number and DNA concentration varied depending on 
the experimental setup (see section 5.4.3). The cell-DNA suspension was transferred into a 
0.4 cm BioRad cuvette and subjected to electroporation. Afterwards cells were cultured on 
MEF coated plates with ES growth medium (day 0). 
4.5.5. Antibiotic selection  
Positive selection with G418 was initiated 48 h after electroporation (day 2). Negative 
selection started with ganciclovir one day later (day 3) with a daily medium change. 
G418/G420 (PAN Biotech GmbH, Germany) concentration was tested for each new batch, 
and when using neomycin resistant MEF cells. The final concentration of the antibiotic varied 
between 200 and 300 µg/ml ES growth medium. Gancyclovir (Cymeven, Syntex GmbH-
Roche, Germany) working concentration was 25 µg/ml. The selection time varied from 9 to 
11 days, and picking was started when round clones with a shiny, well-defined border 
appeared.  
4.5.6. Picking, expansion and freezing of ES cell clones 
Picking ES clones was performed under the microscope in the laminar flow hood. Each 
individual drug-resistant clone was picked from the selection plate containing PBS using a 
pipette with a yellow tip adjusted to a volume of 20 µl. Clones were transferred into a 96-well 
plate, after picking 12 clones, 50 µl trypsin/EDTA was added into each clone-containing well 
and the plate was incubated for 7 min at 37°C. ES growth medium (50 µl) was added to the 
well, and cells of each clone were separated by pipetting up and down, and transferred into a 
MEF coated 48-well plate containing 500 µl ES growth medium.  
Once ES-cell clones reached confluency (usually after 2-3 days), they were split into 
2x 48-well plates as follows: each well was washed once with PBS and incubated with 100 µl 
trypsin 5 min at 37°C. Each clone was treated separately to avoid cross-contamination. After 
adding 500 µl ES growth medium, the cell suspension was homogenized and divided into 
2x 48-well plates: 
• A-plate: coated with MEF cells (planned for freezing) 
• B-plate: coated with gelatin without MEF cells (planned for genotyping).  
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When cells of the A-plate have reached 80% confluency, each well was washed once with 
PBS, cells were trypsinized and after 10 min incubation at 37°C, ES growth medium and 
freezing medium were added. Cells were well suspended, and plates sealed with parafilm and 
frozen at -80°C. It is crucial that cells from the A-plate conserve their non-differentiated 
morphology (grown on MEF, supplemented with LIF). If a specific clone turned out to be 
positive, the corresponding plate would be thawed and cells subjected to injection. The 
B-plates were used only to prepare genomic DNA for genotyping (see section 4.5.7)  
4.5.7. Screening of ES cell clones 
4.5.7.1. Genomic DNA purification 
To purify genomic DNA from ES cells for clone screening, two different methods were used: 
¾ Genomic DNA extraction with phenol-chloroform extraction  
For genomic DNA extraction, confluent ES cells in 48-well plates were washed once with 
PBS and incubated at 37°C overnight with 500 µl lysis buffer per well (plates were sealed 
with parafilm to prevent drying). The cell lysate was subjected to one phenol extraction, 
followed by 2x phenol/chloroform/isoamyl alcohol (in a 25:24:1 ratio) and 2x chloroform 
extractions (1 volume each, with 3 min centrifugation steps at 13000 rpm). Genomic DNA 
was precipitated by the addition of 2 volumes of 100% ethanol and 1/10 volumes of sodium 
acetate 3 M pH 5.2. After incubating at -20°C for 30 min, the precipitated genomic DNA was 
pelleted at 13000 rpm for 5 min. After a 70% ethanol wash, genomic DNA was resuspended 
in 100 µl H2O and stored at 4°C. DNA concentration and quality was assessed with the 
spectrophotometer.  
 Lysis buffer I:  100 mM 5 ml  Tris-HCl (1 M), pH 8.5 
    5 mM  0.5 ml  EDTA (0.5 M) 
    200 mM 5 ml NaCl (2M) 
    1%  2.5 ml  SDS (20%) 
    0.1 mg/ml  5 mg  Proteinase K (Roche) 
    Add H2O to 50 ml. Fresh prepared. 
 
¾ Rapid and direct genomic DNA extraction from 48-well plates 
The following method allowed the rapid extraction of genomic DNA directly from plates. ES 
cells were previously cultured on 0.2% gelatin-coated 48-well plates until the medium turned 
yellow. The plates were rinsed with 500 µl PBS, and then 200 µl lysis buffer II was added. 
They were then sealed with parafilm and incubated at 50°C overnight in a humid atmosphere 
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inside a closed Tupperware containing wet paper towel. The next day, after shortly 
centrifuging the plate at 2500 rpm, 20 µl NaCl was added to each well followed by 
2.5 volumes 100% ethanol. Gentle shaking at RT for 30 min resulted in the precipitation of 
DNA as a filamentous network. Plates were then centrifuged and gently inverted to discard 
the supernatant while the DNA stayed attached to the bottom. After washing wells 3x with 
500 µl 70% ethanol, plates were inverted and the ethanol was discarded. Finally after drying 
in a laminar hood, 70 µl TE was added to each well and the dissolved genomic DNA was 
transferred into microfuge tubes and stored at 4°C. DNA concentration and quality was 
assessed again with the spectrophotometer. 
 Lysis buffer II: 10 mM  250 µl  Tris-HCl (2 M), pH 7.5 
    10 mM  1 ml  EDTA (0.5 M), pH 8 
    10 mM  250 µl NaCl (2 M) 
    0.5%  250 µl  Sarcosyl (Merck) 
    1 mg/ml  50 mg  Proteinase K (Roche) 
    Add H2O to 50 ml. Fresh prepared. 
 
4.5.7.2. DIG-labeling of southern probes 
DIG-DNA probes were used to screen ES clones from which genomic DNA was prepared 
following protocol I (see section 4.5.7.1), because large amounts of digested genomic DNA 
(15 µg) are required to get clear bands by non-radioactive Southern blot analysis. 
DIG-labeling was carried out using the PCR DIG Probe Synthesis kit following the 
manufacturer instructions (Roche). As template, a genomic DNA region (about 500 bp) 
positioned outside of the homologous region of the targeting constructs was chosen to be 
amplified from the genomic DNA using a mix of DIG-dNTPs and unlabeled dNTPs. Presence 
and size of the DIG labeled PCR product were then controlled by agarose gel electrophoreses, 
and the specific DNA band was extracted from the gel. The DIG-labeled probe was titrated as 
described in the manufacturer protocol. 
 PCR reaction mix: 300 ng   Genomic DNA 
    5 µl   10 pmol/µl Sense primer 
    5 µl   10 pmol/µl Anti-sense primer 
    2.5 µl   10 mM dNTP 
    2.5 µl   PCR DIG mix (Roche) 
    5 µl   10x Taq buffer 
    0.75 µl   High Fidelity polymerase 






4.5.7.3. Radioactive labeling of Southern probes 
Radioactive labeled DNA probes were used to screen ES clones where genomic DNA was 
extracted following protocol II (see section 4.5.7.1). The DNA probes were first generated by 
PCR. As described in section 4.5.7.2, a genomic DNA region (about 500 bp) positioned 
outside the homologous region of the targeting constructs was chosen as template. The 
ensuing PCR product 25 ng was radioactively labeled by random prime second-strand 
synthesis with Klenow fragment. After labeling, unincorporated nucleotides were removed by 
MicroSpin™ G-25 column (Amersham, Germany) following the manufacturer’s protocol. 
The radioactively labeled DNA probes were denatured at 95°C for 5 min before hybridization.  
 Labeling reactions:  25 ng  DNA 
    1 µl  Random 9-mer (Ambion, Germany) 
    Add H2O to 28 µl, incubate at 95°C for 10 min. 
    Cool down on ice, and spin down quickly. 
    4 µl 10x Klenow buffer 
    2 µl  dNTPs (without dATPs) 
    1 µl  exo- Klenow (Roche, Germany) 
    5 µl [α-32P]-dATP. 
    Mix, spin and incubate at 37°C for 20 min. 
    Add 2 µl dNTPs. Mix and incubate at 37°C for 10 min. 
 
4.5.7.4. Screening clones by Southern blot analysis 
Southern blotting is the transfer of DNA from a gel to a membrane. First genomic DNA was 
digested overnight with the appropriate enzyme in a final volume of 30 µl. Digested samples 
were analysed on an agarose gel which was run for 4 h with 90 V to allow a good separation 
of DNA bands. After photographing the gel, the blotting procedure was started as following: 
• DNA depurination: shaking the gel 1x 10 min in 0.25 M HCl.  
• Washing the gel 1x with Millipore water.  
• DNA denaturation: shaking the gel 2x 15 min in denaturation buffer. 
• DNA neutralization: shaking the gel 2x 10 min in neutralization buffer. 
• Blotting overnight using a positively charged nylon membrane (Roche), following the 
Northern blotting procedure described in section 4.1.4.4 with some modifications       
(Figure 4.3). 
• DNA fixation on the membrane by UV crosslinking (Stratalinker). 
• Washing the membrane: 1 h with 2x SSC. 
• Drying the membrane: 1 h at RT. 
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• Prehybridization in 10 ml DIG-Easy Hyb (Roche) for 2 h at 42°C (for DIG-labeled probe), 
in 10 ml Rapid-hyb buffer (GE Healthcare biosciences) for 3 h at 65°C (for radioactively 
labeled probe). 
• Probe denaturation: 5 min at 95°C. 
• Hybridization: probe was added into 10 ml hybridization buffer, incubated overnight at 
42°C or 65°C for DIG- or radioactively labeled probes respectively. 
• Membrane washing: 2x 10 min with washing buffer I at RT. 
• Membrane washing: 2x 15 min with washing buffer II (prewarmed at 68°C) at 68°C. 
• Visualization of DIG-probe-target hybrids was performed using chemiluminescence assay 
(Roche). Afterwards labeled membranes were fixed in an exposure cassette with a storage 
phosphor screen and exposed overnight to up to three days. The cassettes were later scanned 
on a phosphoimager Typhoon™ (Amersham Biosciences). 
 
Figure 4.3 Southern blot, DNA 
transfer to nylon membrane. 
The digested DNA was transferred to a 
nylon membrane. The DNA gel was 
placed upside-down on 3 layers of 
20xSSC-soaked Whatman 3MM filter 
papers on glass plates. The membrane 
was laid on the top of the gel, covered 
with 3 layers filter papers soaked with 
20xSSC. A cellulose wadding was 
placed on top and pressed with a glass 
plate.  
 
Required buffers and solutions: 
 Denaturation solution 0.5 M  40 g NaOH 
    1.5 M  175.32 g NaCl 
    Add H2O to 2 l. 
 
 Neutralisation solution 1.5 M   175.32 g NaCl 
    1 M   121.14 g Tris  
    Add H2O to 2 l. 
 
 Southern Blot   2x  100 ml 20x SSC 
 Washing buffer I 0.1%  5 ml 20% SDS 
    Add H2O to 1 l. 
 
 Southern Blot  0.1x  5 ml 20xSSC 
 Washing buffer II 0.1%  5 ml 20% SDS 




To get more insights into the structure of monocyte to macrophage differentiation (MMD) and 
MMD2 genes, the mouse nucleotide sequence was studied and aligned with its orthologues. 
To profile their expression, Northern blot analyses of RNA from different human and mouse 
tissues and cell lines were carried out. In addition a whole-mount in situ hybridization was 
performed in mouse embryo to study MMD and MMD2 transcripts expression during the 
embryogenesis. To determine mouse MMD (mMMD) protein cellular localization, various 
tagged MMD cDNA were transiently or stably expressed in a mouse cell line. In an attempt to 
define the likely function of mMMD, ES cell culture was established in our lab in the course 
of this PhD work, and different targeting vectors were designed, generated, and electroporated 
into ES cells to produce a MMD knock-out ES cells. Finally by using siRNA, the silencing of 
mMMD gene was achieved in two mouse cell lines, which may provide a tool for studying its 
function. 
5.1. Genomic organization of MMD and MMD2 genes 
5.1.1. Analysis of mouse MMD and MMD2 genes 
¾ Mouse MMD 
The mouse MMD gene (mMMD) is located on the chromosome 11D and comprises 7 exons 
with the ATG start codon positioned in exon I (Figure 5.1). The full-length cDNA has about 
2.6 kb encoding 238 amino acids with a predicted molecular weight of 28 kDa. 
¾ Mouse MMD2 
The mouse MMD2 (mMMD2) gene was recently identified as a homologue to MMD, with a 
conserved gene organization (6 exons and ATG start codon also in exon I) (Figure 5.1). The 
MMD2 transcript is about 2 kb long and the ORF is located on chromosome 5qG2. It encodes 
a protein of 247 amino acids with a predicted molecular weight of 29 kDa. 
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Figure 5.1 Genomic organization of mouse MMD and MMD2. 
Schematic representation of the intron/exon structure of mouse MMD and MMD2 as determined by 
BLAST. Exons are depicted as filled boxes and numbered with roman numerals, introns are 
represented by the connecting lines. The start codon is marked with a green arrow. The size of the 
exons and introns is indicated in bp or in kb, respectively.   
5.1.2. Analysis of human MMD and MMD2 genes 
¾ Human MMD 
Human MMD (hMMD) was cloned, in our lab, from in vitro differentiated mature 
macrophages, and identified as monocyte to macrophage differentiation protein (Rehli et al., 
1995). The full-length cDNA consists of around 2.5 kb, located on the reverse strand of 
chromosome 17q. It is organized in 7 exons with the ATG start codon in exon I (Figure 5.2). 
The protein of 238 amino acids has a predicted molecular weight of 28 kDa. 
¾ Human MMD2 
Human MMD2 (hMMD2) is a homologue of hMMD, identified at the same time as its mouse 
orthologue. The full-length cDNA is around 2.3 kb, located on chromosome 7p22 (Figure 
5.2). The hMMD2 protein appears in the UniProt database in two alternative variants, a long 
isoform of 270 amino acids and a molecular weight of 31 kDa, and a short isoform missing 
24 amino acid residues between position 156 and 179 of the first isoform. 
    
Figure 5.2 Genomic organization of human MMD and MMD2. 
Schematic representation of the intron /exon structure of human MMD and MMD2 as determined by 
BLAST. Exons are depicted as filled boxes and numbered with roman numerals, introns are 
represented by the connecting lines. The start codon is marked with a green arrow. The size of the 
exons and introns is indicated in bp or in kb, respectively.  
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5.1.3. Structure and sequence homology of MMD family proteins 
Online database searches classified mouse and human MMD and MMD2 proteins as members 
of the so far uncharacterized Hemolysin-III (Hly-III) family. Based on structural similarities, 
both proteins were recently grouped into the Progestin and AdipoQ receptor (PAQR) family 
and termed as PAQR11 (MMD) and PAQR10 (MMD2) (Tang et al., 2005).  
Multiple sequence alignment using ClustalW revealed 94% identity between mouse and 
human MMD2, and 99% between mouse and human MMD, whereas it showed about 68% 
identity between the paralogues in mouse and human (Figure 5.3, Table 5.1). The high range 
of identity found between the orthologues may suggest a similar function. On the other hand, 
the paralogues MMD and MMD2 may have diverged to fulfill distinctive functions in both 
human and mouse. 
 
     
     Human MMD2/isoform1      -MFAPRLLDFQKTKYARFMNHRVPAHKRYQPTEYEHAANCATHAFWIIPSILGSSNLYFL 
     Human MMD2/isoform2      -MFAPRLLDFQKTKYARFMNHRVPAHKRYQPTEYEHAANCATHAFWIIPSILGSSNLYFL 
     Mouse MMD2               MFTLARLLDFQKTKYARFMNDRVPAHKRYQPTEYEHAANCATHAFWIIPSILGSSNLYFL 
     Mouse MMD                --------MRFRNRFQRFMNHRAPANGRYKPTCYEHAANCYTHAFLIVPAIVGSALLHRL 
     Human MMD                --------MRFKNRFQRFMNHRAPANGRYKPTCYEHAANCYTHAFLIVPAIVGSALLHRL 
                                         :.:: ****.*.**: **:** ******* **** *:*:*:**: *: * 
 
     Human MMD2/isoform1      SDDDWETISAWIYGLGLCGLFVVSTVFHTISWKKSHLRMVEHCLHMFDRMVIYFFIAASY 
     Human MMD2/isoform2      SDDDWETISAWIYGLGLCGLFVVSTVFHTISWKKSHLRMVEHCLHMFDRMVIYFFIAASY 
     Mouse MMD2               SDDDWETISAWIYGLGLCGLFVVSTIFHTVSWKKSHLRMVEHCLHMIDRMVIYFFIAASY 
     Mouse MMD                SDDCWEKITAWIYGMGLCALFIVSTVFHIVSWKKSHLRTVEHCFHMCDRMVIYFFIAASY 
     Human MMD                SDDCWEKITAWIYGMGLCALFIVSTVFHIVSWKKSHLRTVEHCFHMCDRMVIYFFIAASY 
                              *** **.*:*****:***.**:***:** :******** ****:** ************* 
 
     Human MMD2/isoform1      APWLNLRELGPWASHMRWLVWIMASVGTIYVFFFHERTGSCVQFLRGEACPKAGTACLPA 
     Human MMD2/isoform2      APWLNLRELGPWASHMRWLVWIMASVGTIYVFFFHER----------------------- 
     Mouse MMD2               APWLNLRELGPWASHMRWLVWIMASIGTIYVFFFHER----------------------- 
     Mouse MMD                APWLNLRELGPLASHMRWFIWLMAAGGTIYVFLYHEK----------------------- 
     Human MMD                APWLNLRELGPLASHMRWFIWLMAAGGTIYVFLYHEK----------------------- 
                              *********** ******::*:**: ******::**:                        
 
     Human MMD2/isoform1      RYKLVELLCYVVMGFFPALVILSMPNTEGIWELVTGGVFYCLGMVFFKSDGRIPFAHAIW 
     Human MMD2/isoform2      -YKLVELLCYVVMGFFPALVILSMPNTEGIWELVTGGVFYCLGMVFFKSDGRIPFAHAIW 
     Mouse MMD2               -YKLVELLCYVVMGFFPALVILSMPNTDGIWELMTGGAFYCLGMVFFKSDGRIPFAHAIW 
     Mouse MMD                -YKVVELFFYLTMGFSPALVVTSMNNTDGLQELACGGLIYCLGVVFFKSDGIIPFAHAIW 
     Human MMD                -YKVVELFFYLTMGFSPALVVTSMNNTDGLQELACGGLIYCLGVVFFKSDGIIPFAHAIW 
                               **:***: *:.*** ****: ** **:*: **  ** :****:******* ******** 
 
     Human MMD2/isoform1      HLFVAFGAGTHYYAIWRYLYLPSTLQTKVSK 
     Human MMD2/isoform2      HLFVAFGAGTHYYAIWRYLYLPSTLQTKVSK 
     Mouse MMD2               HLFVAFGAGTHYYAIWRYLYLPSTLQTKVSK 
     Mouse MMD                HLFVATAAAVHYYAIWKYLYRSPTDFIRHL- 
     Human MMD                HLFVATAAAVHYYAIWKYLYRSPTDFMRHL- 
                              ***** .*..******:*** ..*   :        
 
Figure 5.3 Multiple sequence alignment of mouse and human MMD and MMD2 proteins. 
Identical residues are boxed in grey and marked with asterisks. Similar residues are marked with dots. 
Predicted transmembrane domains based on UniProt server are shown in red. The multiple protein 




Table 5.1 Multiple protein sequence alignment of mouse and human MMD and MMD2 proteins. 
          Mouse          Human 
   MMD  MMD2   MMD  MMD2 
 Mouse   MMD   100%    69%    99%    68% 
  MMD2    69%   100%    69%    94% 
Human   MMD    99%    69%   100%    68% 
  MMD2    68%    94%    68%   100% 
 
Based on Kyte and Doolittle plots (Kyte & Doolittle, 1982), MMD and MMD2 are 
hydrophobic proteins with seven predicted transmembrane domains. In Figure 5.4 only the 
mouse MMD proteins hydropathy plots are shown. 
Figure 5.4 A hydropathy plot of mMMD 
and mMMD2 according to Kyte and 
Doolittle. 
The predicted hydrophobic transmembrane 
domains (TM) are numbered with I to VII. 
The  mMMD hydropathy plot shows 7TM 
domains, while mMMD2 plot shows an 
additional hydrophobic N-terminal tail, that 
does not correspond to a signal peptide 
(Bendtsen et al., 2004). The graphic was 





A sequence alignment of mMMD and its orthologues in different species showed a markedly 
conserved protein sequence (Figure 5.5). The mouse protein sequence shares around 98% 
identity with its human (Homo sapiens), chimp (Pan troglodytes), and rat (Rattus norvegicus) 
counterparts over its entire length. The chicken (Gallus gallus) and the frog (Xenopus 
tropicalis) orthologues share 88% identity, followed by the zebrafish (Danio rerio) with 74%. 
Less identity was found in the fruitfly, Drosophila melanogaster, with 43%, and 
Caenorhabditis elegans with 36%. A similar degree of conservation between species was also 
seen with mMMD2 and its orthologues (data not shown). 
  
      Figure 5.5 Multiple sequence alignment of mMMD and its orthologues (ClustalW). 
      Predicted transmembrane (TM) regions in mMMD are depicted in black and numbered with I-VII. Conserved amino acid residues (100% identity)  
      between the orthologues are shown in grey. Putative metal binding residues (conserved in other PAQRs including yeast YOL002c) are shown in green. 
    Chicken           MEFYLEIDPVTLNLIILVASYVILLLVFLISCVLYDCRGKDPSKEYAPEVPASSQPPIRLVVMQQGAPGTRWAKGLVSAYETSPDLQGKRTTVVTSQFYVIEVIEDNWEVLTPRPWAVSL  
    C.elegans         ------------------------------------MKSPESADIELKARRIAYQMSRELEKTDVRDDFQNALLSLPMSETDKNVGFNAFLKLQVDIKESLKNYSKFGKKSNFLKLLTAK  
       
    Chicken           RTVLAVHCLAGQQLHRLCAVGWDLVSACKSAQLVQTHCSPCCGVLFFGSLMHCEQGARFHRALGSSCPLSSQDEGVLSLSYGVAVGHPLPPWSCCATAGFSVRLLSESGKLQFDDGITYC  
    C.elegans         QLKSLDHMLKSTSPDVEINEKNDKIWENGSFSGEHVVAKTVKIVDGVAAHLPEHPIPANIPPLHVAQLYDDDFEQEDEDDLEWLSSQPGGSSSRIPDVPSEPLPRSAGISEKVPEKQMST  
   
    Fruitfly          -------------------------------------------------------------------MSNSEGSGHESGIRTLNRNANGNGNGDLSLMQDLQHKYAFLENLFSKFWKSII 
    Chicken           SILDIYRRSRFCSRHVPGLYLVLQCIQLILLIANRRMESGVTSTGRNGLSVDREFPGYDLPVLQPGFWGSTEKTYFAAWPSSKALHSVPNNVALQFYVQKLQIKKLYIQCSRTRLDLELI 
    C.elegans         RKIVSRARQIAKSDAQIQTEQIEKERVDTAEIGTNCNIIVTPRVLENDDPRGSEFVEKSPFLSPISTAISDISEGEVVQLRSTDNVITVTSRGRIVATPRVIEDDDVVDHHFGSFDSNVL 
                                                                                                                                        TM I 
    Fruitfly          KSNSNL----------KLQLRN-------------------------------------------------------------------VKWKNAKAKPGCAYQPTEIEQVANVITHGIW 
    Human             -----------------MRFKN-----------------------RF------------------------------------------QRFMNHRAPANGRYKPTCYEHAANCYTHAFL 
    Chimp             -----------------MRFKN-----------------------RF------------------------------------------QRFMNHRAPANGRYKPTCYEHAANCYTHAFL 
    Mouse             -----------------MRFRN-----------------------RF------------------------------------------QRFMNHRAPANGRYKPTCYEHAANCYTHAFL 
    Rat               -----------------MQFRN-----------------------RF------------------------------------------QRFMNHRAPANGRYKPTCYEHAANCYTHAFL 
    Chicken           GNNESLSFNLNGFYVGPIKFNAGSKKAVISEVHRLGAERSFTRQTRFSCLVKAPCCSACLSAVLHRLRASQATVCLSAAPTEPITTSSSEKFMNHPAPANSRYKPTCYEHAANCYTHAFL 
    X.tropicalis      ------------------QFNS---------------------IVIFF-----------------------------------------DRFMNHRAPANCRYKPTWYEHAANCYTHAFL 
    Zebrafish         ----------------------------------------------------------------------------------------------------------------------LL 
    C.elegans         VEKSTSPQFSFSAALCKMSGSCG-------------------------------------------------------IIDPDTPPPKAISYKNRRAGKGEAYEPTSHEHVANTVSHAIG 
    Bacillus cereus   -----------------------------------------------------------------------------------------------MTEKMTRMTQFVKEEIANAITHGIG 
                                                         TM II                                                TM III                TM IV 
    Fruitfly          ILPAVFAAIKLFERSSS---ASQYLVAWVYGGALCMLFTVSTFFHCSCYCAEHKPPKNVKAWPCLGWQTYQGLKNVLHRCDRAMIYVFIAGSYFPWLTLENTDHSAILFCMEWVIWLMAG 
    Human             IVPAIVGSALLHRLSDD---CWEKITAWIYGMGLCALFIASTVFHIVSWKKSHLR----------------TAEHCFHMCDRMVIYFFIAASYAPWLNLR--ELGPLASHMRWFIWLMAA 
    Chimp             IVPAIVGSALLHRLSDD---CWEKITAWIYGMGLCALFIVSTVFHIVSWKKSHLR----------------TVEHCFHMCDRMVIYFFIAASYAPWLNLR--ELGPLASHMRWFIWLMAA 
    Mouse             IVPAIVGSALLHRLSDD---CWEKITAWIYGMGLCALFIVSTVFHIVSWKKSHLR----------------TVEHCFHMCDRMVIYFFIAASYAPWLNLR--ELGPLASHMRWFIWLMAA 
    Rat               IVPAIVGSALLHRLSDD---CWEKITAWIYGMGLCALFIVSTVFHIVSWKKSHLR----------------TVEHCFHMCDRMVIYFFIAASYAPWLNLR--ELGPLASHMRWFIWLMAA 
    Chicken           IVPAIVGSALLHRLSDD---RWEKITAWIYGMGLCALFIVSTVFHIVSWKKSHLR----------------TMEHCFHMCDRMMIYVFIAASYAPWLNLR--ELGPLASHMRWFIWLMAA 
    X.tropicalis      IVPSIVGSALLHRLSDD---RWEKITAWIYGMGLCALFIVSTVFHIVTWKKSHLR----------------SVEHCFHMCDRMVIYFFIAASYAPWLNLR--ELGPMASHMRWFIWLMAV 
    Zebrafish         IMPAFVGMALLHRLSDD---RWERFTAWVYGMGLIALFLVSTVFHIISWKKSHMR----------------TMEHCFHMCDRVVIYFFIAASYTPWLNLR--ELGPLAAHMRWFVWLMAA 
    C.elegans         IGPTILVFYYFMCAYAHR--DLQHILMIIYGIFTTLLFTSSTVYHFCELLFRQQN-------------KHRKLRYYLHICDRAAIYLFIAASYTPWLTLR--HCGLPGLNLKWMIWVFAI 
    Bacillus cereus   AILSIPALIILIIHASKHGTASAVVAFTVYGVSMFLLYLFSTLLHSIHHPK---------------------VEKLFTILDHSAIYLLIAGTYTPFLLIT--LRGPLGWTLLAIIWTLAI 
                                    TM V                     TM VI                    TM VII 
    Fruitfly          IGIAYQQVFHERYKCLETFFYLVMGLGPALVVVFTGHH--FHGMMQLKFGGGFYILGIVFFKADGTIPMAHAIWHLFVVLAAGCHYYAILVNLYPSE-GAAAP-- 313 
    Human             GGTIYVFLYHEKYKVVELFFYLTMGFSPALVVTSMNN---TDGLQELACGGLIYCLGVVFFKSDGIIPFAHAIWHLFVATAAAVHYYAIWKYLYRSP-TDFMRHL 238 
    Chimp             GGTIYVFLYHEKYKVVELFFYLTMGFSPALVVTSMNN---TDGLQELACGGLIYCLGVVFFKSDGIIPFAHAIWHLFVATAAAVHYYAIWKYLYRSP-TDFMRHL 238 
    Mouse             GGTIYVFLYHEKYKVVELFFYLTMGFSPALVVTSMNN---TDGLQELACGGLIYCLGVVFFKSDGIIPFAHAIWHLFVATAAAVHYYAIWKYLYRSP-TDFIRHL 238 
    Rat               GGTIYVFLYHEKYKVVELFFYLTMGFSPALVVTSMNN---TDGLQELACGGLIYCLGVVFFKSDGIIPFAHAIWHLFVATAAAVHYYAIWKYLYRSP-TDFIRHL 238 
    Chicken           GGTVYVFLYHEKYKIVELFFYLAMGFSPALVVTSMSN---TEGLEEVAWGGLIYCLGVVFFKSDGVIPFAHAIWHVFVATAAAVHYYAIWKYLYRSP-ADIIRHL 680 
    X.tropicalis      GGTVYVFLYHEKYKIVELLFYLAMGFSPALVVTSMNN---TEGLHELAWGGLIYCLGVIFFKSDGIIPFAHAIWHLFVALAAAVHYYAIWKYLYKSPSADLIRHL 241 
    Zebrafish         AGTIYVFNYHEKYLYCALFVYYLLGSLIALLVTKKTN---TEGLSELAFGGLVYCLGVFFFKCDGVIPFAHAIWHVFVALAAAIHYYAIWKYLYRSPALEDIRDA 203 
   C.elegans         LGILYQYNFHERYKTLETILYILIAAGPSVAIFTMND---RTGLEWMMTGGMMYAVGVFFFKLDGIVAFAHAIWHLFVLLGASCHTYAVYAFLLGPDKNNPVPDI 594 
















5.2. Expression analysis of MMD and MMD2 mRNA 
To monitor MMD and MMD2 transcription in mammalian cell lines, total RNA was isolated 
and Northern blot analysis was performed with specific radioactive DNA probes as described 
in section 4.1.4. To monitor MMD and MMD2 RNA expression in adult mouse and human 
tissues, multiple tissue Northern (MTN) blots (Clontech) were hybridized with the same 
radioactive labeled MMD and MMD2 specific DNA probes.  
5.2.1. Expression patterns of human MMD and MMD2 mRNA 
5.2.1.1. MMD and MMD2 expression in human cells 
Northern blot analysis of various cell types confirmed hMMD expression in macrophages and 
not in monocytes (Rehli et al., 1995). In addition, mRNA was detected in monocyte-derived 
dendritic cells (DC), granulocytes and HepG2 (human hepatocellular carcinoma cell line).  
Lower expression levels were found in B- and T-lymphocytes, in HUVEC (dermal 
fibroblasts), and NADFc (human skin fibroblast) cell lines. Although CaCo-2 and HT-29 
represent two human colon carcinoma cell lines, however HT-29 expressed hMMD at lower 
levelsl than CaCo-2 cells (Figure 5.6A).  
Human MMD2 mRNA was not detectable in all studied cell lines (data not shown). This may 
suggest a very low or even absence of hMMD2 expression 
5.2.1.2. Multiple tissue Northern analysis in human 
Multiple tissue Northern (MTN) blots showed an ubiquitous hMMD expression with the 
highest levels in fetal and adult liver, brain, heart and placenta (Figure 5.6B). In addition, 
human spleen, skeletal muscle and kidney showed an elevated expression of hMMD 
comparing to mMMD (Figure 5.9C).  
The MTN blot was stripped and rehybridized using hMMD2 cDNA probe. Expression 
analysis of hMMD2 revealed that the transcript was restricted to the brain and testis (Figure 
5.6C). In testis the expected transcript, described by the UCSC genome browser Database, 
was detected, however there is no published expressed sequence tags (ESTs) that may support 
the size of the brain transcripts. These different hMMD2 transcripts suggest a probably 
functional divergence or regulation.  
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Figure 5.6 Northern blot analysis of human MMD and MMD2 mRNA expression. 
(A) MMD expression in various human cells: total RNA (10 µg/lane) was hybridized with a probe 
positioned at the 3’-UTR region of hMMD cDNA to detect specifically hMMD expression. The 
positions of the 28S (5025 bp) and 18S (1868 bp) rRNA bands are indicated. The bottom inset shows 
the ethidium bromide-stained 18S rRNA bands before blotting. The Northern blot was kindly provided 
by Dr. Sven Heinz. (B) MTN blot (Clontech) analysis hybridized with the probe used in (A) generated 
from the 3’-UTR region of hMMD transcript. (C) MTN blot analysis hybridized with a hMMD2 probe 




5.2.2. Expression patterns of mouse MMD and MMD2 mRNA  
5.2.2.1. Expression of MMD and MMD2 mRNA in mouse embryo 
To assess the expression pattern of MMD and MMD2 during mouse development, 
whole-mount in situ hybridization (ISH) was carried out on mouse embryo of different 
embryonic stages and on isolated embryonic brains. MMD and MMD2 sense and antisense 
digoxigenin (DIG)-labeled RNA probes were generated as described in section 4.1.6.2, and 
used to perform two independent whole-mount ISHs. 
¾ MMD 
 
Figure 5.7 Expression of MMD mRNA in mouse by whole-mount ISH.  
Side view of mouse embryos. (A) E10 embryo (on the right) shows the negative control. (B) A 
close-up of (A) left embryo showing positive signal in the midbrain (mb), facial mesenchyme (fm), the 
maxillary (mx) and mandible (md) components, branchial arches (ba) and in limb buds mesenchyme 
(lm). (C) The left embryo (E11) shows an almost ubiquitous expression of MMD in the brain, 
forebrain (fb), midbrain (mb) and hindbrain (hb), trigeminal ganglia (V), heart (ht) and limb bud 
mesenchyme (lm). E11 embryo on the right exhibits the negative control. (D) shows MMD 
ubiquitously expressed in the isolated brain of E13 embryo. 
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Hybridization of 10 days old embryos with an MMD antisense probe revealed a broad 
expression throughout the whole embryo with strong signals in the fore-, mid- and hindbrain 
as well as in the first and second branchial arches. In addition MMD was higher expressed in 
the limb bud mesenchyme (Figure 5.7A). The almost ubiquitous expression of MMD in the 
embryo was also seen one day later of development (Figure 5.7B andC).  
Isolated brains from 13 days old embryos were also hybridized with the MMD probe and 
indicated signals in the whole brain. In contrast, no specific signal  was detected in control 
hybridization with the sense probe showing its specificity (Figure 5.7A and C embryos at the 
right). A weak background staining could result from retained probes in embryonic cavities, 
due to an inappropriate perforation and permeabilization of the embryo prior to hybridization. 
¾ MMD2 
In contrast to MMD, MMD2 revealed an almost restricted expression pattern. At E10 embryo 
(Figure 5.8A), MMD2 expression was detected in the forebrain and the roof of the midbrain. 
Furthermore, MMD2 is also expressed in the peripheral nervous system (PNS), like the dorsal 
root and cranial ganglia.  
The trigeminal nerve is the fifth (V) cranial nerve, contains sensory and motor fibers and is 
divided into three branches which are the ophthalmic, maxillary and mandible nerves. In 
addition, sensory branches of the trigeminal nerve enter the medulla and the spinal cord 
(Purves et al., 2001). In fact, at E10 embryos, MMD2 mRNA expression was prominent in the 
trigeminal ganglion (V). Furthermore, MMD2 was also detected in the branchial arches.  
At E11(Figure 5.8B-C), this expression pattern becomes more prominent. Brain from E13 
embryos revealed an MMD2 expression in the cortex and midbrain but also in the ventral 




    
Figure 5.8 RNA expression of MMD2 in mouse embryo by whole-mount ISH. 
(A, left panel) Side view of E10 showing MMD2 staining in the forebrain (fb), midbrain (mb), 
trigeminal ganglia (V) in branchial arches (ba) and limb bud mesenchyme (lm). (A, right panel) shows 
the negative control. (B, left panel) Side view of two E11 embryo. (B, right panel) shows the negative 
control with unspecific background staining. (C) A close-up of B showing MMD2 staining in the 
midbrain (mb), forebrain (fb), maxillary (mx) and mandible (md) components, trigeminal ganglia (V), 
and in dorsal root ganglia (DRG). (D) Dorsal view of E11 showing MMD2 expression in dorsal root 
ganglia. (E) Left panel: view from the ventral side of an E13 brain showing MMD2 staining in the 
cerebral cortex (Cx). Right panel: a close-up of the spinal cord region with MMD2 positive staining in 
the spinal cord (sc) and DRG. 
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5.2.2.2. MMD and MMD2 RNA expression in different adult mouse tissues 
The analysis of MTN blots hybridized with a probe generated from the 3’-UTR region of 
mMMD cDNA, revealed an almost ubiquitous expression, that dominates in the brain, heart, 
and liver but is absent in the spleen and testis. Lower expression levels were observed in lung, 
kidney, and skeletal muscles. (Figure 5.9C, middle panel). Although the ubiquitous 
expression pattern of mouse and human MMD generally correlated, the mouse MTN blots did 
not include colon, thymus, lymph nodes, small intestines, placenta or peripheral blood 
leukocytes. It is therefore unclear if mMMD is also expressed in these tissues as its human 
orthologue. Interestingly, different patterns of expression, were obtained especially in liver 
and heart when using different probes. An additional smaller transcript was detected beside 
the expected 2.5 kb band, suggesting the existence of an alternative upstream polyadenylation 
site. This hypothesis was confirmed when the same MTN blot was hybridized with a probe 
generated from the 5’-coding region of MMD cDNA. A third band (around 1.35 kb) appeared 
revealing the transcript, which is generated when the first 5’-polyadenylation site is used 
(Figure 5.9C, first panel). The presence of two consensus polyadenylation sites (AATAAA) in 
the mMMD sequence downstream of the stop codon correlates with the presence of two 
transcript variants detected by MTN analysis. The third small transcript may be due to a 
non-typical polyadenylation site (Zhang et al., 2005).  
A specific expression of mMMD2 was detected in testis, brain and kidney (Figure 5.9C, left 
panel). In contrast to mMMD, only one mMMD2 transcript was detected which is in line with 
the existence of a single polyadenylation site. Weak bands appearing in the liver and heart 
lanes likely correspond to background signals resulting from an inefficient removal of the 
mMMD probe.  
5.2.2.3. MMD and MMD2 mRNA expression in different mouse cell lines 
Total RNA was extracted from various mouse cell lines following the protocol described in 
section 4.1.4.1. Northern hybridization showed that mMMD mRNA was highly expressed in 
bone marrow macrophages (BMM), and weaker in RAW 264.7 (macrophage cell line), P815 
(mastocytoma cell line) and HT-2 (helper T cell line), as well as in the NIH3T3 fibroblast cell 
line. MMD transcript was not detected in J774 (monocyte-macrophage cell line) and in BV-2 
(microglia cell line). Recently, Bräuer et al. (Brauer et al., 2004) identified a MMD 
orthologue in rat as a macrophage/microglia activation factor (MAF). MAF/MMD transcripts 
were only detected in BV-2 and NIH3T3 cells (Tang et al., 2005). A more sensitive 
quantification of mMMD expression in BV-2 was obtained by performing a quantitative 
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RT-PCR analysis, showing that mMMD is expressed about 5-fold lower in BV-2 than in 
BMM (Figure 5.9B). This differential expression correlates with the intensity of the bands 
shown in Figure 5.9A demonstrating the validity of the Northern blot results.  
As described for the human orthologue, mMMD2 expression was not detected in any cell line 
mentioned above (data not shown). 
 
Figure 5.9 RNA expression pattern of mouse MMD and MMD2. 
(A) MMD expression in mouse cell lines: total RNA (10 µg/lane) was hybridized by a probe 
positioned at the 3’-UTR region of mouse MMD. The positions of the 28S (5025 bp) and 18S 
(1868 bp) rRNA bands are indicated. The bottom inset shows the ethidium bromide-stained 18S rRNA 
bands before blotting. (B) Quantitative RT-PCR analysis of mMMD expression on cDNA prepared 
from mouse BMM and BV-2 cells. The results were normalized to HPRT expression and represent 
mean values ±SD of two independent qRT-PCR analyses. (C) MMD and MMD2 expression in MTN 
blots hybridized with a mMMD probe generated from the 5’-coding region (first panel, left), or with a  
probe generated from the 3’-UTR of mouse MMD (middle panel) and MMD2 (right panel) cDNA.
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5.2.3. Regulation of mMMD in bone marrow macrophages 
Macrophages respond to microenvironment stimuli by different activation phenotypes (see 
section 1.1.3). To investigate, mouse bone marrow macrophages were treated with LPS 
(1 µg/ml media). Afterwards, cells were harvested and total RNA was isolated at the indicated 
time points (30 min-25 h), reverse transcribed, and the cDNA was analysed by quantitative 
real time PCR (qRT-PCR) for mMMD expression.  























Figure 5.10 Inducible mMMD expression in BMM after LPS stimulation. 
Quantitative RT-PCR analysis of mMMD expression in cDNA prepared from mouse BMM, 
unstimulated or stimulated with LPS (1 µg/ml media). Results were normalized to HPRT expression, 
and represent mean values ±SD of two independent qRT-PCR experiments. 
LPS drives the innate activation of mouse macrophages mainly through TLR4 signaling (see 
section 1.1.3). Interestingly, mMMD transcript expression was rapidly upregulated about 
7-fold after 2 h incubation with LPS. This effect was followed by a fast downregulation, 
reaching the lowest expression level after 8 h incubation (Figure 5.10). 
 
While in vitro incubation of mouse BMM with INFγ influences their classical activation, 
incubation with IL-4 drives the development of an alternative activation phenotype (see 
section 1.1.3). On the other hand, the cytokine IL-10 was reported to deactivate macrophages, 
resulting in an anti-inflammatory phenotype different from the alternative activation.  
To find out if mMMD is involved in the development of one of these macrophage subsets, 
isolated mouse BMM were treated with INFγ (10x103 U/ml media), IL-4 (10 ng/ml media) or 
IL-10 (20 ng/ml media) for 4 h. Aterwards, cells were harvested and total RNA was prepared, 


























Figure 5.11 Influence of INFγ , IL-4 and IL-10 on mMMD expression in mouse BMM. 
Quantitative RT-PCR analysis of mMMD expression in cDNA prepared from mouse BMM, untreated 
or treated for 4 h with INFγ, IL-4 or IL-10. Results were normalized to HPRT expression, and 
represent mean values ±SD of two independent qRT-PCR experiments. 
Figure 5.11 shows that mMMD expression was not regulated by any of these cytokines, 
suggesting that it is neither involved in the classical or alternative activation of mouse BMM, 
nor in their deactivation process.  
5.3. Characterization of mouse MMD 
5.3.1. Mouse MMD protein expression analysis 
5.3.1.1. Attempts to generate a monoclonal mMMD antibody  
To investigate mMMD at the protein level, it was crucial to have an antibody targeting the 
protein specifically. However, it turned out to be difficult to find an appropriate peptide 
sequence that is specific for mMMD and capable to immunize a mammalian.  
In animals like rabbit and goat, mMMD protein sequences are well conserved, and most likely 
not antigenic. Until recently, the lowest degree of conservation was found in the chicken 
orthologue before the C-terminal region of the protein was correctly sequenced. Speculating 
that a mMMD peptide may succeed in elucidating an immune response in chicken, the 
C-terminal region, KYLYRSPTDFIRHL, was chosen.  
This peptide was conjugated to KLH (a highly antigenic peptide) at Davids Biotechnologie 
GmbH (Regensburg, Germany) and injected in chicken for immunization. Later IgG 
antibodies specific for this peptide were collected from egg yolks and affinity purified.  
Mouse MMD specific anti-sera were tested in Western blot analyses for the detection of the 
endogenous protein in NIH3T3 and RAW264.7 cell lines (where the transcript was previously 
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detected, Figure 5.9A) and for the detection of the overexpressed, tagged protein in NIH3T3 
cells (see section 5.3.2). Unfortunately, the polyclonal chicken antibody detected no mMMD 
protein in none of these cell lines. Recently the correct sequence of the chicken orthologue 
was published in the database and the C-terminal region turned out to be conserved between 
mouse and chicken, explaining the unsuccessful antibody production.  
Because a specific antibody is an indispensable tool for investigating a proteins localization, 
the epitope-tagging approach was followed.  
5.3.1.2. Expression of epitope-tagged mMMD protein 
Epitope tagging was first described in 1984 (Munro & Pelham, 1984), and consists of fusing 
the protein of interest with a short peptide sequence (tag), against which an antibody exists 
already. Many tags are commercially available in combination with their validated antibody. 
Small epitopes were chosen to tag mMMD (Table 5.2), because large tags possibly interfere 
with the normal folding and function of the protein, thus influencing its cellular expression 
and localization.  
Table 5.2 Epitopes used to tag MMD. 
Epitope name   Size       Sequence        Antibody 
     3xFLAG  18 aa  3x (DYKDDDDK) Mouse M2-anti-Flag
         HA   9 aa    YPYDVPDYA Rat anti-HA 
      c-myc  10 aa    EQKLISEEDL Mouse anti-c-myc 
5.3.1.3. Generation and transfection of MMD-3xFLAG construct 
To tag mMMD C-terminally with 3xFLAG, it was taken advantage of the pIRES-hrGFP-1a 
expression vector purchased from Stratagene. This vector contains an Internal Ribosomal 
Entry Site (IRES) sequence which allows a simultaneous translation of two independent 
proteins from a single transcript under the control of one promoter. Mouse MMD cDNA was 
cloned into the multiple cloning site (MCS) of the vector in frame with a FLAG-tag upstream 
of the IRES sequence. The GFP cassette provided in the vector is located downstream (see 
section 4.1.3.11). In order to investigate mMMD expression in mouse macrophages, 
pIRES-MMD-3xFLAG was used to transiently transfect a mouse macrophage cell line, 
RAW264.7. A successful transfection was controlled by monitoring green cells under a 
fluorescence microscope and by checking the protein expression by Western blot analysis. 
Unfortunately, transient mMMD expression in RAW264.7 was not detected. This may be due 
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to a non-tolerance of these cells for an ectopic expression of mMMD. This idea was later 
confirmed by unsuccessful attempts to generate a cell line stably overexpressing mMMD by 
using a retroviral system (see section 5.3.2).  
In contrast, NIH3T3, a mouse embryonic fibroblast cell line, expressed the tagged mMMD 
very efficiently. Although it has a non-myeloid origin, it was shown that it expresses 
endogenously mMMD (Figure 5.9A), suggesting that it may be an apropriate cell system to 
characterize the protein. After successful expression of 3xFLAG-tagged MMD in NIH3T3 
cell line, eight different constructs were generated with three types of epitopes inserted at 
different locations in various combinations (see section 4.1.3.11). They were used to 
investigate the cellular localization of the protein independently from the insertion location of 
the tag. A summary of the generated tagged MMD variants is shown in Figure 5.12.  
 
     
Figure 5.12 Scheme  for cloning tagged MMD constructs into pIRES-hrGFP-1a vector. 
Tagged MMD constructs were generated by PCR amplification using pIRES-MMD-3xFLAG as 
template (A). HA- (yellow circle) and FLAG- (orange rectangle) tags were introduced N- or 
C-terminally of MMD by PCR. c-Myc tag (blue hexagon) was incorporated either in the first (H) or 
the second extramembrane loop (E-G, I) by site specific mutagenesis in a three steps cloning. The stop 
codon (black rectangle) of MMD ORF was either mutated (white cross) to allow the translation of the 
downstream FLAG-tag, or inserted with the primer to prevent expression of the C-terminal tag. The 




5.3.1.4. Expression analysis of tagged mMMD by Western blot 
All tagged MMD constructs were transiently transfected in the NIH3T3 cell line using 
Effecten™ or Lipofectamine 2000™ following the protocols described in section 4.4.1. To 
monitor the expression of the tagged protein, membrane homogenates were prepared two days 
after transfection and analysed by Western blot analysis using specific antibodies for each 
tag (Table 4.5). It was noticed that whole protein lysates tended to smear in the gel, making 
the specific detection of defined MMD bands difficult. By preparing a membrane lysate, the 
genomic DNA contamination as well as the background signal was reduced. 
                   
Figure 5.13 Western blot analysis showing expression of tagged MMD in NIH3T3 cell line. 
Membrane cell lysats of transiently transfected NIH3T3 cell line with various tag constructs were 
separated by SDS gel electrophoresis and blotted. Detection of tagged-MMD protein was done using 
mouse anti-FLAG antibody (upper pannel), rat anti-HA antibody (middle pannel) and mouse 
anti-cMyc antibody (last pannel). The asterisk marks an unspecific band. 
 
Figure 5.13 shows that almost all of the tagged constructs were expressed. As expected, the 
apparent molecular weight of mMMD proteins corresponds to the calculated weight of wild 
type MMD (28 kDa) plus the molecular weight of the incorporated tags (3xFLAG: 2.8 kDa; 
HA: 1.1 kDa; and c-Myc: 1.2 kDa). Furthermore, it was shown that introducing tags at the N- 
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or C-terminus, in the first or the second extramembrane loop of MMD, or in different 
combinations did not influence its expression in NIH3T3 cells.  
However, when a single FLAG was incorporated at the N-terminus and an HA-tag at the 
C-terminus of MMD, none of these tags were detected (Figure 5.13, lane 7). This result was 
confirmed by immunocytochemistry (see section 5.3.1.5), suggesting that the presence of 
these tags in this order impaired mMMD expression.  
5.3.1.5. Subcellular localization of tagged MMD in NIH3T3 
Since the subcellular localization of mMMD was unknown, NIH3T3 cells transfected with 
tagged MMD constructs were subjected to immunostaining following the protocol described 
in section 4.4.1. Cells were seeded in chamber slides and transfected with the tagged 
constructs (see section 4.4.1). After two days, they were fixed with 2% PFA, permeabilized 
with methanol/acetone (1:1) and incubated with the corresponding primary and secondary 
antibody (see section 4.2.5.2). The GFP gene downstream of the IRES sequence is expressed 
constitutively under the control of the CMV promoter, thus the green fluorescence staining 
was taken as an indicator of successful transfection. In contrast, the expression of the 
exogenous tagged mMMD protein, shown in red, was only detected when cells were 
permeabilized, indicating that mMMD is localized exclusively inside the cell with one 
exception (MMD(cMyc1)). The staining suggests a perinuclear and probably endoplasmic 
reticulum (ER) and nuclear membrane localization in NIH3T3 cells. 
FLAG-MMD-HA protein was not detected by immunocytochemistry as it was also seen with 
Western blot analysis (Figure 5.13), independently of transfection efficiency. In fact, green 
cells were observed (data not shown), suggesting that the expression of this variant is not 
controlled on the transcription level but more likely on the translational level (see section 6.2). 
When c-Myc tag was incorporated in the first extramembrane loop of mMMD a vesicular 
localization was observed (Figure 5.14G). The different cellular localization may indicate that 
this region of the protein plays a crucial role in the correct integration of MMD into the lipid 
bilayer and its retention in the perinuclear space. 
To confirm the perinuclear localization and to eliminate any possibility of an artefact due to 
receptor overexpression particuliary in NIH3T3 cells, human embryonic kidney cells, 
HEK293T, were transfected with HA-MMD, MMD-3xFLAG, or HA-MMD-3xFLAG 
constructs. A similar staining was obtained suggesting that the predominant perinuclear and 
nuclear membrane localization is not cell-line specific (data not shown). 
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Figure 5.14 Perinuclear localization of tagged mMMD in NIH3T3 cell line. 
Immunofluorescence microscopy of NIH3T3 cells transiently transfected with different tagged 
mMMD constructs (A-H). The GFP panel shows a diffuse staining in NIH3T3 and is a marker for 
transfected cells. In the MMD panel, tagged MMD protein was visualized by using mouse anti-FLAG, 
rat anti-HA or mouse anti-cMyc antibodies with their corresponding secondary antibodies. MMD 
perinuclear and membrane nuclear localization was seen with tagged MMD (A-F and H) but not in G 




5.3.2. Stable overexpression of mMMD in NIH3T3 cell line 
To further examine MMD localization and orientation in the membrane lipid bilayer, a 
NIH3T3 cell line stably overexpressing the tagged protein was generated by using a retroviral 
expression system. The significant advantage of stable cell lines is that once the gene of 
interest is transfected, it integrates into the genome of the recipient cell, leading to a constant 
and stable expression of the corresponding protein over many cell passages. A NIH3T3 cell 
line, expressing tagged mMMD stably, offers an easy model for immunocytochemistry 
analysis. In addition, the influence of mMMD overexpression on the cell signaling may be 
studied.  
5.3.2.1. Stable expression of tagged mMMD in NIH3T3 cell line 
The expression and the packaging plasmids (see section 4.4.2.1) were introduced into 
HEK293T cells as described in section 4.4.2.2. The IRES sequence in pQCXIP vector allows 
the generation of a single mRNA containing tagged MMD and puromycin resistance 
transcripts. Produced viral particles from HEK293T cells were harvested and used to 
transduce the NIH3T3 target cell line four times. After selection, pyromycin resistant cells, 
were expanded and used for further experiments. The retroviral transduction efficiency was 
controlled by transfecting HEK293T separately with a control vector pQCXIP-EYFP, 
containing an Enhanced Yellow Fluorescence Protein gene (EYFP). Transduction was 
monitored by fluorescence microscopy 48 h after the first infection.  
 
 
Figure 5.15 NIH3T3 and RAW264.7 cell 
lines  transfected with pQCXIP-EYFP 
control vector using the retroviral 
system.  
NIH3T3 (first row) and RAW264.7 
(second row) transduction using a 
retroviral transfection system. Expression 
of EYFP protein was visualized by 
fluorescence microscopy, and indicated the 
high transduction efficiency for the target 





A high transduction efficiency of NIH3T3 and RAW264.7 cell lines was achieved        
(Figure 5.15), however tagged MMD expression was not detected in RAW264.7. In fact after 
puromycin selection the majority of the target cells died and the transduction of a mouse 
microglia cell line (BV-2) was unsuccessful as well (data not shown).  
Taken together, this result suggests that mMMD overexpression in RAW264.7 and in BV-2 
may be toxic for the cells, driving them into apoptosis or to silence the gene expression. 
Consequently, NIH3T3 cell line was chosen as an overexpression model for mMMD. 
 
The stable expression of tagged mMMD in NIH3T3 cell lines was confirmed by Western blot 
analysis. NIH3T3 cells transduced with an empty pQCXIP vector served as a negative control 
cell line (Figure 5.16). The molecular weight of tagged proteins matched the one shown in 
section 5.3.1.4, indicating that the tagged protein was properly translated.  
 
                      
Figure 5.16 Western blot analysis showing stable tagged MMD expression in NIH3T3 cell line. 
Membrane lysates from NIH3T3 cells were assessed for stable expression of the tagged MMD protein. 
As a negative control, a cell line transduced with an empty vector was used. Detection of MMD 
protein in HA-MMD cells was done by using a rat anti-HA antibody (right panel), and in MMD-
3xFLAG with a mouse anti-FLAG antibody (left panel). The asterisks mark an unspecific band.  
Expression of tagged MMD in the stably transfected NIH3T3 cell lines was quantified on 
RNA level by qRT-PCR. Figure 5.17 shows about 20-fold MMD-3xFLAG and 10-fold 
HA-MMD transcript overexpression compared with the endogenously expressed MMD in the 
negative control cell line. The difference between HA- and FLAG-tagged transcript 
abundance may depend on a lower amount of cells expressing stably HA-MMD.  
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Figure 5.17 Quantitative RT-PCR analysis of tagged mMMD expression in NIH3T3 cells. 
For qRT-PCR analysis, cDNA was prepared from NIH3T3 cell lines stably expressing HA-MMD or 
MMD-3xFLAG. The negative control cell line was generated by using the empty pQCXIP vector for 
transduction. Results were normalized to HPRT expression, and represent mean values ±SD of two 
independent qRT-PCR experiments. 
5.3.3. MMD cellular localization in NIH3T3 cell line 
5.3.3.1. Perinuclear localization of mMMD in NIH3T3 cells 
To study mMMD cellular localization in stably transfected NIH3T3 cell lines, 
immunocytochemistry was performed on cells seeded on chamber slides. Again a perinuclear 
staining of tagged-MMD was observed (Figure 5.18A and I), which correlates with the 
localization described in transiently transfected cells (Figure 5.14).  
Recently, Bräuer et al. reported that rat MMD protein was associated with the lysosomal 
associated membrane protein (LAMP)-1 in COS-7 and BV-2 cell lines (Brauer et al., 2004). 
To assess whether HA-MMD and MMD-3xFLAG proteins were also located in lysosomes, 
tagged mMMD was compared to the lysosomal marker LAMP-1. 
Cell lines expressing tagged MMD were incubated with anti-FLAG and anti-HA antibodies 
and visualized with Alexa Fluor (red fluorescence) coupled secondary antibodies. Lysosomes 
were visualized using a monoclonal FITC-conjugated anti-LAMP-1 (CD107) antibody 
(Figure 5.18, panels B, F, J and N). Surprisingly, no lysosomal colocalization was observed 
with either tagged-MMD proteins (panels D and L). Staining of MMD was mainly confined at 
the nuclear envelope and at the reticulate network. Additional control stainings may be 
required to determine the exact localization of MMD, such as a costaining with specific nulear 





Figure 5.18 Perinuclear localization of stably expressed tagged MMD in NIH3T3 cell lines. 
Immunofluorescence microscopy of NIH3T3 cells stably expressing tagged MMD, seeded on chamber 
slides and processed for immunocytochemistry 24 h later. (A) and (I) depict NIH3T3 cell lines 
expressing HA-MMD and MMD-3xFLAG visualized with rat anti-HA and mouse anti-FLAG 
antibodies, respectively. A perinuclear staining is seen. (E) and (M) show the corresponding negative 
controls where NIH3T3 is transduced with the empty pQCXIP vector and thus does not express any 
tagged version of mMMD. Lysosomes were visualized using the anti-LAMP-1 antibody (green, B, F, J 
and N). The nuclei were counterstained with DAPI in blue (C, G, K and O). The last panel represents a 
merge of all staining, accentuating the absence of a colocalization of tagged MMD with LAMP-1 (D 
and L) (Original magnification x400).  
 
5.3.3.2. Mouse MMD orientation in the lipid bilayer 
Based on Kyte and Doolittle plot (Figure 5.4), it was predicted that mMMD contains a seven 
transmembrane domain (7TM) featuring a N-terminal tail of 28 amino acids and a smaller 
C-terminal domain of 19 amino acids (Figure 5.3). So far, the localization of mMMD in the 
lipid bilayer had not been determined. Studying the orientation of mMMD in the membrane 
may allow the localization of binding sites and to determine the orientation of active site 
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residues, relative to the membrane. This information may in turn suggest possible functions 
and reaction mechanisms. 
To determine mMMD orientation, we took advantage of the digitonin detergent. If used at 
low concentrations, it permeabilizes specifically the plasma membrane leaving the nuclear 
membrane intact (Adam et al., 1990). The nuclear envelope is composed of two lipid bilayers, 
the outer nuclear membrane, which is continuous with the endoplasmic reticulum (ER) and 
the inner nuclear membrane. Thus by digitonin permeabilization, the entry of antibodies only 
to the cytoplasm and not to the nucleoplasm should allow the identification of cytoplasmic 
and outer nuclear membrane components.  
For this purpose, immunocytochemistry was performed with NIH3T3 cell lines, stably 
expressing HA-MMD and MMD-3xFLAG, as described in sections 4.2.5. Briefly, one day 
after seeding on gelatin coated chamber slides, cells were fixed on ice with 2% PFA. 
Afterwards, they were either incubated on ice with acetone/methanol (1:1), or with 
0.003% digitonin for different times to optimize the permeabilization conditions. Cells were 
then labeled with either mouse anti-FLAG or rat anti-HA. In addition, the nucleus was 
counterstained with DAPI. 
Whereas Figure 5.19F revealed a perinuclear and nuclear membrane localization of 
HA-MMD after digitonin permeabilization, FLAG-MMD was only detected after 
methanol/acetone permeabilization (panel G and I) of the cells. These findings suggest that 
the N-terminal region of mMMD probably faces the cytoplasm whereas the external 





Figure 5.19 Orientation of stably expressed tagged MMD in NIH3T3 cell lines. 
Immunofluorescence microscopy of NIH3T3 cells expressing stably tagged MMD. Cells were seeded 
on chamber slides, and after 24 h permeabilized either with acetone/methanol (panels A-C and G-I) or 
with 0.003% digitonin (panels D-F and J-L) before proceeding with immunostaining. Panels A-F 
represent cells expressing HA-MMD stained with rat anti-HA antibody (red, A and D). Panels G-L 
depict cells expressing MMD-3xFLAG stained with mouse anti-FLAG antibody (red, G and J). Nuclei 
were counterstained with DAPI (panels B, E, H, and K). HA-tag was always detected (panels C and 
F), whereas FLAG-tag was only stained after complete permeabilization of the cells (panels I) 
(Original magnification x400).  
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5.4. Generation of MMD knock-out ES cells 
5.4.1. Gene targeting strategy 
Since little is known about mMMD and its protein function, we followed a gene targeting 
approach to study mMMD function.  
Gene targeting has become a powerful tool in the field of mouse genetics, and allows to 
inactivate a gene of interest at the genetic level in order to investigate its function in the 
context of the whole animal. Homologous recombination in mouse embryonic stem (ES) cells 
is the key of this concept. An artificial targeting construct, containing selectable markers 
surrounded by two regions of homology to the targeted locus, is electroporated into mouse ES 
cells. In a fraction of those cells, which were successfully transfected with the targeting 
construct, homologous recombination takes place at the regions of homology between the 
construct and the ES cells-genomic DNA. This event leads to the replacement of the intact 
fragment of the gene with a selectable cassette. When ES cells with the disrupted gene are 
injected into blastocysts, they can colonize all tissues of the future embryo including the germ 
line, thus giving birth to chimeras. Further breeding of chimeras may lead to homozygote 
knock-out mice bearing the targeted gene.  
Unfortunately, in ES cells, random integration of the targeting construct happens to be the 
rule and not the exception. The specific integration of the vector via homologous 
recombination is a rare event. To be able to distinguish between homologous and 
non-homologous recombination, strategies are employed helping selecting positive clones. 
Besides the design of the targeting vector, many other factors influence the efficiency of the 
homologous recombination and were taken into consideration in the following section. 
5.4.2. Generation of the gene targeting vectors 
In the course of this work, five replacement vectors (Thomas et al., 1992), including the 
following elements, were designed to target MMD gene in mouse ES cells (see section 4.5.1).  
¾ Arms of homology 
A short and a long arm were selected on both sides of the genomic region, that should be 
replaced by selection markers during homologous recombination. In this work, arms of 
homology were generated by PCR from isogenic DNA because sequence mismatches 
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between the homologous arms of the vector and the target locus can reduce the efficiency of 
the homologous recombination (te et al., 1992). 
¾ GFP reporter gene 
A GFP reporter gene (1 kb) was cloned in frame with the ORF of mMMD, downstream of the 
left homologous arm, which contains the first ATG start codon. After successful insertion of 
the targeting vector into the genome of ES cells, GFP expression can be driven by the 
endogenous promoter of mMMD. This approach is also called “knock-in” and can allow the 
spatial and temporal tracking of mMMD expression in adult mice. 
¾ Positive selection marker 
For positive selection, a “NeoR” cassette (2 kb) was subcloned out of a pBS vector (kindly 
provided by Prof. Dr. Klaus Pfeffer, Institut of Medical Microbiology, Düsseldorf, Germany). 
The neomycin resistance gene (neor) encodes the neomycin phosphotransferase enzyme under 
control of the strong PGK (phoshoglycerate kinase I) promoter. Because the constitutive 
translation of the selection gene is independent from its insertion location, the NeoR cassette 
allows selection of both cells which integrated the cassette either via random or homologous 
recombination. It was reported that after homologous recombination neor expression may 
interfere with the expression of neighboring genes (Muller, 1999), therefore two loxP sites 
flank the NeoR cassette and allow its subsequent excision by using the Cre-loxP-site-specific 
recombinase system.  
¾ Negative selection marker 
As negative selection markers, the TK (thymidine kinase)-cassette (2.8 kb) in pGEM7 vector 
(kindly provided by Prof. Dr. Klaus Pfeffer) or the DT-ApA (Diphterie toxin A with poly(A) 
signal)-cassette (1.37 kb) in pBS vector (kindly provided by Yanagawa.Y (Yanagawa et al., 
1999)) were used. After homologous recombination, the negative selection cassette is not 
inserted and thus inactivated because of its location outside of the homologous regions. But if 
the targeting vector integrated randomly, the negative selection cassette will be co-inserted, 
and consequently its gene product is expressed. The TK of Herpes Simplex virus causes 
premature termination of DNA synthesis in the presence of the drug Gancyclovir driving cells 
into apoptosis (Nagy et al., 2003). In contrast, expression of the diphteria toxin via the 
DT-ApA cassette leads to the toxin accumulation, which directly inhibits chain elongation in 
protein synthesis without addition of drugs (Nagy et al., 2003; Yanagawa et al., 1999).  
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¾ A linearization site 
In order to increase the integration efficiency of the targeting vector into the ES cell genome, 
the vector is linearized prior to electroporation. A NotI restriction site was chosen to linearize 
each targeting vector described below, because it does not cut within the whole mMMD locus, 
nor within the selection cassettes or reporter gene.  
 
Once generated, the targeting construct was transfected into ES cells via electroporation. 
Homologous recombination leads to the “replacement” of the genomic region of the gene of 
interest with the elements located between the homologous arms of the vector. In order to 
disrupt the function of this gene, exons should be removed which have drastic consequences 
on the ORF, generating a null allele. As described in section 5.1.1, mMMD has 7 exons with 
the starting ATG codon located in exon I. In most MMD targeting constructs, (see section 
4.5.1) the GFP reporter gene and the NeoR cassette were inserted into the middle of exon II to 
ablate the intron-exon transition (Table 5.3) and thereby the transcription of mMMD. The 
targeting construct IV was the exception, where the genomic region between exons V and VI 
was targeted. 
Table 5.3 Intron-exon boundaries in the mouse MMD. 
 Exon Size (bp)     5’-splice donor Intron (bp)   3’-splice acceptor Amino acid interrupted
    I      231 GATTCCAGCGgtgagagttc-      7784 -gtctccacagTTTCATGAAC       Gln-Ar/g-Phe 
   II      82 CACACACGCAgtgagtacaa-      2225 -ttcctcccagTTCCTCATTG          Ala-/-Phe 
  III     161 GCCACTTGAGgtatagtggg-      4515 -cccccaacagAACAGTGGAG       Leu-Ar/g-Thr 
  IV      75 ACGCCCCATGgtaagatagc-     1467 -gcatctatagGTTAAATCTC       Pro-Tr/p-Leu 
   V     102 ACCATGAAAAgtaagagaaa-     1365 -gtccctacagGTATAAAGTG       Glu-Ly/s-tyr 
  VI      70 GACATCAATGgtgagacgtg     9082 -ctgttgacagAATAACACTG         Met-/-Asn 
  VII    1915                   - 
 
To identify false positive NeoR clones, which integrated the vector at random positions, the 
genomic DNA of every single clone was isolated, digested with an appropriate enzyme and 
analysed by Southern blot. Two specific external probes, 5’ (of the left arm) and 3’(of the 
right arm), positioned outside of the homologous arms, were designed for each vector. In 
addition it was necessary to identify a restriction site cutting the genomic DNA outside of 
these homologous region and thereby giving differential band patterns after targeting. 
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5.4.3. ES cells transfection and screening  
Generated targeting constructs were transfected into ES cells following the procedure 
summarized in Figure 5.20. To improve the electroporation efficiency, various protocols were 
followed and are described below. Results are represented in Table 5.4. 
                                     
Figure 5.20 Different stages of ES cells transfection and screening. 
Generated targeting construct was linearized and electroporated into ES cells, which were previously 
expanded on EF plates. After electroporation and selection (positive and negative selection), ES cell 
clones were picked into 24-well plates and expanded. Once ES cells reached confluency, they were 
split into an A-plate (planned for freezing) and a B-plate (used for screening). 
5.4.3.1. Transfection and screening of targeting construct I  
The cloning procedure of targeting construct I, TOPO-[KA-GFP-Neo-LA]-TK, was described 
in section 4.5.1.1, and its map is schematically depicted in Figure 5.21.  
The transfection of targeting construct I into ES cells was performed as follows 
(Prof. Dr. Thomas Hehlgans, Institut of Immunology Regensburg, personal communication): 
ES cells (kindly provided by Prof. Dr. Klaus Pfeffer) were seeded on a monolayer culture of 
EF cells. EF CD1 cells were kindly provided by the lab of Prof. Dr. Thomas Hehlgans, and 
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were expanded for three weeks. Prior to electroporation, their mitosis was inactivated by 
incubation with Mitomycin C.  
The electroporation of 20 µg linearized DNA into 5x106 ES cells/cuvette was performed with 
Biorad electroporator (340 V, 250 µF, constant time between 5.2 and 6.4 ms). After 10 days 
selection (with Neomycin and Gancyclovir), 200 ES clones were picked and cultured for two 
weeks in ES cell medium without any selection pressure. Afterwards, ES cells plates were 
frozen and genomic DNA was phenol/chloroform extracted from each clone separately (see 
section 4.5.7.1). The screening of ES clones was performed by using a 5’ and 3’ DIG-labeled 
Southern probe. From 200 clones, only one was screened positive for homologous 
recombination. Unfortunately, because the whole procedure was very much time consuming 




Figure 5.21 Schematic representation of MMD targeting construct I. 
TOPO[KA-GFP-Neo-LA]-TK targeting vector contains a reporter cassette (GFP, in green) and a 
positive selection cassette (NeoR, in pink) with loxP sites (black arrows). Both cassettes are flanked by 
a homologous short ( 0.5 kb) and long (2.5 kb) arms displayed as bold lines also on the endogenous 
locus. A negative selection cassette (TK, in grey) was inserted outside the homologous regions. After 
homologous recombination (dotted lines), part of exon II and the following intron (regular line) were 
replaced with NeoR and GFP cassettes to generate the targeted locus. Southern blot analysis was 
performed after digestion of the genomic DNA with XbaI restriction enzyme. Detection followed by 
using a 5’ and 3’ probes (green lines). The expected size of the WT band is 4.9 kb and after 
recombination the 5’probe detects a 2.1 kb and the 3’probe a 3.3 kb band (dashed arrows). (B) BamHI; 
(E) EcoRI; (H) HindIII; (K) KpnI; (N) NotI and (S) SalI restriction sites. 
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5.4.3.2. Transfection and screening of targeting construct II 
The recombination efficiency obtained with targeting vector I was not sufficient (Table 5.4). 
Possibly the length of the homology regions may have influenced the homologous 
recombination efficiency (Hasty et al., 1991), therefore in the second targeting construct the 
short 500-bp arm (KA) was replaced by a longer 4600-bp arm (see section 4.5.1.2). The map 
of targeting construct II is represented in Figure 5.22. 
 
 
Figure 5.22 Schematic representation of MMD targeting construct II.  
TOPO-[LLA-GFP-Neo-La]-TK targeting construct includes GFP, Neo and TK cassettes. The 
homologous regions (in bold) consist of the long (4.6  kb) and short (2.5 kb) arms. The Southern blot 
analysis was performed following digestion of the genomic DNA with XbaI, and screening with the 
3’probe (green line). The expected WT band has the size of 4.9 kb and after homologous 
recombination an additional 3.3 kb band was expected. (B) BamHI; (E) EcoRI; (H) HindIII; (K) KpnI; 
(N) NotI and (S) SalI restriction sites. 
Amplification and purification of large amounts of this construct were possible only after 
growing the transformed bacterial DH10B strain under non-stringent conditions (50 µg/ml 
ampicillin and at 32°C). Afterwards, the targeting construct II was introduced into ES cells 
following the protocol described in section 5.4.3.1. Additionally, an Amaxa electroporator 
was used to electroporate 2.5x106 ES cells with 10 µg DNA following the manufacturer’s 
instructions. Although no negative selection was done, only 60 NeoR clones were picked and 
screened negative for homologous recombination. The absence of homologous recombination 
and a high mortality rate of the electroporated ES cells were the two main reasons to design a 
third targeting construct. 
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5.4.3.3. Transfection and screening of targeting construct III 
Taking advantage from the results of previous targeting vectors, targeting construct III, 
pBS-[SA3-GFP-Neo-LA]-DT, was generated as described in section 4.5.1.3 (Figure 5.23).  
 
 
Figure 5.23 Schematic representation of MMD targeting construct III. 
The pBS-[SA3-GFP-Neo-LA]-DT vector contains in addition to GFP and Neo cassette, a DT negative 
selection cassette (in blue). The bold lines depict the homologous short (1.5 kb) and long (2.5 kb) 
arms. The WT genomic DNA was digested either with NcoI or XbaI to generate a 4.3 kb or a 4.9 kb 
band, respectively. After homologous recombination (dotted lines), an additional band with the size of 
5.7 kb by using the 5’probe, and of 3.3 kb by using the 3’probe is expected. (B) BamHI; (E) EcoRI; 
(H) HindIII; (K) KpnI; (N) NotI, and (S) SalI restriction sites. 
pBS-[SA3-GFP-Neo-LA]-DT was electroporated into a new batch of ES cells which were 
kindly provided by Dr. Marina Karaghiosoff (Institut of animal breeding and genetic, Vienna, 
Austria). In addition, a new FCS batch was tested for these ES cells. To improve the plating 
and adherence of electroporated ES cells, a new batch of EF cells was prepared from inbred 
mice expressing the neor gene (see section 4.5.2.3). EFneor cells have the advantage to 
preserve the non-differentiated morphology of ES cells during their selection more efficiently. 
In addition, EFneor cells were inactivated via radiation before cryo-conservation. Whenever 
needed, they were thawed and directly used without expansion. In this way the targeting 
experiment time was reduced to at least 3 weeks.  
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For electroporating the targeting construct III, the Amaxa protocol described in section 5.4.3.2 
was followed. Unfortunately only 29 NeoR clones were picked from six electroporation 
reactions. In contrast, Biorad electroporation of 50 µg linearized DNA into 3x107 ES cells 
(500 V, 340 µF and between 7.1 and 8.3 ms) allowed to pick 600 NeoR clones from five 
electroporation reactions. Again all clones were screened negative for homologous 
recombination. 
5.4.3.4. Transfection and screening of targeting constructs IV  
Suspecting that the genomic region between exon I and II could be inappropriate for a 
homologous recombination event in construct IV, the short homologous arm (1.4 kb) was 
positioned between exons IV and V, and the long arm (4.4 kb) upstream of exon VI. 
Consequently, after homologous recombination exons V and VI are replaced with the Neo 
cassette, which disturbs the ORF of the gene. Although, the first four exons of mMMD will be 
translated, however the protein will be lacking 122 amino acids (out of 238) which may 
severely affect its membrane integration and therefore its functional property.  
 
 
Figure 5.24 Schematic representation of the MMD targeting construct IV. 
pBS-[SAex5-Neo-LAex6]-DT targeting construct contains Neo and DT cassettes. The homologous 
regions (in bold) consist of a short (1.4 kb) and a long (4.4 kb) arms. After homologous recombination 
(dotted lines), exons V and VI were replaced with the Neo cassette. A 3’southern probe (green line) 
was used to distinguish between a WT (6.2 kb) and knock-out (8.6 kb) band. 
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The targeting construct IV, pBS-[SAex5-Neo-LAex6]-DT (Figure 5.24), was cloned as 
described in section 4.5.1.4. It was electroporated following the instructions described in 
section 5.4.3.3. This led to the isolation of 551 NeoR clones. Genomic DNA was isolated 
following a fast method (see section 4.5.7.1) which reduced enormously the hands-on time 
needed in phenol/chloroform genomic DNA extraction. The Southern blot screening was 
performed using radioactively labeled probes, reducing the screening procedure to 2 weeks. 
Again, all 551 NeoR clones were negative for homologous recombination. 
5.4.3.5. Transfection and screening of targeting vector V 
The elements of targeting vector V are the same as described in Figure 5.21. However, 
because no enrichment of clones with a successful homologous recombination event was seen 
with the previously described targeting vectors, negative selection markers were omitted from 
construct V. This has an additional advantage, which is to reduce the size of the vector. 
 
TOPO-[KA-GFP-Neo-LA] was chosen to electroporate ES cells because it was the only 
vector, which yielded to a single homologous recombination event. After isolation and 
expansion of 553 NeoR clones, the genomic DNA was extracted and Southern blot analysis 
was carried out with radioactively labeled probes. Besides the expected wild type (WT) band, 
many clones displayed additional bands, which however can not be explained by a 
homologous recombination event. It seems that the targeting construct integrated 
inappropriately into the MMD locus. 
 
Table 5.4 Summary of the targeting experiments 
             Targeting constructs    Number of isolated clones   Number of positive clones 
      TOPO-[KA-GFP-Neo-LA]-TK                     200                        1  
     TOPO-[LLA-GFP-Neo-LA]-TK                      60                        0 
     pBS-[SA3-GFP-Neo-LA]-DT                     629                        0 
     pBS-[SAex5-Neo-LAex6]-DT                     551                        0 




5.5. Mouse MMD silencing in NIH3T3 and RAW264.7 cell 
lines 
Gene silencing using short intereference RNA (siRNA) is a more recent approach to 
knock-down a gene of interest. After many unsuccessful attempts to generate a mutant ES cell 
line by gene targeting, the next step was to silence mMMD in NIH3T3 and RAW264.7, which 
can then be used as tools for investigating mMMD function. It will be interesting, for example 
to study the influence of mMMD silencing on the gene expression pattern in these cells.  
Four siRNA duplexes were commercially available (Qiagen, Germany): 
• Mm_Mmd_1_HP siRNA: CCG GAT TAT GAT AGT ATT ATT 
• Mm_Mmd_2_HP siRNA: ATG CAT GAT TCT GAA CAG TTA 
• Mm_Mmd_3_HP siRNA: TTG GTG TTT AAG AGA AAT GAA 
• Mm_Mmd_4_HP siRNA: CTG TGT ATA TTT GAC TTT AAA 
NIH3T3 and RAW264.7 cell lines were transfected with siRNA duplexes following the 
procedure described in section 4.1.5. After 48, 72, and 96 h cells were harvested and mMMD 
transcript expression was evaluated by qRT-PCR. A complete and stable reduction of mMMD 
was reached only with the “Mm_Mmd_1_HP siRNA” siRNA (data not shown).  
 
In NIH3T3 cells, mMMD expression was reduced to about 90% (Figure 5.25) and in 
RAW264.7 cells to about 80% of the initial level after 48 h.  
However mMMD mRNA expression was remarkably lower in RAW264.7 cells and 
decreased after 72 h culture independently of siRNA transfection. This may have reduced the 
general silencing effect. It seems that stress factors (such as consumption of medium 
nutriments after long period of culture) may influence mMMD expression in RAW264.7 but 
not in NIH3T3 cell lines. No significant growth inhibition or apoptosis was observed during 
the culture period, suggesting that MMD knock down does not interfere with survival or 
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Figure 5.25 Silencing of mMMD in NIH3T3 and RAW264.7 via siRNA. 
NIH3T3 and RAW264.7 cell lines were transfected with the “Mm_Mmd_1_HP siRNA” duplexes, and 
RNA was prepared from cells harvested after 48, 72, and 96 h. Expression of mMMD transcript was 
quantified with qRT-PCR. As negative control a non silencing siRNA purchased from Qiagen was 
transfected. Mouse MMD transcript was specifically and efficiently depleted in NIH3T3 (A) and 





Macrophages are a main cellular component of the innate immune system. They are 
responsible for an efficient elimination of pathogens, as well as tissues homeostasis. The 
Monocyte to Macrophage Differentiation (MMD) gene was identified in our lab as being 
up-regulated during the differentiation of human monocytes to macrophages (Rehli et al., 
1995).  
In this work, the expression patterns of MMD and its homologue, MMD2, were studied in cell 
lines and primary tissues of human and mouse origin, as well as during mouse embryogenesis. 
At the protein level, mouse MMD (mMMD) subcellular localization and orientation were 
determined.  
To gain insights into mMMD function, ES cell culture was established in the course of this 
work, to generate a mMMD ES knock-down cell line. In addition, siRNA silencing, was 
considered as an alternative approach to silence the gene. Gene silencing offers many distinct 
advantages when investigating an unknown protein. The fact that both mouse and human 
MMD proteins share 99% sequence identity, makes a MMD knock-down mouse a useful tool 
for studying MMD function in vivo and its putative role in the human organism.  
The recent classification of MMD and MMD2 into the newly defined Progestin and AdipoQ 
Receptor (PAQR) family (Tang et al., 2005) raises many questions about their functional 
association with these receptors. To date, PAQRs are divided into three subgroups: 
adiponectin receptors (AdipoRs), membrane progestin receptors (mPRs) and Hemolysin 
(Hly)-III related proteins. They differ in their genome and cellular localization, and in their 
gene organization (Tang et al., 2005), but they all share a seven transmembrane (7TM) core 
and conserved amino acid residues. Discussing their wide range of function may help getting 
more insights into MMD and MMD2 role in mammals. 
6.1. Messenger RNA expression patterns 
In mouse embryo, whole mount in situ hybridization showed that MMD was expressed in all 
tissues and brain structures, although at different expression levels (Figure 5.7). In contrast, 
MMD2 expression was highly restricted to certain structures of the central and peripheral 
nervous system such as the dorsal root ganglia and the trigeminal nerve (Figure 5.8). Dorsal 
root ganglia (DRG) along the spinal cord contain sensory neurons (Gilbert, 2000). The strong 
expression of MMD2 mRNA in these locations suggests its association with neurons. 
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Although both MMD and MMD2 transcripts are localized in the nervous system and brain 
region, MMD was absent from the spinal cord and DRG, and exhibited a rather diffused 
expression pattern. This finding suggests that MMD and MMD2 may be involved in different 
processes of the mouse development. In addition to the above, Menke et al. (Menke & Page, 
2002) showed MMD2 expression in testis from E13.5 mouse embryos by whole mount in situ 
hybridization. In testicular cords MMD2 expression was attributed to Sertoli cells (Menke & 
Page, 2002), that play a pivotal role in the regulation and maintenance of spermatogenesis 
(Russell & Griswold , 1993), suggesting a putative role of MMD2 in this process as well.  
 
Northern blot analyses showed that the ubiquitous MMD and restricted MMD2 expression 
patterns were maintained during adult age, and conserved in mouse and human (Figure 
5.6B-C and Figure 5.9C). 
Taking into consideration the strong expression of MMD in macrophages, it is tempting to 
attribute its ubiquitous expression pattern partially to resident and recruited macrophages in 
tissues (see section 1.1.2). Tissue macrophages are responsible for immune surveillance and 
maintenance of tissue homeostasis (Burke B & Lewis Claire E., 2002). Moreover they are 
found in different parts of the developing embryo, including the brain, the central nervous 
system (Lichanska et al., 1999), and in areas of active tissue remodeling such as the branchial 
arches (giving rise to mandibular components) and developing limbs (Lichanska et al., 1999; 
Hume et al., 1995). Thus the ubiquitous expression of MMD in the embryonic brain may be 
as well attributed to macrophages.  
Nevertheless, Northern blot from different cell types showed that MMD expressions is not 
restricted to macrophages but is also found in other myeloid lineages (such as in T cells) and 
non-myeloid cell lines. The human skin (NHDFC) and dermal (HUVEC) fibroblasts, and the 
mouse embryonic fibroblast cell line, NIH3T3, expressed MMD as well, suggesting an 
involvement of this gene in connective tissues.  
Moreover, CaCo-2, and HepG2, which are colon and hepatocyte carcinoma cell lines 
respectively, expressed strongly MMD as well. This finding is in agreement with the presence 
of human MMD (hMMD) transcript in colon and liver (Figure 5.6). According to the GNF 
SymATLAS database (Su et al., 2002), hMMD is strongly expressed in the hepatoma cell 
line, huh-7, various pancreatic cell lines such as Capan1 and Panc1 and in the myoblast cell 





Interestingly, multiple mouse MMD (mMMD) transcripts of different length were observed in 
the liver and heart, possibly resulting from the use of different polyadenylation (Poly-(A)) 
sites. Additionally, several ATTTA motifs are present in the 3’-untranslated region (UTR) of 
the mRNA. This sequence motif has been associated with mRNA stability and translational 
efficacity allowing fast changes in the proteins synthesis (Ross, 1995). It is therefore possible 
that these motifs may play a role in mMMD mRNA stability in the liver and heart. 
 
In contrast to MMD, MMD2 transcript was not detected in any of the tested myeloid cell 
lines, nor in the non-myeloid fibroblasts cells (data not shown). Based on its restricted mRNA 
expression patterns in specific tissues, one can speculate that MMD2 may function in 
reproductive tissues (testis, ovary). However we cannot rule out the possibility that it may 
also be developmentally regulated or enriched in cell lines that have not been analysed in the 
present study. 
 
Given the differential spatial expression of MMD and MMD2 despite high protein sequence 
homology (around 68% identical amino acids), one can speculate that these two genes arose 
from gene duplication of Hly-III. Subsequently a gene divergence occurred in regulatory 
elements leading to alteration of their expression pattern (Strachan T & Read A.P, 2004; Tang 
et al., 2005). The high degree of sequence homology shared between the orthologues results 
likely from a high selection pressure and suggests a conserved function among species.  
 
As previously mentioned, mMMD was found strongly expressed in bone marrow 
macrophages (BMM) (Figure 5.9). Inflammatory stimuli activates macrophages and alter their 
gene expression pattern (see section 1.1.3). To investigate a possible regulation of mMMD 
expression in inflammation, mouse BMM were treated with bacterial lipopolysaccharides 
(LPS). LPS is a component of a Gram-negative bacteria, which binds to its receptor CD14 
with the help of the soluble LPS-binding protein (LBP). The LPS-CD14 complex is then 
recognized by TLR4 which activates multiple signaling pathways leading to the activation of 
the transcription factor, NFκB (Abul K.Abbas & Andrew H.Lichtman, 2003). Consequently, a 
large number of genes are up- or downregulated, and their protein products provide 
macrophages with defense mechanisms against infection. Treatment of BMM with LPS 
induced a rapid increase of mMMD transcript, that reached the highest levels after 2 h, and 
was then downregulated 8 h after stimulation (Figure 5.10). This rapid response shows an 
association of mMMD with the macrophage innate activation (see section 1.1.3), which is 
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characterized by an increased phagocytotic capacity, and the production of cytokines and 
chemokines. These in turn can promote or inhibit inflammation (Burke B & Lewis Claire E., 
2002). For instance IL-10, mainly produced by activated macrophages, functions as a 
feedback regulator, promoting their deactivation and thus protects against the damaging 
effects of persisting inflammation (Barsig et al., 1995; Abul K.Abbas & Andrew H.Lichtman, 
2003). However, stimulation of BMM with IL-10 did not affect mMMD transcription levels, 
indicating that mMMD is probably not regulated by IL-10.  
Cytokines, such as INFγ and IL-4, which prime macrophages towards a classical or an 
alternative activation phenotype respectively (see section 1.1.3), did not influence mMMD 
expression (Figure 5.11). These results lead to the conclusion, that mMMD expression is 
associated with the first phase of the macrophage activation by LPS, as it is regulated 
independently of IL-10, and not altered by INFγ or IL-4 priming.  
6.2. Protein structure 
As previously described in section 5.1.3, MMD and MMD2 were predicted to be seven 
transmembrane (7TM) proteins (Figure 5.4), to be highly conserved between species (Rehli et 
al., 1995) and to be related to Hemolysin (Hly)-III of Bacillus cereus (Rehli et al., 1995; 
Fernandes et al., 2005; Tang et al., 2005).  
Hemolysin-III is one of the potential virulence factors of Bacillus cereus. Once secreted it 
binds to the cell membrane of erythrocytes and forms oligomeric pores thereby causing their 
lysis (Baida & Kuzmin, 1996). At present, very little is known about this protein. Multiple 
sequence alignment (Figure 5.5) showed significant identity with the mammalian MMD 
proteins especially within the transmembrane domain. It is however not clear whether MMD 
proteins can form oligomeric pores. 
MMD and MMD2 also termed PAQR11 and 10 respectively (Tang et al., 2005), share a high 
degree of sequence conservation with other PAQRs within the UPF0073 motif (see section 
1.3). PAQRs are characterized by the following features:  
• An UPF0073 motif, which contains at least seven transmembrane (TM) domains. 
• N- and C-terminal tails that vary in length and sequence between different PAQRs. 
• Highly conserved protein sequence between orthologues. 
• Conserved amino acid residues between all paralogues in all species. 
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In fact, five regions with conserved residues were first described in the yeast PAQR 
orthologue, YOL002c. A potential metal-binding property was attributed to these residues 
(Lyons et al., 2004). Four of them were found in MMD and MMD2:  
• 1st region: EX[X2NX2T/H]TM I exhibits a truncated form of the first region in yeast. 
• 2nd region: [SX2HX6]TM IIS. 
• 3rd region: D[X10S] or D[X9S]. 
• 4th region of YOL002c is missing. 
• 5th region: [G]TM VIX6D[X6HX3HX2VX6H]TM VII. 
Amino acid residues between brackets are located in predicted TM regions of MMD and are 
outlined in green in (Figure 5.5). In MMD2, some of these residues were found outside the 
predicted TM region such as asparagine (N) of the first region, histidine (H) of the second 
region and aspartate (D) of the third region. Because there is still no experimental evidence 
that would confirm the predicted length of the TM regions in MMD and MMD2, it is not 
certain whether these residues are really located in the extramembrane loops.  
Interestingly, conserved residues that were predicted outside the TM domains were found 
located on one side of the membrane. Thereby they may play a role in the choice of 
physiological substrates of the MMD proteins, and influence the underlying molecular 
mechanisms, which have not been yet identified . 
 
Therefore, determining the subcellular localization and orientation of mMMD constitutes an 
important step toward elucidating its role in the cell. The protein topology and the high level 
of homology existing between the ortholgues were two main hindrances for generating a 
specific mMMD antibody (see section 5.3.1.1). Consequently, an epitope tag strategy was 
employed to determine mMMD cellular localization. 
Initially, a carboxy-terminally FLAG-tagged version of mMMD (MMD-3xFLAG), was 
transfected into a mouse macrophage cell line (RAW264.7), by using various methods 
without success (see section 5.3.1). The transient and stable high expression of mMMD were 
not tolerated by these cells (see section 5.3.2). In contrast, NIH3T3, tolerated ectopic 
expression of the tagged protein and was used for further experiments. 
Immunocytochemistry performed on NIH3T3 cells expressing tagged versions of mMMD 
revealed an intracellular perinuclear localization, suggesting a reticulate network with a 
nuclear membrane localization. Western blot analysis confirmed the predicted size of 
recombinant expressed mMMD (about 28 kDa). During the course of this work, additional 
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seven tagged versions of the protein were generated and confirmed the mMMD perinuclear 
localization (Figure 5.14).  
 
In contrast to the other seven versions of tagged recombinant mMMD proteins, for the 
FLAG-MMD-HA protein none of the tags were detectable neither by Western blot nor by 
immunocytofluorescence analyses. It seems that the N- and C-terminal tagging of mMMD 
with FLAG and HA respectively, influenced the protein stability. It is unlikely that the 
expression disturbance is on the transcriptional level, since mMMD was expressed from the 
first cistron of a bicistronic eGFP co-expressing construct, and the cells were eGFP-positive. 
A second exception to the perinuclear localization was observed when mMMD was tagged 
with c-Myc at the first extramembrane loop leading to a vesicular localization. Generally, in a 
transmembrane proteins the first hydrophobic domain initiates the insertion of the growing 
peptide into the endoplasmic reticulum (ER) membrane, followed by the second TM domain, 
which functions as a “stop transfer” signal. After a hydrophilic stretch, the third TM domain 
functions again as an internal signal anchor sequence and so on, until the 7TM domains span 
the ER membrane (Lodish H et al., 2004). It seems that introducing a c-Myc tag in the first 
extramembrane loop of the protein altered its correct integration in the lipid bilayer, probably 
leading to its export from the ER-Golgi compartment. 
In silico analysis using the SignalP program (Bendtsen et al., 2004) showed that mMMD 
lacks any signal sequence primary structure, supporting the notion that it is probably retained 
in the ER. PSORT II program (Nakai & Horton, 1999) predicted a putative cleavage site 
between the amino acid residues HRL and SD (Figure 5.3) located in the first extramembrane 
loop behind the TM I in mMMD protein sequence. However Western blot analysis of all 
tagged mMMD versions used for transfection experiments did not corroborate the presence of 
the cleavage site since none of the recombinant proteins was found to be truncated (Figure 
5.16).  
Based on these immunocytochemistry analyses, mMMD is an intracellular membrane protein. 
However, the possibility that it can be targeted to the outer cell membrane under certain 
conditions cannot be ruled out. It would be therefore interesting to investigate its localization, 
for instance, after LPS stimulation.  
 
The rat MMD orthologue was recently identified by Bräuer et al. as a macrophage/microglia 
activation factor (MAF), specifically expressed in activated microglia cells after brain trauma 
(Brauer et al., 2004; Lunemann et al., 2006). Furthermore, they showed colocalization of 
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exogenous eGFP-tagged MAF with the lysosome associated membrane protein (LAMP)-1 in 
monkey kidney fibroblasts (COS7) and mouse microglia cells (BV-2) (Brauer et al., 2004). 
This result was confirmed by a generated MAF antibody, which also showed a vesicular 
staining pattern similar to LAMP-1. However, in Western blot analysis, a MAF antibody 
detected a 62 kDa band in U937 cell line (Lunemann et al., 2006), which by far exceeds the 
predicted molecular weight of MAF (28 kDa). From the publication is not clear if 
homodimers were detected, or if the protein was complexed with unknown factors, maybe 
helping its transport to lysosomes. Also, post-translational modifications such as 
glycosylation could lead to a larger apparent weight.  
To explore a possible mMMD localization in lysosomes, an N-terminally HA- or a 
C-terminally 3xFLAG-tagged mMMD were stably expressed in NIH3T3 cells using a 
retroviral transfection system (see section 5.3.2). Interestingly, both tagged proteins localized 
mainly in the nuclear membrane (colocalization with DAPI staining) and the perinuclear 
region without any colocalization with the lysosomal marker LAMP-1 (Figure 5.18). The 
staining pattern suggests again an endoplasmic reticulum (ER) localization, however, a 
co-staining with an additional ER marker would be required to confirm this putative 
localization. 
 
Bräuer et al. (Brauer et al., 2004) reported that addition of phorbol 12-myristate 13-acetate 
(PMA), an enhancer of exocytosis, drove eGFP-tagged MAF secretion in COS7 cells. 
However, treatment of NIH3T3, stably expressing tagged MMD proteins, with PMA did not 
induce changes in the protein localization. In addition, an increase in its expression was 
observed, resulting from an upregulation of the exogenous CMV promoter, which drove the 
expression of the tagged proteins (AbuBakar et al., 1990). 
 
The discrepancy between eGFP-tagged MAF lysosomal localization (Brauer et al., 2004) and 
the perinuclear staining of HA or 3xFLAG tagged MMD may be partially explained by the 
fact that the fusion of MAF with eGFP may have influenced the correct spanning of the 
transmembrane domain in the lipid bilayer. This in turn may have exposed some potential 
domains allowing the export of the protein outside the ER. On the other hand, it is difficult to 
rule out the possibility that HA or 3xFLAG tags may have influenced the correct protein 
folding, thus leading to its accumulation in the ER. However it is unlikely that these small 
tags (HA, 9 aa; 3xFLAG, 18 aa) should alter mMMD localization more than the much larger 
eGFP tag (239 aa).  
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Another possible scenario to explain the observed discrepancies in localization would be that 
mMMD may form homodimers. The fusion with eGFP or with small tags may have 
influenced its lysosomal or perinuclear localization. It is difficult to confirm one scenario or 
the other, therefore to resolve the discrepancy between the results presented in this work and 
MAF staining, further experimental studies will be needed. Unfortunately, because 
mMMD/MAF function and its ligand identity has not yet been ascertained, it is not possible to 
test the functional integrity of the tagged proteins at this time.  
 
Most 7TM proteins are classified as G-protein-coupled receptors (GPCRs), which are 
characterized by conserved cystein residues, a large extracellular Nexterior and an intracellular 
Ccytosol terminal domain (Bockaert & Pin, 1999). GPCRs respond to a wide range of signals 
such as lipids, peptides, neurotransmitters, nucleotides and are involved in numerous 
physiological processes. The third cytosolic intracellular loop is important for interaction with 
G-protein (Karnik et al., 2003; Lodish H et al., 2004). Binding of ligand induces a change in 
receptor conformation leading to a G-protein activation, which in turn alters the activity of a 
variety of downstream effector molecules (Lodish H et al., 2004). Determining the topology 
of mMMD in the lipid bilayer was the second approach to investigate the protein as well as 
the location of putative ligand binding sites but also its relation to GPCRs.  
 
Based on the 7TM prediction (Figure 5.4), mMMD N- and C-termini have to be positioned on 
different sides of the lipid bilayer of perinuclear compartment. Mild permeabilizing of the 
plasma membrane using digitonin showed that the mMMD N-terminus faces the cytosol and 
the C-terminus faces the lumen of the perinuclear compartments (see section 5.3.3.2). This 
membrane topology that corresponds to a type IV-A multipass protein (Lodish H et al., 2004) 
differs from that of GPCRs.  
Consequently, the predicted amino acid residues that were associated with metal-binding 
properties and located in predicted extramembrane loops would be all positioned at the 
cytosolic side of the protein (Figure 6.1). This may suggest a possible role of mMMD as 




                  
Figure 6.1 Proposed membrane topology of mMMD protein in the lipid bilayer of NIH3T3. 
Mouse MMD protein traverses the perinuclear (probably ER and outer nuclear) lipid bilayer seven 
times and has the N-terminal domain facing the cytosol. The N-, and C-terminal tails as well as 
extramembrane loops are depicted in bold letters and comprise the number of amino acids indicated 
between brackets. Conserved amino acids between mMMD and PAQRs are shown in pink, 
transmembrane domains in grey (I-VII).  
The high protein sequence identity found between mouse and human MMD proteins, suggests 
a similar cellular localization and orientation. However, human and mouse MMD2 proteins 
differ from their MMD paralogue, both in their N- and C-teminal tail and in some amino acid 
residues in the extramembrane loops, which may influence their membrane topology, and 
probably their cellular localization and orientation. Therefore, it would be very interesting to 
determine MMD2 cellular localization and orientation. 
6.3. Mouse MMD gene inactivation 
Knocking-out MMD gene may provide valuable clues about MMD function and the processes 
in which it is involved.  
Five attempts to knock out mMMD in ES cells were undertaken, using five different targeting 
vectors. However, from a total of 1993 clones isolated, only one was screened positive for 
homologous recombination, which unfortunately did not survive the thawing procedure from 
the replicate plate (see section 5.4).  
Although homologous recombination at the target locus in ES cells is much more efficient 
than in somatic mammalian cells, it remains a rare event and the random integration of the 
targeting vector into the ES cell genome is rather the rule than the exception (Joyner, 2001). 
Numerous factors influencing gene targeting efficiency were taken into consideration for the 
construction of the different targeting vectors, in addition to various ES cell electroporation 
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methods that were tested in this work (see section 5.4.3.4). The unsuccessful attempts to 
generate an mMMD deficient ES cell line remains a problem to be resolved. One can 
speculate that the mMMD locus may be inaccessible for the recombination machinery in ES 
cells (Muller, 1999). One clue supporting this assumption, was provided by a qRT-PCR 
analysis showing that mMMD mRNA endogenous expression in ES cells was very low when 
compared to its expression in BMM (data not shown). In many cases, unexpressed genes are 
associated with a tightly packed chromatin organization (Strachan T & Read A.P, 2004). If 
this is the case with mMMD, the gene locus would be inaccessible for the recombination 
machinery, and therefore the efficiency of the homologous recombination would be affected 
negatively. 
 
The second approach for silencing mMMD gene was to employ RNA interference (iRNA). 
After transfection into RAW264.7 and NIH3T3, mMMD-specific small interference RNA 
(siRNA) mediated a successful degradation reaching a transcript reduction of 90% in 
NIH3T3, and 80% in RAW264 7. Interestingly, the mMMD mRNA level in RAW264.7 
decreased after 72 h cell culture, independently of siRNA transfection. One explanation may 
be the rapid nutrient depletion in RAW264.7 low glucose medium. In contrast NIH3T3 were 
grown in DMEM high glucose medium and did not show any reduction in mMMD transcript 
levels over time. It remains to be determined whether mMMD is involved in glucose uptake 
or energy metabolism, and whether this effect is cell type-specific.  
Recently, it has been reported that using a lentiviral shRNA vector, stable transgenic 
knock-down mice can easily be produced from infected transgenic ES cells (Szulc et al., 
2006; Tiscornia et al., 2003). Consequently, the identified siRNA can be further used to 
generate a mMMD knock-down mouse by expressing a short hairpin-forming RNA (shRNA) 
containing the sequences of the siRNA duplex. 
6.4. Possible functions  
To date there is no published data for MMD and MMD2 protein functions. In mouse BMM, 
the rapid increase of mMMD transcript expression upon LPS stimulation suggests an 
association of the protein with the first phase of the immune response. This latter involves 
pro-inflammatory processes and the activation of transcription factors such as NFκB, which in 
turn promotes gene transcription and expression. It is not known whether the increase in 
mMMD expression is directly induced by NFκB or by other unknown factors, or whether it 
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contributes to the inflammatory response mediated by NFκB (Abul K.Abbas & Andrew 
H.Lichtman, 2003).  
 
A second hint involving MMD in activated macrophages processes was provided by 
Sawcer S. et al. (Sawcer et al., 2002), who classified hMMD as a susceptibility gene for 
Multiple Sclerosis (MS). MS is a chronic inflammatory demyelinating disease of the central 
nervous system, resulting in impaired nerve conduction. The keys to the pathophysiology are 
activated lymphocytes, macrophages, astrocytes and microglia. Activated 
microglia/macrophages are involved in the demyelination and secrete inflammatory cytokines 
such as TNFα, IL-1 and IL-6 which additionally contribute to the formation of free radicals 
and tissue damage (Burke B & Lewis Claire E., 2002). The involvement of hMMD in these 
processes suggests either a role in inflammation or as protector against brain damage.  
 
Recently, Lünemann et al. (Lunemann et al., 2006) showed that MAF/MMD (rat MMD 
orthologue) was upregulated in regions of the brain after an entorhinal cortex lesion (ECL). 
ECL models post-traumatic tissue remodeling of neuronal structure and connectivity 
(Lunemann et al., 2006). The early phase of this process is characterized by the recruitment, 
into the lesion site, of inflammatory cells such as microglia and newly infiltrated 
macrophages, whichs produce IL-1β. In the late phase of ECL (two days later), tissue repair 
and remodeling are initiated, where microglia were shown to play a crucial role (Mabuchi et 
al., 2000). MMD/MAF expression in this latter stage of ECL suggests its role in tissue 
remodeling rather than inflammation (Lunemann et al., 2006). However, Lünemann et al. did 
not investigate whether MAF/MMD was also expressed during the early phase of ECL.  
Taken together, MMD function may be associated with immediate post-stimulatory activation 
of macrophages, and is likely associated with tissue remodeling. 
 
The recent classification of MMD and MMD2 into PAQRs family (Tang et al., 2005) shed 
more light into their putative functions, however few clues are available linking MMD 
proteins to these receptors.  
On the transcript level, Northern blot analysis showed that both MMD and AdipoRs mRNA 
were expressed in macrophages but also in liver, skeletal muscle, adipose tissue and placenta 
(Yamauchi et al., 2003a). On the other hand, MMD2 shared with mPRα (PAQR7) the 
expression in testis and with mPRβ and MMD the expression in brain. However, apart from 
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the similar expression pattern, there is no other evidence which relates functionally MMD 
proteins to PAQRs. 
Interestingly, in the placenta in addition to hMMD and AdipoRs (Yamauchi et al., 2003a), 
mPRα and PAQR9 were expressed (Fernandes et al., 2005; Zhu et al., 2003a) and functionally 
associated with the onset of pregnancy. PAQR3 was also strongly and constantly expressed in 
the endometrium during the cycle and upon pregnancy, where it was predicted to responsible 
for the maintenance of the tissue homeostasis (Fernandes et al., 2005). In fact, in the early 
phases of pregnancy, a balance between pro- and anti-oxidant factors is important in the 
placenta microenvironment for the trophoblast invasion (Biondi et al., 2005). Macrophages, 
which are in close contact with trophoblasts, play a pivotal role in this process by supporting a 
certain grade of inflammation (Mor & Abrahams, 2003; Zhu et al., 1997). Interestingly, 
PAQR3 orthologue in Drosophila melanogaster, CG7530, was identified as a resistant gene 
against oxidative stress (Monnier et al., 2002). It is therefore likely that PAQR3 may play the 
same role in the placenta during the pregnancy. The next question would be if hMMD can 
also be involved in the onset of pregnancy and in oxidative stress as well.  
 
On the protein level, PAQRs differ in their subcellular localization. PAQR1 and PAQR2 
(Yamauchi et al., 2003a) as well as the yeast YOL002c (Narasimhan et al., 2005) were 
defined as plasma membrane proteins (Zhu et al., 2003b). PAQR8 was located in lysosomes 
(Suzuki et al., 2001) and only mPRα (PAQR7) shares with mMMD the perinuclear and 
nuclear membrane localization (Fernandes et al., 2005). However, amino acid residues with a 
predicted metal-binding property were found conserved in all PAQRs (see section 6.2) (Tang 
et al., 2005; Lyons et al., 2004).  
In the yeast PAQR orthologue, YOL002c, the metal-binding amino acid residues were 
associated with zinc metabolism. YOL002c, also termed “Implicated in Zinc Homeostasis” 
(IZH)-2 was found to be induced by a zinc limited environment. Its function was also 
associated with lipid metabolism (Karpichev et al., 2002). Additionally, it has been speculated 
that IZH-2 could be an ion channel (Lyons et al., 2004).  
In AdipoRs and mMMD proteins, where the membrane topology was determined, the 
metal-binding residues, located outside the TM regions, face the cytosol. It is therefore 
tempting to propose that both proteins may be implicated in the cellular zinc homeostasis.  
 
An ion channel property was proposed for the human PAQR8 (mPRβ, also termed as 
lysosomal membrane protein brain (LMPB)-1). PAQR8 was associated with a brain 
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pathology, namely juvenile myoclonic epilepsy (JME), which is characterized by seizures 
without detectable brain lesions (Suzuki et al., 2001). Defects in ion channel proteins were 
implicated in JME.  
One can assume that MMD proteins could be an ion channels as well. The fact that they were 
defined as related to Hly-III (Rehli et al., 1995; Tang et al., 2005), which was shown to form 
membrane pores in erythrocytes (Baida & Kuzmin, 1996), may support this assumption.  
 
Taken together, MMD and MMD2 expressed in different tissues, are likely to be involved in 
different processes. Mouse MMD intracellular localization and topology suggest a putative 
role in maintenance of the cellular homeostasis. Whether the metal-binding property of the 
conserved amino acid residues plays a role in oxidative stress, or whether MMD protein are 
ion channels, remains to be determined.  
6.5. Outlook 
After assessing MMD and MMD2 expression patterns, in human and mouse adult tissues, 
there are still fairly many unanswered questions.  
At the protein level, the finding that mMMD is a perinuclear transmembrane protein, whose 
transcript is rapidly induced by stimulation with LPS, paves the way for more interesting 
experiments, such as determining in which signaling pathway mMMD may be involved.  
On the other hand, the finding that MMD2 is specifically expressed in brain and testis of 
mouse and human, and not in macrophages or any other tested cell line, raises many questions 
on its role in these tissues. Therefore, in situ hybridization in brain and testis, in addition to its 
subcellular localization and orientation have to be assessed prior to the search for its ligand.  
Although the generation of a MMD knock-down mouse may offer many advantages, this 
technology still has some limitations, which have been encountered particularly in cases of 
genes expressed ubiquitously in adult animals and in embryonic tissues. Whole mount ISH 
showed early expression of MMD in mouse embryo that becomes ubiquitous after 13 dpc, 
indicating the importance of this gene during the embryogenesis and mouse development. 
Thus, inactivating MMD may have dramatic consequences and cause early lethality, which 
makes difficult the analysis of its function in adult tissues.  
On the other hand, in cases of genes ubiquitously expressed at an adult age, alteration of its 
expression at early embryonic stages is more likely to activate compensatory pathways, 
leading to complicated phenotypes (Gerlai, 2001). Taken these into consideration, the 
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generation of a MMD deficient mice using the Cre/lox recombinase system under temporal 
control would be the most promising approach.  
Generating a MMD2 conditional knock-out mouse is as well of great interest to investigate 
MMD2 function.  
Finally, the established siRNA against mMMD can be further used to silence MMD in various 
cell lines. Additionally this approach, when coupled to microarray gene expression analysis, 
may help to gain insight into mMMD association in different processes such as lipid and 
glucose metabolism as well as the nongenomic action of progestin. Through this approach 
putative genes regulated by mMMD can be identified.  
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7. Summary  
During the course of this work the monocyte to macrophage differentiation factor (MMD) and 
its homologue MMD2 were characterized. Both genes encodes for orphan proteins with a 
predicted seven transmembrane domain very well conserved between species.  
 
MMD mRNA expression could be shown to be upregulated in macrophages and to be 
ubiquitously distributed in mouse and human. In contrast, MMD2 mRNA was only detected 
in brain and testis and in none of the tested cell lines. This differential expression pattern 
indicates differences in gene regulation although MMD and MMD2 share about 68% 
sequence identity at the protein level.  
Furthermore, mouse MMD (mMMD) regulation on the mRNA level was investigated in bone 
marrow macrophages and found to be rapidly induced by LPS, associating MMD function 
with processes that occur during the first stage of the macrophage innate activation. 
 
At the protein level, mMMD cellular localization and topology were determined. For this 
purpose various tagged versions of the protein were generated, and used to determine its 
subcellular localization. Additionally, a retroviral transfection system was established in our 
lab, and used to generate two cell lines stably expressing two tagged versions of MMD. By 
performing immunocytochemistry, tagged MMD proteins were localized in perinuclear 
compartments with an Ncytosol and Clumen orientation.  
 
The second and main aim of this project was to investigate the effect of a MMD null-mutation 
in mice in an attempt to elucidate its function. For this purpose ES cell culture was 
established, MMD targeting constructs were generated and transfected into ES cells with the 
aim to generate an ES knock-out cell line and to establish an MMD knock-out mouse line by 
blastocyst injection. 
As an alternative to gene targeting, an siRNA sequence was determined that can be used for 
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AA     Acrylamide  
AP     Alakaline Phosphatase 
BLAST    Basic Local Alignment Search Tool 
BSA     Bovine Serum Albumine 
cDNA     complementary DNA 
CFU     Colony Forming Unit 
cpm     count per minute 
DAPI     4’,6’-diamidino-2-phenylindol 
DC     Dendritic cell 
DEPC     Diethyl Pyrocarbonate 
DIG     Digoxigenin  
DMEM    Dulbecco’s Modified Eagle Medium 
DMSO    Dimethyl Sulfoxyde 
DNA     Deoxyribonucleic Acid 
dNTP     deoxinucleotide Triphosphate 
dpc     day post coitus 
DTT     Dithiothreitol 
ECL     Enhanced Chemiluminescence 
EDTA     Ethylenediaminetetraacetic Acid  
ES     Embryonic stem cell  
EST     Expressed Sequence Tag 
EtOH     Ethanol 
FCS     Fetal calf serum 
FITC     Fluorescein Isothiocyanate 
GM-CSF    Granulocyte Macrophage Colony Stimulating Factor 
HA     Hemaglutanin 
HRP     Horseradish Peroxidase 
IL     Interleukin 
INFγ     Interferon gamma 
INM     Internal nuclear membrane 
ISH     In situ hybridization 
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LAMP     Lysosomal-associated membrane protein 
LB     Luria Bertani 
M-CSF    Macrophage Colony Stimulating Factor 
MEF     Mouse Embryonic Fibroblast 
MHC     Major Histocompatibility Complex  
MMD     Monocyte to Macrophage Differentiation  
MMD2    Monocyte to Macrophage Differentiation 2 
MNC     Mononuclear cell 
MOPS     3-(N-Morpholino) Propanesulfonic acid 
mRNA     messenger RNA 
NaOAc     Sodium Acetate 
Neo     Neomycin 
NP-40     Nonidet P-40 
OD     Optical Density (Absorbance) 
PBS     Phosphate Buffered Saline 
pBS     Plasmid Bluescript 
PCR     Polymerase Chain Reaction 
PEG     Polyethyleneglycol 
PFA     Paraformaldehyde 
qRT-PCR    Quantitative Real-time PCR 
RNA     Ribonucleic Acid 
rpm     round per minute 
RT     Room Temperature 
SDS     Sodium Dodecyl Sulfate 
siRNA     small interference RNA 
SSC     Saline Sodium Citrate 
TAE     Tris Acetate /EDTA electrophoresis buffer 
TE     Tris-EDTA 
TEMED    N,N,N’,N’,-Tetramethylenediamine 
tRNA     transfer RNA 
UV     Ultraviolet 
WB     Washing Buffer 
WT     Wild Type 
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